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ABSTRACT 
 
Background 
Indian Asians are at increased risk of type-2 diabetes (T2D), insulin resistance 
and related metabolic disturbances compared to Europeans. The contribution 
of known lifestyle and genetic risk factors to the excess risk of T2D in Indian 
Asians is not well understood.  
 
Methods and materials 
I investigated 16,774 Indian Asian and 7,301 European men and women 
participating in the in the London Life Sciences Population Study to determine 
the prevalence of T2D and related glycaemic disorders. I examined the 
contribution of adiposity, leisure time physical activity, major dietary 
macronutrients and known genetic susceptibility factors to the increased risk of 
T2D and related metabolic disturbances amongst Indian Asians compared to 
Europeans. Lastly I carried out a genome-wide association and replication 
study amongst 58,687 Indian Asian participants to identify novel genetic 
factors in this ethnic group. 
 
Results 
The prevalence of T2D is ~4-fold higher amongst Indian Asians than 
Europeans, and is not accounted for by differences in adiposity and leisure 
time physical activity. In dietary studies, intake of fibre is inversely related to 
risk of insulin resistance among Indian Asians. However, major dietary 
macronutrients do not account for differences in insulin resistance between 
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Indian Asians and Europeans. In genetic studies I demonstrate association of 
25 previously reported T2D genetic variants with T2D amongst Indian Asians. 
Of the 48 T2D genetic variants examined, risk allele frequencies were similar 
and effect sizes lower amongst Indian Asians compared to Europeans; 
therefore known T2D genetic variants do not account for the increased risk of 
T2D in this racial group. In the GWAS I discover 6 novel T2D genetic variants 
among Indian Asians (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and 
HNF4A).  
 
Conclusions 
T2D has emerged as a major healthcare problem worldwide, with rates highest 
among individuals of Indian Asian descent. For the first time I discover six novel 
genetic susceptibility factors for T2D amongst Indian Asians. However, there is 
a ~4-fold higher risk of T2D among Indian Asians compared to Europeans, 
which remains largely unexplained.  
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GENERAL INTRODUCTION
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1.1 INTRODUCTION 
Type-2 diabetes (T2D) is a metabolic disorder characterised by chronic 
hyperglycaemia and disturbances in fat, carbohydrate and protein metabolism. 
These abnormalities are the consequences of either inadequate insulin 
secretion or impaired insulin action, or both1. T2D is associated with reduced 
life expectancy, significant morbidity due to related microvascular 
complications, increased risk of macrovascular complications, as well as 
reduced quality of life2. The exact mechanisms underlying T2D remain to be 
established. 
 Indian Asians (persons originating from India, Pakistan, Sri Lanka and 
Bangladesh) are at increased risk of T2D, insulin resistance and related 
metabolic disturbances compared to Europeans3. The contribution of known 
lifestyle and genetic risk factors to the excess risk of T2D in Indian Asians is not 
well understood.  
 
1.2 DEFINITION OF T2D 
The World Health Organization (WHO) published the first widely used 
classification of diabetes in 19804. In these guidelines a distinction was made 
between two classes of diabetes; Type-1 diabetes (Insulin dependent diabetes 
mellitus [IDDM]) and type-2 diabetes (non-insulin dependent diabetes mellitus 
[NIDDM]). Type-1 diabetes results from β-cell destruction, leading to absolute 
insulin deficiency. T2D results from progressive insulin secretory defect on a 
background of insulin resistance. Other classes of diabetes are recognised: 
gestational diabetes; diabetes due to specific genetic defects in β-cell function, 
genetic defects in insulin action, diseases of the exocrine pancreas (cystic 
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fibrosis), and drug/chemical induced diabetes (such as in the treatment of AIDS 
or after organ transplantation). 
The diagnosis of T2D has historically been based on plasma glucose 
criteria, either fasting plasma or 2 hour 75-g oral glucose tolerance test values 
(table 1.1). An international expert committee now recommend use of the 
HbA1c test to diagnose T2D with a threshold of 6.5% (47.5 mmol/mol)5.  
 
1.3 DEFINITION OF PRE-DIABETES 
Pre-diabetes refers to an intermediate state in which fasting plasma 
glucose levels are above the normal range but below that of clinical T2D6, and 
can be identified as either impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT) or both are impaired. American Diabetes Association (ADA) 
considers both IFG and IGT as “pre-diabetic conditions”, and HbA1c values in 
the range of 5.7 – 6.4% (38.8 – 46.4 mmol/mol) mark the pre-diabetic state. 
The WHO defines IFG as fasting plasma glucose levels between 6.1 – 
6.9mmol/l, and pre-diabetes based on HbA1c as 6.1 – 6.4% (42.1 – 46.4 
mmol/mol), while it retains the same criteria for the diagnosis of IGT (table 1.2).  
 
1.4 EPIDEMIOLOGY OF TYPE-2 DIABETES 
1.4.1 Global burden of T2D 
The International Diabetes Federation (IDF) Diabetes Atlas estimated 
the global prevalence to be 285 million in 20107. Danaei et al. estimated trends 
in mean fasting plasma glucose and T2D by sex, for 199 countries and 
territories in the 21 sub regions of the Global Burden of Diseases, Injuries, and 
Risk Factors study between 1980 and 20088. Their final dataset included 370 
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country-years with 2.7 million participants. Age-standardised global T2D 
prevalence was 9.8% (8.6 – 11.2) in men and 9.2% (8.0 – 10.5) in women in 
2008, up from 8.3% (6.5 – 10.4) and 7.5% (5.8 – 9.6) in 1980. The number of 
people with T2D increased from 153 (127 – 182) million in 1980, to 347 (314 –
382) million in 2008.  
In the fifth edition of the IDF diabetes atlas it is estimated that the global 
prevalence of T2D will rise to 552 million by 20307. The greatest relative 
increases will occur in the Middle East, sub-Saharan Africa, and India. The 
greatest absolute increase in the number of people with T2D will be in India. 
The IDF estimate that 50% of people with T2D are undiagnosed. 
 
1.4.2 Prevalence of T2D in the Indian Subcontinent 
Roughly 80% of people with T2D are in developing countries, of which 
India and China share the largest contribution. Danaei et al. 2011, reported 
temporal changes in the prevalence of T2D amongst populations residing on 
the Indian Subcontinent (India, Pakistan, Sri Lanka and Bangladesh). Between 
1980 and 2008, the prevalence of T2D rose from ~8% to ~11% on the Indian 
Subcontinent (table 1.3)7. The greatest increase was observed among 
Pakistani women where mean rates doubled from 7.1 in 1980 to 14.1 in 20087. 
The prevalence of T2D is uniformly high in all urban regions of India and 
between both genders. In urban regions the prevalence of T2D in adults has 
risen from 5% in 1984 to just fewer than 15% in 20049. In contrast lower rural 
levels of T2D have been evident for decades, but more recently prevalence 
appears to have increased from 2% to 6%. In Sri Lanka, estimates of 
prevalence of T2D range from 9.9% to 19.6%10,11.  
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WHO estimates that between 2000 and 2030, the world population will 
increase by 37% and the number of people with T2D will increase by 114%. 
Asia is the major site of a rapidly emerging T2D epidemic. Conservative 
estimates based on population growth and ageing and rate of urbanisation in 
Asia show that India and China will remain the two countries with the highest 
numbers of people with T2D (79.4 million and 42.3 million, respectively) by 
20307.  
 
1.4.3 Prevalence of T2D amongst Indian Asians residing overseas 
Indian Asians who have migrated from the Indian subcontinent are 
reported to have higher prevalence of T2D compared to native populations in 
all countries studied (table 1.4). The reported prevalence of T2D among 
migrant Indian Asians ranges from ~10% in East Africa to ~34% in Singapore12-
25.  
In the UK, the prevalence of T2D is ~3-fold higher amongst Indian 
Asians compared to Europeans12. The Southall and Brent Study (SABRE), a 
cross-sectional study investigating the determinants of CHD among first 
generation migrants living in the UK, reported that the prevalence of T2D was 
22% amongst Indian Asian men compared to 7% amongst European men, and 
15% amongst Indian Asian women compared to 4% amongst European 
women. According to the Health Survey for England 2004 (table 1.5), doctor-
diagnosed T2D is almost 4 times as prevalent in Bangladeshi men, and ~3 
times more common among Pakistani and Indian men compared with men in 
the general population26 Among women, T2D is more than 5 times more 
prevalent among Pakistani women, ~3 times more common in Bangladeshi 
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women, and ~2.5 time more frequent among Indian women, compared with 
women in the general population. The reasons underlying increased 
susceptibility to T2D amongst migrant Indian Asian populations are not known.  
Recent reviews examining UK Indian Asians highlight the paucity of 
robust epidemiological data on T2D prevalence in this population and the need 
for large population-based studies to identify the current trends in prevalence of 
T2D and the proportion of undiagnosed cases in this population27 . 
 
1.4.4 Prevalence of undiagnosed T2D amongst Indian Asians 
The prevalence of undiagnosed T2D is also high amongst Indian Asians. 
In the DECODA study the proportions of previously undiagnosed T2D varied 
with age, with rates highest in the youngest age-groups and lowest in the 
elderly28. The proportion of undiagnosed T2D was slightly higher in women 
than in men at younger age groups. 
The ADDITION-Leicester study, a systematic screening program for 
T2D, demonstrated that undiagnosed glucose disorders occurred more 
frequently in Indian Asian than Europeans29. A random sample of 6,041 
participants, without a previous diagnosis of T2D, aged 40 – 75 years, were 
recruited from 20 GP practices. The prevalence of undiagnosed T2D was 5.1% 
and 2.1% amongst Indian Asians and Europeans respectively. Age and sex 
adjusted odds ratio for undiagnosed T2D was 2.30 (95% CI: 1.68 – 3.16, 
P<0.001) amongst Indian Asians compared to Europeans.  
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1.4.5 Mortality and morbidity of T2D amongst Indian Asians 
The pattern of complications among Indian Asian populations differs 
from that in Europeans, with more deaths among Indian Asians being attributed 
to coronary heart disease and renal failure. T2D presents ~10 years earlier 
amongst Indian Asians, additionally increasing life time exposure to 
hyperglycaemia and its complications30. The Southall Diabetes Survey31 
comprised a cohort of Indian Asian and European people with T2D in London, 
UK. They carried out an 11-year follow-up of a population-based sample of 730 
Indian Asians and 304 Europeans. The all-cause mortality rate ratio was 50% 
higher amongst Indian Asian participants compared to Europeans at baseline. 
The mortality rate ratio for circulatory deaths was 1.80 (95% CI: 1.03 – 3.16, 
P<0.05) and for heart disease was 2.02 (95% CI: 1.04 – 3.92, P<0.05) in those 
aged 30-64 years at baseline. 77% of Indian Asian deaths were caused by 
circulatory disease, compared with 46% of European deaths. Indian Asian 
survivors were 3.8 times (95% CI: 1.8 – 8.0, P=0.001) more likely to report a 
history of myocardial infarction than Europeans. 
There is considerable evidence that micro- and macro-vascular 
complications are commoner amongst Indian Asian diabetic patients, 
particularly with respect to cardiovascular32 and renal disease33. UKPDS 
demonstrated that Indian Asian ethnicity is independently associated with 
development of both albuminuria and renal insufficiency in T2D34.  
 
1.4.6 Pre-diabetes and development of T2D 
Individuals with pre-diabetes are at increased risk for the development of 
T2D6. The American Diabetes Prevention Program (DPP) showed that 
22 
 
approximately 10% of individuals with IGT developed T2D on an annual 
basis35. An analysis of 6 prospective studies showed that T2D development in 
IGT subjects varies from 23 to 62% within 2 to 27 years of follow up36. Patients 
diagnosed with both IFG and IGT have increased risk of developing T2D 
compared to individuals with isolated IFG or IGT37.  
 
1.4.7 Complications of pre-diabetes 
Previous studies show that pre-diabetes can be associated with micro-
vascular complications38,39. The Diabetes Prevention Programme showed that 
7.9% of individuals with IGT progressed to diabetic retinopathy before the 
development of T2D40. Similarly, neuropathy may present in the pre-diabetic 
patient, before the onset of T2D41.  
Individuals with pre-diabetes are at increased risk for developing CVD 
before a diagnosis of overt T2D is made42. In the Diabetes Epidemiology the 
Collaborative Analysis Of Diagnostic Criteria in Europe (DECODE) study, 
impaired glucose tolerance increased the hazard ratio for cardiovascular 
mortality up to 34% (adjusted for body mass index (BMI), blood pressure, and 
cholesterol)43. The National Health and Nutrition Examination Survey 
(NHANES) II showed a 42% increase in all-cause mortality and a 19% 
increased risk for cardiovascular death amongst Individuals with IFG44. In 
contrast data from a meta analysis showed that the estimated relative risk for 
cardiovascular disease associated with IGT and IFG ranges from 0.97 to 1.30 
and 1.12 to 1.37 respectively, suggesting that pre-diabetes results in a modest 
increase in cardiovascular risk45.  
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1.4.8 Prevalence of pre-diabetes amongst Indian Asians 
In the DECODA study the age-specific prevalence of impaired glucose 
regulation (IFG or IGT) was higher among Indian Asians than East Asians28. 
There were no gender differences in the prevalence of pre-diabetes within 
Indian Asians, except at the youngest ages, where rates were higher among 
women. 
Few studies have investigated on the prevalence of pre-diabetes 
amongst Indian Asians residing overseas. From the available data, the 
prevalence of pre-diabetes is consistently higher among Indian Asians 
compared to native populations. In the Newcastle Heart Project the prevalence 
of IFG was 20% and 14% among Indian Asians and Europeans respectively20. 
In sub-group analysis, rates of IGT were highest amongst individuals of 
Pakistani descent (24%). The Leicester-Addition study investigators reported 
higher frequency of impaired glucose regulation amongst Indian Asian 
individuals compared to their European counterparts (14.3% vs 12.1%). 
Following adjustment for age and sex, Indian Asians were at ~60% increased 
risk of IGR compared to Europeans (OR [95% CI]: 1.61 (1.33 – 1.93), 
P<0.05)29. 
 
1.5 PATHOGENESIS OF T2D 
The natural history of T2D involves progression from normal glucose 
tolerance, to IGT to overt hyperglycaemia. Both insulin resistance and β-cell 
dysfunction leading to impaired insulin secretion are important in the 
pathogenesis of T2D1.  
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1.5.1 Insulin resistance 
Insulin resistance is a pathophysiological state in which a given 
concentration of insulin produces a less-than-expected biological effect. Insulin 
resistance has a strong genetic component and is additionally influenced by 
obesity, ectopic fat accumulation, aging, exercise and dietary constituents46. 
The family of IRS proteins is a key regulator of the insulin-signalling cascade47. 
IRS-1 and IRS-2 are found in most tissues and have a major role in 
coordinating the actions of insulin in peripheral carbohydrate and lipid 
metabolism, and β-cell function48. Studies with knockout mice show that IRS-1 
and IRS-2 deficiency is associated with insulin resistance48. The other two IRS 
proteins are less widely distributed, with IRS-3 found in adipose tissue49, β 
cells50 and possibly liver51, and IRS-4 restricted to the thymus, brain and 
kidney52. Cell-specific expression of IRS proteins provides a possible 
mechanism for tissue-specific responses to insulin.  
 
1.5.2 Pancreatic -cell dysfunction and T2D 
In T2D, the ability of pancreatic β-cells to maintain glucose homeostasis 
through insulin secretion is compromised, resulting in hyperglycaemia53,54. The 
defect in insulin secretion in T2D is a result of reduced functional β-cell mass 
and intrinsic β-cell dysfunction. The UKPDS demonstrated that pancreatic β-
cell dysfunction commences ~10 years before the onset of hyperglycaemia, 
and there is progressive loss of β-cell function over time55. Data from autopsy 
studies demonstrate a 63% and 40% reduction in islet mass amongst patients 
with T2D and IFG respectively, compared to normoglycaemic individuals54. 
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Five mechanisms have been proposed underlying β-cell dysfunction 
amongst individuals with T2D: 
1. Genetic disposition: This is supported by results from genome-wide 
association studies, which identify an excess of common genetic variants 
influencing insulin secretion and β-cell function56. 
2. In utero malnutrition: This leads to suboptimal β-cell development and 
defective insulin secretion in later life57.  
3. Glucotoxicity: This refers to the adverse effects of chronically elevated 
glucose levels on β-cell function. A number of mechanisms have been 
proposed including endoplasmic reticulum stress, oxidative stress and 
mitochondrial dysfunction and islet cell inflammation58. However, most of 
the evidence is derived from in vitro studies and should therefore be 
interpreted with caution. 
4. Lipotoxicity: A number of mechanisms have been proposed to explain the 
detrimental effect of free fatty acids (FFA) on β-cell function 59. First, FFA 
induce endoplasmic reticulum stress, through overstimulation of non-
esterified fatty acid (NEFA) esterification, which reduces the capacity of the 
endoplasmic reticulum for other processes. Secondly, NEFA induces 
oxidative stress both in vitro and in vitro. Third, FFA such as palmitate, 
which serve as a substrate for the formation of ceramide and other 
metabolites, are pro-apoptotic and reduce insulin gene expression. 
5. Ectopic deposition of triglycerides in pancreatic islets60: Obesity also 
causes fat infiltration of organs such as the liver, striated muscle, heart and 
pancreas61. In animal models, triglyceride overload in pancreatic β-cells 
leads to lipotoxicity and lipoapoptosis62. The increased pancreatic 
26 
 
triglyceride levels observed in non-alcoholic fatty pancreas disease 
(NAFPD) are thought to reflect an increased amount of triglycerides in 
pancreatic β-cells, which then causes β-cell dysfunction63. Another 
hypothesis is that intrapancreatic adipocytes have a negative paracrine 
effect on β-cells. Alternatively, NAFPD and T2D are both consequences of 
obesity, and that NAFPD is not involved in the pathogenesis of T2D. 
Pancreatic steatosis is present in the pre-diabetic phase and the amount of 
pancreatic fat increases before T2D occurs63. Moreover, in patients with 
impaired fasting glucose and impaired glucose tolerance, pancreatic fat is 
negatively associated with insulin secretion (P<0.03), which suggests that 
β-cell dysfunction is present in these individuals64. This finding was 
confirmed by Tushuizen et al. who found a negative correlation between 
NAFPD and β-cell function in non-diabetic individuals (P<0.01)65. However,  
there is insufficient evidence available to define a causal relationship 
between NAFPD and T2D; the inactive role of NAFPD in the pathogenesis 
of T2D is still to be proven66. 
 
1.5.3 Homeostasis model assessment of pancreatic β-cell function and 
insulin resistance 
Homeostasis model of assessment (HOMA) equations were based on 
physiological studies which identified a feedback loop between the liver and 
pancreatic β-cells which balances insulin secretion and hepatic glucose 
output67. Theoretically it is therefore possible to compute steady-state insulin 
and glucose concentrations and therefore estimate pancreatic β-cell function 
and insulin resistance. The original model was calibrated to give normal 
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pancreatic β-cell function of 100% and normal insulin secretion of 168. 
However, the original model did not account for differences between hepatic 
and peripheral insulin resistance, increases in insulin sensitivity or decreases in 
hepatic glucose production for plasma glucose concentrations above 
10mmol/L, renal glucose losses or the contribution of circulating pro-insulin.  
 An updated HOMA model (HOMA 2) has since been created, however, it 
is a computer model and has not a simple equation but does account for the 
aforementioned variation. It models insulin sensitivity (HOMA2-S%) where 
100% is normal (which is the reciprocal of insulin resistance(100/S%)). In 
addition, the original model uses equations that were calibrated to insulin 
assays used in the 1970’s which result in underestimation of insulin resistance 
and overestimation of pancreatic β-cell function. Although the gold standard for 
assessing insulin resistance remains the hyperinsulinaemic glucose clamp, it is 
not feasible to use it in large scale population studies. There is good correlation 
between estimates of insulin resistance derived from HOMA and from the 
euglycemic clamp (Rs= 0.88, P<0.0001; Rs = 0.85, P<0.0001; and r=0.73, 
P<0.001) and between HOMA and the minimal model (r=0.7, P<0.001)69,70.  
 
1.6 LIFESTYLE RISK FACTORS FOR T2D 
1.6.1 Obesity 
The WHO defines overweight and obesity as abnormal or excessive fat 
accumulation that may impair health. Body mass index (BMI) is used to classify 
overweight and obesity in adults; BMI greater than or equal to 25kg/m2 is 
overweight and BMI greater than or equal to 30 kg/m2 is obese. Central 
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adiposity is defined using gender specific cut-offs for waist-to hip ratio (WHR); 
Men WHR>0.9 and women WHR>0.8571.  
 
1.6.1.1 Obesity and T2D  
The prevalence of obesity has increased sharply in the last decades, not 
only in industrialized countries but also in developing regions. In 2008, an 
estimated 1.46 billion adults (1.41-1.51 billion) worldwide had BMI of 25 kg/m2 
or greater, of these 205 million men (193-217 million) and 297 million women 
(280-315 million) were obese7. The positive association between obesity and 
risk of developing T2D has been observed both in cross‐sectional studies and 
in prospective data sets72-76. Amongst European populations, obese individuals 
have ~10-fold higher risk of T2D, compared to non-obese. In the Nurses’ 
Health Study (NHS), following adjustment for age, family history of T2D, 
smoking, exercise, and several dietary factors, the relative risk of T2D for the 
90th percentile versus the 10th percentile of BMI was 11.277. Similarly in the 
Health Professionals study (HPS), a strong association between BMI and risk 
of T2D was demonstrated78. Men with a BMI of 35 kg/m2 had a relative risk of 
42.1 (95% C.I. 22.0 – 80.6) for T2D compared with men with a BMI <23.0 
kg/m2, following adjustment for smoking, family history of T2D, and age.  
 
1.6.1.2 Interventional studies 
Evidence from randomized controlled trials demonstrates that lifestyle 
intervention to lose weight results in prevention of obesity and T2D. The 
Finnish Diabetes Prevention Study (DPS)79 and the US Diabetes Prevention 
Program (DPP)35 independently reported reduction in T2D incidence of 58% 
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accompanied by significant reduction in body weight (5-7%) as a result of 
lifestyle modification. These findings were also confirmed in Japanese and 
Indian populations, reporting 67.4% and 28.5% reduction in T2D incidence, 
respectively80,81. Recent findings of bariatric surgery treatment of very obese 
subjects showed that weight loss reduces not only T2D risk but also total 
mortality82.  
1.6.1.3 Mechanisms linking obesity with T2D 
The influence of obesity on T2D risk is determined by degree of obesity 
as well as distribution of body fat. Increased upper body fat including visceral 
fat accumulation, reflected as increased waist-to-hip ratio, is associated with 
T2D, T2D-related metabolic disturbances, and cardiovascular disease83-87. 
Studies that have quantified the amount of fat in subcutaneous and visceral 
adipose depots with computer tomography (CT) or magnetic resonance 
imaging (MRI) have demonstrated that centrally located visceral fat has more 
influence on insulin resistance than does centrally located subcutaneous 
fat88,89. Furthermore, the amount of visceral adipose tissue has been shown to 
predict fasting insulin levels, as well as insulin and glucose responses to oral 
glucose loads, independent of both the degree of obesity and the amount of 
subcutaneous abdominal fat90.  
Three distinct mechanisms have been proposed to link obesity to insulin 
resistance and predispose to T2D: 
1. Increased production of adipokines/cytokines, including tumour necrosis 
factor-α, resistin, and retinol-binding protein-4, that contribute to insulin 
resistance as well as reduced levels of adiponectin91. 
2. Ectopic fat deposition: is defined as storage of triglycerides in tissues 
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other than adipose tissue, such as the liver, skeletal muscle, heart, and 
pancreas. Ectopic fat deposition interferes with organ function and is 
associated with insulin resistance92.  
3. Mitochondrial dysfunction, evident by decreased mitochondrial mass 
and/or function. Mitochondrial dysfunction may be linked to obesity and 
diabetes, by decreasing insulin sensitivity and by compromising β-cell 
function93. 
1.6.1.4 Obesity as risk factor for T2D amongst Indian Asians  
  In 2004 the WHO recommended revised BMI cut-off points for the 
classification of overweight (23 kg/m2) and obesity (27.5 kg/m2) in Indian Asian 
populations. However, further evidence suggests that these revised 
categorisations may still under represent the risk of cardiometabolic disease in 
Indian Asians. A recent consensus statement advised that BMI cut-off points for 
overweight and obesity should be lowered to 23 kg/m2 and 25 kg/m2 
respectively for Indian Asians94. 
Compared to Europeans, Indian Asians have higher WHR for any given 
level of body mass index7,95-99. The superficial adipose tissue compartment, 
mainly in the lower part of the body is smaller in Indian Asians and is exhausted 
earlier in its storing capacity when an Indian Asian becomes obese100. This 
leads to overflow and deposition of fat in metabolically active secondary 
compartments of the upper body part, mainly around abdominal area and 
subsequently in ectopic sites such as liver and skeletal. The excess amount of 
intracellular fat tissue in these cells then interferes with insulin signalling 
leading to insulin resistance and associated adverse metabolic effects. 
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Histological studies of subcutaneous adipose tissue have shown Indian 
Asians have larger adipocytes compared to Europeans at comparable levels of 
total body fat, and comparable intra-abdominal fat and subcutaneous 
abdominal fat. Increased adipocyte size in Indians Asians is inversely 
correlated to glucose disposal rate and plasma adiponectin concentrations101. 
Increased subcutaneous abdominal adipocyte size independently predicts 
insulin resistance and T2D. Weyer et al. demonstrated that mean adipocyte 
size was 11 and 19% higher in subjects with IGT and T2D, respectively, as 
compared with normoglycemic individuals, independent of insulin resistance102. 
Furthermore, in normal subjects, 33% of those who developed T2D, enlarged 
mean subcutaneous abdominal adipocyte size, but not high percent body fat, 
was an independent predictor of T2D.  
 
1.6.2 Physical activity 
Physical activity is defined as bodily movement produced by the 
contraction of skeletal muscle that requires energy expenditure in excess of 
resting energy expenditure. Exercise, a subset of physical activity, is defined as 
planned, structured, and repetitive bodily movement performed to improve or 
maintain one or more components of physical fitness103. Physical activities are 
often classified into domains that reflect the purpose of the activity. A common 
four-category classification for physical activity is104 : 
1. Occupational (work-related). 
2. Domestic (housework, yard work, physically-active child care, chores). 
3. Transportation (walking or bicycling for the purposes of going 
somewhere). 
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4. Leisure-time (discretionary or recreational time for hobbies, sports, and 
exercise). 
1.6.2.1 Assessment of physical activity 
The four main facets of physical activity are frequency, intensity, time, 
and type; these need to be measured in order to arrive at an accurate 
assessment of an individual’s overall activity level105:  
1. Type of activity. 
2. Frequency of the activity. How often is the activity done per day or per 
week?  
3. Intensity: is the activity enough to get the person warm and slightly out 
of breath (to signify moderate intensity activity) or out of breath and 
sweaty (vigorous activity). 
4. Time: for how long is the individual active?  
Exercise intensity is typically measured in kilocalories burned per minute 
of activity or in metabolic equivalent (MET), deﬁned as the ratio of the 
metabolic rate during exercise to the metabolic rate at rest106. Moderate-
intensity activities, such brisk walking, are those that expend 3-6 METs; 
vigorous activities, such as running, are those that expend >6 METs107.  
 
1.6.2.2 Physical activity and T2D risk 
It is well established that reductions in physical activity increase the risk 
of T2D in all ethnic groups108,109. Cohort studies among European populations 
consistently demonstrate that physical activity is inversely correlated with T2D 
in men and women. In the Health Professionals Follow-up Study, which 
examined ~8k male health professionals aged 40 – 75 years for 10 years, each 
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10 MET-hour increment in weekly walking energy expenditure was associated 
with a 11% reduction in T2D risk; an equivalent increase in weekly vigorous 
activity conferred a 12% reduction in T2D risk110. Among ~70,000 initially 
healthy US women participating in the Nurses’ Health Study, walking briskly for 
at least 2.5 hours per week was associated with 25% reduction in T2D over 8 
years of follow-up after adjustment for age, body mass index (BMI), and other 
risk factors for T2D111. Data from some prospective studies that included both 
male and female participants suggest that the inverse association between 
physical activity and risk of T2D may be stronger for women than for men112, 
though the reasons for this are not clear.  
 
1.6.2.3 Interventional studies  
Interventional studies clearly demonstrate the beneficial effects of 
lifestyle modification including increased levels of physical activity on reduction 
of T2D risk. In the US Diabetes Prevention Program, study participants were 
randomized to lifestyle-modification program (with the goals of at least a 7% 
weight loss and ≥150 minutes of physical activity per week), metformin, or 
placebo35. After an average follow-up of 2.8 years follow-up, the incidence 
of T2D was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, 
metformin, and lifestyle groups, respectively. Lifestyle intervention reduced the 
incidence of T2D by 58% (95% CI: 48 - 66) and metformin by 31% (95 % CI: 17 
to 43), compared with placebo. The investigators concluded that lifestyle 
intervention was significantly more effective than metformin at reducing risk of 
T2D.  
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In the Finnish T2D Prevention Study, 522 middle-aged, overweight men 
and women with IFG were randomly assigned to an intensive lifestyle 
intervention designed to promote healthy eating and exercise patterns or to a 
control group79. Members of the diet and exercise intervention group lost more 
weight than controls (3.5 vs. 0.8 kg) and reduced their risk of developing T2D 
by 58% over 3 years. Improvements in exercise reduced risk of T2D even when 
participants did not attain the weight loss goal.  
 
1.6.2.4 Government recommendations for physical activity 
In 1995 the recommendation by the Centres for Disease Control and the 
American College of Sports Medicine was that adults should engage in 30min 
of moderate-intensity physical activity on most days of the week (450 Met-
mins per week)107.  
 
1.6.2.5 Physical activity amongst Indian Asians and T2D risk 
Among native Indian Asians, data from the National Urban Diabetes 
Survey identified physical inactivity and unemployment as independent 
predictors of T2D risk113. Compared to those residing in rural districts, low 
levels of physical activity have been reported amongst Indian Asian urban 
inhabitants. The effect of urbanization and associated changes from labour-
intense to sedentary occupations are thought to contribute to T2D risk. 
Available data suggests that Indian Asians residing in the UK exhibit 
lower levels of physical activity compared to other ethnic groups. A systematic 
review of studies describing levels of physical activity and fitness in UK Indian 
Asians identified 12 studies examining physical activity in adults. The 
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differences in physical activity levels in Indian Asians, compared with general 
the population, were substantial; Indian Asian groups reported physical activity 
levels that were 50 – 75% lower than those of Europeans114. Investigators from 
the Health Survey for England compared levels of leisure time physical activity 
(LTPA) among the ethnic groups115. Total energy expenditure from physical 
activity was 60% lower in UK Indian Asians than Europeans (973 versus 1465 
MET-mins/week, P<0.001) even after adjustment for age, sex, education, 
adiposity and self-reported health variations. There was evidence for 
heterogeneity in profiles of exercise across India Asian subgroups, with Indians 
engaging in more exercise than Pakistanis and Bangladeshis. Indian Asians 
who were born in the UK reported higher levels of physical activity than those 
born elsewhere. 
In the Newcastle Heart Project, Hayes et al. reported reduced levels of 
physical activity and physical fitness among all Indian Asian sub-groups 
compared to Europeans; lowest levels were observed in women, the elderly 
and among persons of Pakistani and Bangladeshi descent116. Socio-economic 
factors, thought to influence participation in physical activity, were cited as 
possible reasons underlying these differences. Hayes et al. were unable to 
correlate their LTPA index with biological risk markers of T2D amongst Indian 
Asian men and women. A lack of association was thought to reflect language 
barriers, cultural differences, and limitations of questionnaire-based tools to 
capture fully complex behaviours such as physical activity amongst Indian 
Asians.  
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1.6.2.6 Intervention studies amongst Indian Asians 
Trials investigating the contribution of lifestyle interventions on T2D risk 
among Indian Asians show that healthy diet and increased levels of physical 
activity are as important as pharmacotherapy for attenuating T2D risk in this 
population. The Indian Diabetes Prevention Program (IDDP) randomized 531 
South Indian adults (421 men and 110 women) aged 35 to 55 years with IGT to 
one of four study arms: standard health advice (control arm); lifestyle 
modification; metformin, or lifestyle modification plus metformin81. Compared to 
the control arm, there was a 28.5% relative reduction in T2D incidence in the 
lifestyle modification arm, a 28.2% reduction in the lifestyle-plus-metformin arm, 
and a 26.4% reduction in the metformin arm. A pooled analysis of participants 
in the IDPP and the IDPP-2 (which compared the IDPP lifestyle intervention 
with placebo or pioglitazone) studies confirmed that lifestyle intervention was 
equally effective for T2D risk reduction in participants with isolated IGT and 
those with both IGT and IFG. The IDPP intervention was shown to be cost 
effective and efficient for T2D prevention in India; the number of individuals 
needed to treat to prevent one case of T2D was 6.4.  
 
1.6.2.7 Mechanisms for the protective effect of physical activity on risk of 
T2D 
Regular physical activity reduces risk of CHD and T2D through a range 
of mechanisms including reduced adiposity, improved endothelial function, 
improved lipid and glucose profiles and lowering blood pressure117. Exercise 
decreases concentrations of fatty acid metabolites, which decreases the risk of 
fatty acid-induced insulin resistance and stimulates the translocation of glucose 
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transporter type 4 to the plasma membrane, thereby improving glucose 
uptake118.  
 
1.6.3 Dietary factors 
Diet and nutrition are widely regarded as important determinants of T2D 
risk119, though specific dietary factors have not been clearly defined. Most of 
the earlier cohort studies did not observe associations between diet and 
incidence of T2D (table 1.6). More recent studies, using validated food 
frequency questionnaires and repeated measures and with large sample size, 
are more powerful to examine the association between diet and T2D.  
 
1.6.3.1 Methods for assessing dietary patterns 
Most commonly used methods for estimating diet composition have 
been weighed 7-day diaries and food frequency questionnaires. Although many 
food-frequency questionnaires have been validated, they suffer from 
considerable measurement error that can profoundly affect the analysis and 
interpretation of studies in the relationship of nutrition with disease states120,121. 
Studies involving biomarkers that represent valid reference measurements 
(such as doubly labelled water for measuring energy expenditure and urinary 
nitrogen for measuring protein intake) confirm biased reporting on food records 
or recalls towards under-reporting122. In addition diet-reporting tools are limited 
by food composition databases, which are recognised to be poorly 
representative of Indian Asian foods, and even among Europeans are based 
mainly on historical chemical analysis dating back several decades, and thus 
may not accurately reflect more recent dietary habits121.  
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1.6.3.2 Dietary fat and risk of hyperglycaemia and T2D 
Dietary fats are classified as polyunsaturated, monounsaturated and 
saturated on the basis of their chemical structures. Early epidemiological 
studies reported that total fat intake was positively associated with risk of 
T2D123. In these studies animal fat was shown to be associated with greater 
risk of T2D than vegetable fat. In the San Luis Valley Diabetes Study, 134 
subjects with IGT were followed for 3 years; fat consumption in those who 
developed T2D was 43.4% total energy intake compared with 40.6% in those 
who still had IGT and 38.9 % in those who reverted to normal glucose 
tolerance124-126. 
More recent prospective and cross-sectional studies suggest a role of 
specific types of fat, rather than total fat, and development of T2D. After 14 
years of follow-up, results from the Nurse’s Health Study demonstrated that 
increased intake of vegetable fat and polyunsaturated fat (PUFA) were 
associated with decreased risk of T2D, independent of BMI, physical activity, 
alcohol intake, cigarette smoking, family history of T2D, total energy intake, or 
intake of other fats127. They found no association between total fat, 
monounsaturated fat or saturated fat intake and incidence of T2D. 
 
1.6.3.2.1 Polyunsaturated fatty acids and T2D 
Association of polyunsaturated fatty acids (PUFA) with T2D is 
inconsistent. In an Italian study, higher consumption of PUFA was associated 
with lower fasting plasma concentrations of glucose128. In contrast, one study 
reported a positive association between polyunsaturated fat intake and 
hyperglycaemia in men128, although no association was observed in women129. 
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In other studies, polyunsaturated fat was not associated with hyperglycaemia or 
with incidence of T2D in men130.  
Data from prospective studies indicate that n-6 PUFAs, which are found 
primarily in plants, have beneficial effects on insulin sensitivity131 and are 
associated with reduced risk of T2D 132,133. For n-3 PUFA derived from fish oils, 
prospective cohort studies do not demonstrate an association between long-
chain n-3 fatty acid and T2D 134.  
PUFA may reduce insulin resistance through their anti-inflammatory 
properties, and this action may be mediated through toll-like receptors (TLR)135. 
Long- chain n-3 PUFAs are independently associated with low levels of pro-
inflammatory interleukin-6, interleukin-1ra, tumour necrosis factor-α, CRP and 
high levels of anti-inflammatory cytokines [soluble interleukin-6r, interleukin-10, 
tumour growth factor-α]136. In addition n-3 PUFA have been shown to increase 
leptin and adiponectin expression, leading to improvements in insulin sensitivity 
137. Further effects of PUFA on insulin action include increased fluidity of cell 
membranes and increased binding affinity of the insulin receptor and improved 
glucose transport into cells via glucose transporters138-140. 
 
1.6.3.2.2 Monounsaturated fatty acids and T2D 
Overall, high-monounsaturated fatty acids (MUFA) diets have shown 
beneficial effects in T2D, but their influence on insulin resistance, although 
appearing beneficial, is still inconclusive. A MUFA rich diet is associated with 
significant increases in insulin sensitivity with modest total fat intake in healthy 
subjects. MUFA-rich diets lower mean plasma glucose and plasma triglyceride 
levels and reduce insulin requirements in patients with T2D. In the Nurses’ 
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Health Study, the relation between MUFA consumption and T2D risk 
disappears after adjustment for body mass index and other covariates127. 
However, interventions such as the KANWU study have shown that substituting 
MUFA for saturated fatty acids has beneficial effects on insulin sensitivity in 
glucose intolerant141 or healthy subjects 142. In general MUFAs are generally 
regarded as useful fat sources, especially for subjects with an ‘insulin-resistant 
phenotype’134.  
An increase in insulin sensitivity induced by MUFA-rich diets may be due 
to their effects on gastric emptying and increased basal glucose uptake 
mediated by increased levels of glucagon-like peptide-1143. In addition up-
regulation of glucose transporters GLUT1 and GLUT4 by MUFA leads to 
increased basal glucose uptake144. In insulin-resistant individuals, an isocaloric 
MUFA-rich diet prevents central fat redistribution, postprandial decrease in 
peripheral adiponectin gene expression and insulin resistance induced by a 
carbohydrate-rich diet145. MUFA have additionally been shown to have 
cytoprotective actions in pancreatic β-cells146.  
 
1.6.3.2.3 Saturated fatty acids and T2D 
Saturated fatty acids (SFA) are independent predictors of fasting and 
postprandial insulin concentrations. Two cross-sectional studies and one small 
prospective study suggest a positive association between saturated fat and 
hyperglycaemia or glucose intolerance147,148. Large cohort studies report that 
SFA are directly associated with incidence of T2D. The KANWU study141, which 
compared an SFA-rich diet with diets high in MUFAs, showed that SFA 
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consumption leads to a 10% decrease in insulin sensitivity, whereas no change 
was observed with the MUFA-enriched diet.  
Several mechanisms have been proposed for the action of SFA on risk 
of T2D and related metabolic disturbances. Saturated fats have been shown to 
affect cell membrane’s lipid composition by inducing changes in the membrane 
microenvironment, and interact with membrane proteins such as the insulin 
receptor149,150. SFAs also influence key intracellular enzymes and transcription 
factors involved with glucose metabolism151. SFA-rich diets increase 
intramyocellular lipid content, leading to activation of specific serine kinases 
which reduce insulin-dependent glucose transporter type 4 (GLUT-4) 
translocation and glucose uptake151.  
Glucolipotoxicity, the deleterious effects of hyperglycaemia and fatty 
acids on pancreatic β-cells, is mediated primarily by SFA both in vitro and in 
vivo models152-155. A further potential mechanism is endoplasmic reticulum 
stress leading to sterol-regulatory element-binding protein-1 activation156, which 
has also been proposed as a mechanism linking high-fat-diet-induced obesity 
with insulin resistance. Finally, SFA may differentially affect inflammatory 
pathways, which are tightly related to impaired insulin sensitivity157.  
 
1.6.3.2.4 Trans fatty acids and T2D 
Trans-fatty acids (TFA) are formed when vegetable or fish oils are 
hardened by partial hydrogenation158. Dietary TFA intake has been associated 
with dyslipidaemia and increased risk of T2D. In the Nurses' Health study, 
comparing the highest quintile of intake (median 2.9 % energy) with the lowest 
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quintile (median 1.3% energy), high intake of trans-fatty acids were associated 
with a 30% increased relative risk of T2D159.  
Interventional studies investigating influence of dietary TFA on insulin 
resistance in healthy subjects are limited. Studies in rats have shown that TFA 
induces insulin resistance, when compared with low-fat 160 or even SFA-rich 
diets 161,162. A 6-year randomized controlled trial in non-human primates 
evaluated diets containing 8% total energy from either TFA or MUFA163. TFA 
diet was associated with significantly elevated fructosamine (a circulating 
marker of hyperglycaemia), markedly reduced insulin sensitivity in muscle, 
unaccounted for by changes in weight. It is unclear whether these mechanisms 
are applicable to humans. 
 
1.6.3.3 Carbohydrate and T2D 
Traditionally, carbohydrates are classified as monosaccarides, 
oligosaccharides and polysaccharides on the basis of chemical structures164. 
High intake of carbohydrate may lead to hyperinsulinaemia, high serum 
triglycerides and low HDL-cholesterol levels associated with insulin resistance. 
Several epidemiologic studies have examined total amount of carbohydrate 
and traditional classifications of carbohydrates in relation to hyperglycaemia or 
risk of T2D. In general, neither total carbohydrate nor intake of simple sugars 
such as sucrose predicts future risk of T2D165.  
 
1.6.3.4 Dietary fibre and T2D 
Large prospective studies such as the Nurses’ Health Study I and II, the 
European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam 
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study, and the Finnish Diabetes Prevention Intervention Study have shown that 
high intakes of dietary fibre are consistently associated with reduced incidence 
of T2D166,167. This association persists after controlling for confounders such as 
age, education, body mass index, waist circumference, whole-energy intake, 
physical activity, and alcohol consumption.  
The mechanisms by which fibres achieve their effects have not been 
confirmed. A number of potential mechanisms have been proposed including 
the beneficial effects on satiety and body weight, dilution of energy density, 
reduction of postprandial glycaemic and insulin levels, reduction of postprandial 
lipaemia and fasting blood lipids, interactions with incretins and other 
gastrointestinal hormones, reduction of low-grade inflammation, effects 
mediated through colonic fermentation and others168. 
 
1.6.3.5 Protein intake and T2D 
Data from cross-sectional studies demonstrate that high intake of dietary 
protein is associated with insulin resistance and glucose intolerance169.  
Prospective studies indicate that high protein intake increases incidence of T2D 
170,171. In particular, increased consumption of red meat, especially processed 
meat, is positively correlated with T2D171. One study reported increased T2D 
risk with higher animal protein intake and no association with vegetable protein 
intake172.   
Despite findings from epidemiological studies, intervention studies have 
consistently demonstrated improvements in glycaemic control in parallel to 
augmented weight loss during high-protein intake173,174. Reasons for 
contradictory results from short-term dietary interventions are not clear, but 
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may be attributed to limitations of study design including poor compliance, 
small group size and short duration of dietary intervention studies.  
Several mechanisms have been proposed to explain the relationship 
between protein intake and T2D175. Experimental amino acid infusion directly 
induces insulin resistance and stimulates endogenous glucose production. 
Insulin resistance arises as amino acids can inhibit glucose transport and 
phosphorylation, leading to impaired glucose synthesis. Furthermore, amino 
acids disrupt glucose metabolism by stimulating insulin and glucagon secretion 
and by serving as substrates for gluconeogenesis.  
 
1.6.3.6 Recommended dietary nutrient intake 
Dietary recommendations are that between 45–65% of energy intake 
should be derived from carbohydrates, 20–30% from fat and 10–35% from 
protein, with a maximum of 25% of total energy from added sugars176. 
 
1.6.3.7 Dietary patterns amongst Indian Asians and association with T2D 
1.6.3.7.1 Dietary saturated fatty acids  
Yagalla et al. reported an average energy intake of 8% from SFA of total 
energy intake among migrant Indian Asians in the US177, while mean SFA 
intake was 6.5% in adult city dwellers living in India96. High intakes of SFA were 
reported to be independently associated with increased subclinical 
atherosclerosis among migrant Indian Asians living in Canada, but association 
with T2D risk has not been demonstrated96.  
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1.6.3.7.2 Polyunsaturated fatty acids  
Sevak et al. showed that Indian Asians consumed significantly lower n-3 
PUFA (0.08 v. 0.13% energy; P=0.02), but higher n-6 PUFA (5.4 v. 5.0% 
energy, P=0·05) than Europeans in the UK178. Lovegrove et al. have also 
reported similar findings, in addition to a significantly higher dietary n-6:n-3 
PUFA ratio in diets of UK Indian Asians compared to Europeans (11.2 v. 6.7, 
P<0.001)179. Intervention studies with n-3 PUFA amongst Indian Asians have 
not demonstrated a role for n-3 PUFA supplementation and reduced T2D risk. 
Long-chain n-3 PUFA supplementation in Europeans and Indian Asians in the 
UK, showed no effect on insulin sensitivity179.  
 
1.6.3.7.3 Dietary monounsaturated fatty acids  
Sevak et al. showed lower dietary intake of MUFA (% of energy) in 
Indian Asians compared to Europeans (11.9 v. 14.7, P<0·001) in the UK180. 
Indian Asians belonging to low socio-economic groups in India consumed low 
MUFA (% of energy): males, 4.7%; females, 5.7%. In Rajasthan, the daily 
intake of MUFA (% energy) was higher in illiterate individuals than in educated 
individuals (15.6 v 8.6, respectively; P<0·05). In South India, however, the 
middle-income group consumed higher MUFA (11.9g/d) compared to the low-
income group (8.5 g/d)178.  
 
1.6.3.7.4 Trans fatty acids 
Previous work has shown that Indian Asian diets may be high in TFA. 
However, there is little data on the association of trans fatty acids and T2D 
amongst Indian Asians96.  
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1.6.3.7.5 Dietary carbohydrates  
Indian Asians residing in the Indian subcontinent consume relatively 
more carbohydrates (as percentage of total energy, ~ 60-67%), compared with 
the migrant Indian Asians in the UK (~46%)96,181. Burden et al. reported higher 
carbohydrate content (% energy) in an Indian Asian meal (45%) than in a 
European meal (25%)182. In a UK study investigating dietary habits of Indian 
Asians, a ‘typical’ Indian Asian vegetarian diet as compared with a ‘typical’ 
European diet induced higher and more prolonged rises in mean plasma 
glucose levels (5.29 v. 4.32mmol/l, P<0.02) and higher 2-hour postprandial 
insulin levels (28.2 v 8.1mU/l; P<0.02). Sevak et al. showed that total 
carbohydrate and sucrose contents of diets were positively correlated with 
postprandial hyperinsulinaemia amongst Indian Asians residing in the UK, but 
no association with T2D180. 
 
1.6.3.7.6 Fibre 
Few studies in India have reported data on fibre intake. Poor intake of 
fruit and vegetables resulting in low fibre intake was reported in subjects 
residing in West Bengal, India (reported as crude fibre intake; 5.7g/day)183 and 
in an urban slum population in North India (reported as crude fibre intake; 
males, 8.5 g/day; females, 4.1 g/day)183. Studies in rural populations in India, 
have shown a poor intake of fruits and vegetables. In migrant Indians Asians, 
fibre intake has been reported to be low, particularly in vegetarians184. Data 
regarding interventions with high-fibre diets among Indians Asians is limited.  
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1.7 GENETIC RISK FACTORS FOR T2D 
T2D has a major genetic component. Twin studies show high 
concordance for T2D in monozygotic twins (0.29 to 1.00), with 50% lower 
concordance rates in dizygotic twins (0.10 – 0.43)185. Family studies indicate 
nearly 4-fold increased risk for T2D in siblings of a diabetic proband compared 
with the general population186. 
 
1.7.1 Genetics of T2D in the pre-genome wide association era 
Linkage studies were initially used to identify genes associated with 
T2D. This technique was successful in indentifying rare genetic variants with 
strong effects for disorders such as maturity-onset diabetes of the young. 
However, linkage analysis proved less effective in identifying common variants 
with small effects that underlie a large proportion of the genetic risk of T2D.  
Before the advent of whole genome scans, candidate gene approaches 
were used to evaluate the association of genetic loci with T2D. PPARG, 
TCF7L2, and KCNJ11 were identified as plausible biological candidates and 
robust associations were demonstrated with T2D187-189. However, the candidate 
gene approach yielded disappointing results for several reasons including 
limitations posed by inadequately powered studies to detect effect sizes of the 
order of 1.1 to 1.5; candidate genes studied were selected on the basis of 
limited knowledge of underlying pathophysiology; poor appreciation of the 
architecture of genetic variation; liberal cut-offs for statistical significance; and 
over-interpretation of experimental findings.  
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1.7.2 Genome-wide association studies in T2D 
Genome-wide association studies have advanced understanding of the 
genetic basis of complex diseases including T2D. The first round of GWA 
studies for T2D were carried out exclusively in populations of European 
descent. Sladek et al. published the first GWAS for T2D in 2007190. They 
reported four novel associations for eight different SNPs at five distinct genetic 
loci with T2D: TCF7L2, SLC30A8, HHEX, LOC387761 and EXT. As proof of 
concept they confirmed the previously known association of TCF7L2 with T2D. 
Following this landmark study, three additional GWAS were published by 
the Diabetes Genetics initiative, the Wellcome Trust Case Control Consortium, 
and the Finland–United States investigation of non-insulin- Dependent 
Diabetes Mellitus Genetics (FUSION) research groups191-193. This work 
confirmed previously reported associations between T2D and TCF7L2, 
KCNJ11, and PPARG, as well as HHEX and SCL30A8. Furthermore they 
reported the discovery of CDKAL1, IGF2BP2 and CDKN2A/B as novel loci in 
association with T2D.  
To increase power to detect further T2D loci of modest effect size, a 
collaboration was formed comprising the FUSION group, the Wellcome Trust 
Case Control Consortium, and the Diabetes Genetics initiative, under the 
collective name of Diabetes Genetics replication and Meta-analysis 
(DIAGRAM) study194. Data from ~10k participants were combined and SNP 
coverage was extended to 2,000,000 by imputing untyped SNPs on the basis 
of patterns of haplotype variation from HapMap. This led to the discovery of six 
additional loci that harbour common genetic variants that influence T2D 
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susceptibility (JAZF1, CDC123-CAMK1D, TSPAN8-LGR5, THADA, ADAMTS9 
and NOTCH2- ADAM30).  
The DIAGRAM+ consortium has carried out the largest meta-analysis for 
T2D to date. They combined genome-wide association data for 8130 T2D 
cases and 38,987 controls from eight cohorts of European descent195. SNPs 
from 23 autosomal regions and one signal on the X chromosome were followed 
up in a second round of replication. Novel associations were identified at 
BCL11A, ZBED3, KLF14, TP53INP1, CHCHD9, KCNQ1, CENTD2, HMGA2, 
HNF1A, ZFAND6, PRC1 and DUSP9. The signal at KCNQ1 is independent 
from the previously identified signal in East-Asian samples. Overall, 14 SNPs 
achieved genome-wide significance, of which, two had been previously 
reported (MTNR1B, IRS1)196. 
Genetic studies of continuous glycaemic traits by the Meta-Analyses of 
Glucose and Insulin related traits (MAGIC) collaboration have reported 7 loci in 
association with elevated levels of fasting glucose that also confer increased 
risk for T2D197. These include two loci in the known T2D susceptibility genes 
TCF7L2 and SLC30A8, and five newly discovered associations for loci in or 
near ADCY5, GCK, GCKR, PROX1 and DGKB- TMEM195.  
 
1.7.3 Genome-wide association studies in non-European populations 
Following the success of genetic studies among Europeans, two 
independent GWAS carried out in Japanese T2D cohorts provided clear 
evidence of the value of extending the search for complex-trait associations 
beyond the current focus in Europeans, to populations with different genetic 
structure. Both groups independently identified KCNQ1, which encodes the 
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pore-forming α-subunit of the voltage-gated potassium channel KvLQt1, as a 
T2D risk locus amongst persons of East Asian ancestry198,199 Further GWA 
studies in larger East Asian collaborations have identified 8 further genetic risk 
factors in this ethnic group200-203.  
In summary GWAS has provided deeper insights into the mechanisms 
underlying T2D. Majority of T2D genetic variants discovered so far have been 
common with small effects, and together, the loci explain ~10% of observed 
familial clustering in Europeans195. The role of T2D genetic variants amongst 
Indian Asians has not been fully investigated.  
 
1.7.4 Mechanism of action of reported T2D common genetic variants 
Most of genetic loci discovered to date appear to exert their deleterious 
effects either through pancreatic β-cell dysfunction or via disruption of the cell 
cycle56 (table 1.7). Other than PPARG, FTO and IRS1, none of the identified 
loci are associated with insulin resistance. Potential reasons underlying a lack 
of insulin resistance loci identified through GWAS include; deliberate matching 
of cases and controls for BMI; lower heritability of insulin resistance traits; 
variants that affect insulin resistance may be less frequent in the population 
and may have modest effect sizes; and current measures of insulin sensitivity 
may be poorly correlated with insulin resistance at the tissue or molecular level. 
The discovery of novel T2D genetic variants has also shed light on the 
pleiotropic effects of these loci on other quantitative traits/ diseases. Loci near 
ADCY5, BCL11A, ZBED3, KLF14, CHCHD9, HMGA2, HNF1A and PRC1 also 
exhibit independent associations with phenotypes other than T2D, such as 
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adult height (HMGA2)204, basal cell carcinoma (KLF14)205, low-density 
lipoptrotein cholesterol (HNF1A)204 and birth weight (ADCY5)206.  
 
1.7.5 Contribution of genetic factors to risk of T2D amongst Indian Asians  
There are no previous twin studies carried out among Indian Asians, and 
therefore the heritability of T2D is not known in this ethnic group. Researchers 
have attempted to test previously reported T2D common genetic variants (not 
all) discovered in GWAS, among Indian Asian T2D cases and controls (table 
1.8). Sanghera et al. confirmed association of PPARG2, IGF2BP2, TCF7L2 
and FTO with T2D, but were unable to demonstrate significant associations for 
variants in IGF2BP2, CDK5, SLC30A8, CDKN2A, HHEX with T2D in this 
cohort207. Following this, Yajnik et al. replicated the strong association of FTO 
variants with T2D amongst Indian Asians, and showed that this relationship 
may not be entirely mediated through BMI, implying differences between 
Indians and Europeans underlying mechanisms linking body size with T2D208.  
In the largest Indian Asian-centric study to date, Chauhan et al. 
confirmed associations of common variants in PPARG, KCNJ11, TCF7L2, 
SLC30A8, HHEX, CDKN2A, IGF2BP2 and CDKAL1 with T2D among 5164 
Indians of Euro-Indian descent209. Furthermore, their association analyses 
demonstrated larger effect sizes for most of the T2D susceptibility loci than 
those reported in Europeans. Additionally, this group investigated the functional 
role of reported T2D loci amongst Indian Asians. They demonstrated significant 
association of PPARG and TCF7L2 with homeostatic pancreatic β-cell function 
(HOMA- B) among Indian Asians. The mechanism of action of other common 
genetic variants in this high-risk ethnic group is not known.  
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To date, 49 common genetic variants have been identified in association 
with T2D among persons of European and East Asian ancestry. These genetic 
factors have not been assessed in a single population or in the setting of a well-
powered study; the role of previously reported genetic loci as risk factors for 
T2D among Indian Asians merits further work. 
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1.8 STUDY AIM 
To investigate the role of lifestyle and genetic factors on the increased 
risk of type-2 diabetes (T2D) amongst Indian Asians compared to Europeans. 
 
1.8.1 Specific aims 
1. Within the LOLIPOP study, determine the prevalence of T2D in Indian 
Asians compared to Europeans living in UK. 
2. To evaluate the contribution of obesity and physical inactivity on T2D risk 
amongst Indian Asians compared to Europeans.  
3. To investigate the role of dietary nutrients to insulin resistance amongst 
Indian Asians compared to Europeans. 
4. To investigate the contribution of reported genetic risk factors to the risk 
for T2D observed in Indian Asians. 
5. To carry out a three stage genome-wide association and replication 
study among Indian Asians T2D cases and controls to discover novel 
genetic variants underlying T2D in this high-risk ethnic group. 
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Table 1.1: World Health Organisation (WHO) and American Diabetes Association (ADA) definition of T2D. 
Test Criteria for diagnosis of T2D 
 
HbA1c 
 
HbA1c 6.5% (47.5 mmol/mol) 
 
The test should be performed in a laboratory 
using a method that is National Glycohemoglobin 
Standardization Program (NGSP) certified and 
standardized to the Diabetes Control and 
Complications Trial (DCCT) assay. 
 
Fasting plasma 
glucose  
 
Fasting plasma glucose 7.0 mmol/l 
 
Fasting is defined as no caloric intake for at least 
8 hours. 
 
Two-hour plasma 
glucose  
Two-hour plasma glucose 11.1 mmol/l  
 
The test should be performed using a glucose 
load containing the equivalent of 75 g anhydrous 
glucose dissolved in water. 
 
Random plasma 
glucose  
Random plasma glucose 11.1 mmol/l 
 
Valid in patients with classic symptoms of 
hyperglycaemia or hyperglycaemic crisis. 
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Table 1.2: Definition of pre-diabetes by WHO and ADA criteria. 
 
Criteria Criteria for diagnosis of pre-diabetes 
 
World Health Organisation (WHO) 
 
 
Fasting plasma glucose (mmol/L) 6.1 – 6.9 
 
Two hour oral glucose tolerance test (mmol/L) 
 
7.8 – 11.0 
HbA1c (%, mmol/mol) 6.0 – 6.4, 42.1 – 46.4  
  
American Diabetes Association (ADA) 
 
 
Fasting plasma glucose (mmol/L) 
 
5.6 – 6.9 
Two hour oral glucose tolerance test (mmol/L) 
 
7.8 – 11.0 
HbA1c (%, mmol/mol) 5.7 – 6.4, 38.8 – 46.4 
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Table 1.3: Prevalence of T2D amongst native Indian Asians in 2008 (adapted from Danaei et al., 2011). 
 
 Male  Female 
Country Prevalence of T2D (%)  Prevalence of T2D (%) 
India 
 
11.1 (8.1 – 14.4) 
 
 10.8 (7.9 – 14.1) 
Pakistan 
 
11.7 (6.9 – 17.8) 
 
 14.1 (8.5 – 21.1) 
Sri Lanka 9.3 (5.7 – 13.8)  
 
8.6 (5.3 – 12.6) 
 
 
Bangladesh 
 
9.2 (4.9 – 14.8) 
  
9.9 (5.5 – 15.6) 
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Table 1.4: Prevalence of T2D among migrant Indian Asians. 
Author Country N Populations studied Prevalence of  T2D (%) 
Forouhi NG et al., 2006 
Southall and Brent study 
UK 3660 men  
1198 women 
Indian Asian men 
Afro-Caribbean men 
European men 
 
Indian Asian women 
Afro-Caribbean women 
European women 
 
22.0 
10.0 
7.0 
 
15.0 
11.0 
4.0 
 
McKeigue et al., 1991 UK  3754 men and women Indian Asians 
Europeans 
19.0 
4.0 
 
Chambers et al., 2001 UK 1025 men Indian Asians 
Europeans 
 
16.0 
4.0 
Ramaiya KL et al., 1991 
 
Tanzania 1147 men and women 
 
Indian Asians 
 
9.8 
Zimmet P et al. 1983 Fiji 241 men and women 
 
 
 
 
 
 
212 men and women 
Melanesians 
Rural females  
Urban Females  
Rural males 
Urban males  
 
Indians 
Rural females 
Urban Females  
Rural males 
 
1.2  
7.1 
1.1  
3.5 
 
 
11.3  
11.0 
12.1  57 
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Urban males 
 
12.9 
 
Dowse GK et al. 1990 Mauritius 
 
5080 men and women Hindu Indian men 
Hindu Indian women 
 
Muslim Indian men 
Muslim Indian women 
 
Creole men 
Creole women 
 
Chinese men 
Chinese women 
14.0 
10.9 
 
12.7 
13.8 
 
7.7 
13.0 
 
13.5 
9.5 
 
Zheng Y et al., 2012  
Singapore Indian Eye Study  
 
 
Singapore 
 
1839 men and women Indian Asians 1st generation 
Indian Asian 2nd generation 
 
34.4 
29.0 
 
Miller G et al., 1991 
 
Trinidad 1185 men and women 
 
Indian men 
Indian women 
 
European men 
European women 
 
African men 
African women 
 
Mixed descent men 
Mixed descent women 
20.1 
23.4 
 
4.3 
10.5 
 
8.1 
16.7 
 
7.8 
7.5 
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Venkataraman R et al., 2004  US 1046 men and women Indian Asian men 
Indian Asian women 
Indian Asian Overall 
 
22.5 
13.6  
18.3 
Bhopal R et al., 1999 
Newcastle Heart Project 
UK 6448 men and women Indian Asian 
European 
18 
4 
     
Ramachandran A et al. 1991 
San Antonio Heart study 
US  Indian Asian men 
Mexican American men 
Non-hispanic white men 
 
Indian Asian women 
Mexican American women 
Non-hispanic white women 
 
10 
20 
4.5 
 
9 
26 
4 
Cheah J et al., 1979 Singapore 5280 men and women Indian Asians 
Chinese 
Malay 
 
2.76 
0.30 
0.48 
Cruickshank et al., 1980  
 
UK 
 
27,667 men and women Indian Asian men 
European men 
West Indian men 
Other men 
 
Indian Asian women 
European women 
West Indian women 
Other women 
5.0 
1.8 
5.9 
1.9 
 
5.7 
1.9 
8.6 
3.8 
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Table 1.5: Prevalence of self-reported, doctor-diagnosed diabetes in England by minority ethnic group and sex (Adapted from the 
Health Survey for England). 
  
 
 
 
 Prevalence of T2D (%) 
Ethnic minority Men Women 
Bangladeshi 8.2 5.2 
Indian 10.1 5.9 
Pakistani 7.3 8.6 
Black African 5.0 2.1 
Chinese 3.8 3.3 
General population 4.3 3.4 
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Table 1.6: Major prospective studies on dietary macronutrient intake and risk of T2D (FFQ= food frequency questionnaires). 
 
    
 
ASSOCIATION WITH T2D 
 
Study N Follow up (years) Methodology Saturated fat Unsaturated fat Total fat 
 
Carbohydrate 
 
 
Gothenburg 
 
1,462 12 24-hour recall NA NA No No 
 
Zutphen study 
 
841 25 24-hour recall Positive No Positive No 
Nurses’ Health 
study 65,173 6 FFQ Positive Negative No 
 
 Inverse with fibre 
 Positive with 
glycaemic load 
 
Health 
professionals 
study 
42,759 6 FFQ Positive No Positive 
 
 Inverse with fibre 
 Positive with 
glycaemic load 
 
Iowa Women’s 
Health study 35,988 6 FFQ Positive Negative No 
 
 Inverse with fibre 
 No association with 
glycaemic load 
 
ARIC 
12,251 9 
 
FFQ 
Cholesteryl esters 
 
Positive Negative NA 
 
 Inverse with fibre 
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Table 1.7: Common genetic variants discovered to date in association with T2D and their mechanisms of action. 
 
SNP Chm Nearest gene 
Discovery 
population Function 
Mechanism 
in T2D 
rs10923931 1 NOTCH2 European Transmemebrane receptor involved in formation of the 
pancreas. 
 
Beta-cell 
rs340874 1 PROX1 European A co-repressor of HFN4A, involved in beta cell 
development. 
 
Beta-cell 
rs780094 2 GCKR European Regulatory protein that inhibits glucokinase in liver and 
islet cells.  
 
Beta-cell 
rs11899863 2 THADA European Expressed in thyroid adenomas. 
 
Not known 
rs243021 2 BCL11A European C2H2 type zinc-finger protein: Function not known. 
 
Beta-cell 
rs7593730 2 RBMS1 European Member of a small family of proteins, which bind single-
stranded DNA/RNA. These proteins have been implicated 
in DNA replication, gene transcription, cell cycle 
progression and apoptosis. 
 
Insulin resistance 
rs7578326 2 IRS1 European Protein that is phosphorylated by the insulin receptor 
tyrosine kinase. 
 
Insulin resistance 
rs13081389 3 PPARG European Transcription factor involved with adipocyte development. 
 
Insulin resistance 
rs6780569 3 UBE2E2 East Asian Part of the ubiquitin-mediated protein degradation 
pathway. 
 
Not known 
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rs831571 3 PSMD6 East Asian Proteasome 26S subunit, non-ATPase 6: Acts as a 
regulatory subunit of the 26S proteasome which is 
involved in the ATP-dependent degradation of 
ubiquitinated proteins. 
 
 
rs6795735 3 ADAMTS9 European ADAM metallopeptidase with thrombospondin type 1 
motif, 9:  It is a secreted metalloproteinase expressed in 
muscles and pancreas. This gene is localized to 
chromosome 3p14.3-p14.2, an area known to be lost in 
hereditary renal tumors. 
 
Beta-cell 
rs11708067 3 ADCY5 European Adenylate cyclase 5: Protein catalyzes generation of 
cAMP. Involved with insulin secretion. 
 
Beta-cell 
rs1470579 3 IGF2BP2 European Insulin-like growth factor 2 mRNA binding protein 2: 
Functions by binding to the 5' UTR of the insulin-like 
growth factor 2 mRNA and regulating IGF2 translation. 
 
Not known 
rs6815464 4 MAEA East Asian Macrophage erythroblast attacher: mediates the 
attachment of erythroblasts to macrophages presumably 
by suppressing apoptosis. 
 
Not known 
rs1801214 4 WFS1 European Wolfram syndrome 1: Tansmemebrane protein of the 
endoplasmic reticulum. It is expressed with highest levels 
in brain, pancreas, heart, and insulinoma beta-cell lines. 
Mutations in this gene are associated with Wolfram 
syndrome, also called DIDMOAD (Diabetes Insipidus, 
Diabetes Mellitus, Optic Atrophy, and Deafness), an 
autosomal recessive disorder.  
 
Beta-cell 
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rs4457053 5 ZBED3 European Zinc finger, BED-type containing 3: Function unknown. 
 
Not known 
rs10440833 6 CDKAL1 European CDK5 regulatory subunit associated protein 1-like 1: 
Member of the methylthiotransferase family, which inhibits 
CDK5. Islet glucose toxicity sensor. 
  
Beta-cell 
rs9470794 6 ZFAND3 East Asian Zinc finger, AN1-type domain 3: Function unknown. 
 
Not known 
rs1535500 6 KCNK16 East Asian Potassium channel, subfamily K, member 16: Belongs to 
the family of potassium channel proteins containing two 
pore-forming P domains. This channel is an open rectifier, 
which primarily passes outward current under 
physiological K+ concentrations. This gene is expressed 
predominantly in the pancreas and is activated at alkaline 
pH.  
 
Beta-cell 
rs2191349 7 DGKB European Diacylglycerol kinase, beta: Regulator of intracellular 
concentration of diacylglycerol and plays a key role in 
cellular processes. 
 
Not known 
rs849134 7 JAZF1 European JAZF zinc finger 1: Transcriptional repressor associated 
with prostate cancer.  
 
Not known 
rs4607517 7 GCK European Glucokinase (hexokinase 4) Hexokinase: isoenzyme 
which facilitates phosphorylation of glucose. There are 
three tissue-specific forms of glucokinase, one found in 
pancreatic islet beta cells and two found in liver. 
Mutations in this gene have been associated with maturity 
onset diabetes of the young, type 2 (MODY2) and 
persistent hyperinsulinemic hypoglycemia of infancy. 
Beta-cell 
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rs6467136 7 GCC1-PAX4 East Asian  
 
Not known 
rs972283 7 KLF14 European Kruppel-like factor 14: Transcription factor. 
 
Not known 
rs896854 8 TP53INP1 European Tumor protein p53 inducible nuclear protein 1: Function 
unknown. 
 
Not known 
rs3802177 8 SLC30A8 European Solute carrier family 30, member 8: Zinc efflux transporter 
involved in the accumulation of zinc in intracellular 
vesicles. This gene is expressed at a high level only in the 
pancreas, particularly in islets of Langerhans. The 
encoded protein colocalizes with insulin in the secretory 
pathway granules of the insulin-secreting INS-1 cells. 
 
Beta-cell 
rs7041847 9 GLIS3 East Asian GLIS family zinc finger 3:  Repressor and activator of 
transcription and is specifically involved in the 
development of pancreatic beta cells, the thyroid, eye, 
liver and kidney. Mutations in this gene have been 
associated with neonatal diabetes and congenital 
hypothyroidism. 
 
Beta-cell 
rs17584499 9 PTPRD East Asian Protein tyrosine phosphatase receptor type D: Signalling 
molecules that regulate cell growth, differentiation, mitotic 
cycle, and oncogenic transformation.  
 
Not known 
rs10965250 9 CDKN2A/B European Cyclin-dependent kinase inhibitor 2A/2B: Cyclin-
dependant kinase inhibitor involved in islet development. 
 
Beta-cell 
rs13292136 9 CHCHD9 European  Not known 
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rs12779790 10 CDC123 European Cell division cycle 123: Function unknown. 
 
 
rs5015480 10 HHEX European Hematopoietically expressed homeobox: Transcription 
factor involved in pancreatic development.  
 
Beta-cell 
rs7903146 10 TCF7L2 European Transcription factor 7-like 2: Transcription factor which 
plays a key role in the Wnt signaling pathway. Regulates 
genes that encode proglucagon and insulin. 
 
Beta-cell 
rs2334499 11 DUSP8 European Dual specificity phosphatase 8: Phosphotase associated 
with cellular proliferation and differentiation. It is 
expressed in the adult brain, heart, and skeletal muscle 
and is induced by nerve growth factor and insulin. 
 
Beta-cell 
rs231362 11 KCNQ1 European Potassium voltage-gated channel, KQT-like subfamily, 
member 1: Required for repolarization phase of the 
cardiac action potential. Mutations in this gene are 
associated with hereditary long QT syndrome 1 (also 
known as Romano-Ward syndrome), Jervell and Lange-
Nielsen syndrome, and familial atrial fibrillation. This gene 
is located in a region of chromosome 11 amongst other 
imprinted genes that are associated with Beckwith-
Wiedemann syndrome (BWS). 
 
Beta-cell 
rs163184 11 KCNQ1 East Asian As above. 
 
Beta-cell 
rs5215 11 KCNJ11 European Pore-forming alpha subunit of potassium channel. 
 
Beta-cell 
rs1552224 11 CENTD2 European Centaurin delta 2: Function unknown. Not known 
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rs1387153 11 MTNR1B European Melatonin receptor 1B: Encodes a high affinity receptor 
for melatonin.  
 
Beta-cell 
rs4760790 12 TSPAN8 European Tetraspanin 8: Cell-surface proteins which mediates 
signal transduction events that play a role in the 
regulation of cell development, activation, growth and 
motility. 
 
Beta-cell 
rs7957197 12 HNF1A European HNF1 homeobox A: Transcription factor required for the 
expression of several liver-specific genes. Defects in this 
gene are a cause of maturity onset diabetes of the young 
type 3 (MODY3) and also can result in the appearance of 
hepatic adenomas. 
 
Beta-cell 
rs7172432 15 C2CD4A/B East Asian C2 calcium-dependent domain containing 4B: Function 
unknown. 
 
Not known 
rs11634397 15 ZFAND6 European Zinc finger AN1-type domain 6: Function unknown. 
 
Not known 
rs8042680 15 PRC1 European Protein regulator of cytokinesis 1: Involved in cytokinesis.  
 
Not known 
rs11642841 16 FTO European Fat mass and obesity associated: Nuclear protein of the 
AlkB related non-haem iron and 2-oxoglutarate-
dependent oxygenase superfamily but the exact 
physiological function is not known. Plays a role in 
nervous and cardiovascular systems and a strong 
association with body mass index and obesity risk. 
 
Insulin resistance 
rs391300 17 SRR East Asian Serine racemase: Catalyzes the synthesis of D-serine Not known 
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from L-serine. D-serine is a key coagonist with glutamate 
at NMDAreceptors. 
 
rs4430796 17 HNF1B European HNF1 homeobox B: Member of the homeodomain-
containing superfamily of transcription factors. Has a role 
in nephron development, and regulates development of 
the embryonic pancreas. Mutations in this gene result in 
renal cysts and diabetes syndrome and types of cancer. 
 
Beta-cell 
rs3786897 19 PEPD East Asian Aminoacyl-histidine dipeptidase: Role in collagen 
metabolism. 
 
Not known 
rs5945326 X DUSP9 
 
European Dual specificity phosphatase 9: Negatively regulate 
members of the mitogen-activated protein, and plays a 
role in cellular proliferation and differentiation. 
 
Not known 
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Table 1.8: Previously reported associations of known T2D genetic variants with T2D in Indian Asian populations. (- = Not tested. A 
SNP was only considered to be associated with T2D if p<0.05 after correcting for multiple testing). 
 
 GUPTA 2012 REES 2011 CHAUHAN 2010 SANGHERA 2009 JANIPALLI 2012  
 (N=3,089) (N=3,262)  (N=5,164) (N=918) (N=3,357) 
Gene India Pakistan India India India 
NOTCH2 No association No association - - No association 
PROX1 - No association - - - 
GCKR - No association - - Associated 
THADA Associated No association - - Associated 
BCL11A No association No association - - No association 
RBMS1 - - - - - 
IRS1 - Associated - - - 
PPARG No association No association Associated Associated Associated 
UBE2E2 - - - - - 
PSMD6 - - - - - 
ADAMTS9 - No association - - - 
ADCY5 - Associated - - - 
IGF2BP2 - Associated Associated Associated Associated 
MAEA - - - - - 
WFS1 No association No association - - Associated 
ZBED3 - No association - - - 
CDKAL1 No association No association Associated - Associated 
ZFAND3 - - - - - 
KCNK16 - - - - - 
DGKB - - - - - 
JAZF1 - No association - - No association 
GCK No association No association - - No association 
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GCC1-PAX4 - - - - - 
KLF14 - No association - - - 
TP53INP1 - No association - - - 
SLC30A8 No association No association Associated No association Associated 
GLIS3 - Associated - - - 
PTPRD - - - - - 
CDKN2A/B No association Associated Associated No association Associated 
CHCHD9 - No association - - - 
CDC123 No association No association - - Associated 
HHEX No association No association Associated No association Associated 
TCF7L2 No association Associated Associated Associated Associated 
DUSP8 - - - - - 
KCNQ1 - No association - - - 
KCNQ1 No association No association - - No association 
KCNJ11 - No association Associated No association Associated 
CENTD2 - No association - - - 
MTNR1B - No association - - - 
TSPAN8 - No association - - No association 
HNF1A - No association - - - 
C2CD4A/B - No association - - - 
ZFAND6 - - - - - 
PRC1 - No association - - - 
FTO No association No association - Associated Associated 
SRR - - - - - 
HNF1B - - - - Associated 
PEPD - - - - - 
DUSP9 - No association - - - 
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CHAPTER 2 
METHODS AND MATERIALS 
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2.1 INTRODUCTION  
I have performed population studies to investigate the contribution of 
lifestyle, genetic and dietary factors to risk of T2D amongst Indian Asians 
compared to Europeans. I have additionally carried out a genome-wide 
association study to discover common genetic variants in association with T2D 
in Indian Asians. Written protocols were prepared for all studies prior to 
commencement. Each study and accompanying protocol was reviewed, and 
approved, by a Research Ethic Committee. All subjects gave written informed 
consent to participate in the research projects.  
This chapter describes the methods used for recruitment and 
characterisation of participants, biochemical and genetic tests performed, and 
the approaches to analyses.  
 
2.2 RESEARCH TEAM 
  Data collection was facilitated by trained research nurses under the 
supervision of the principal investigators. Roles of the nurses included making 
appointments for study participants, undertaking structured and standardised 
assessment of cardiovascular risk factors, anthropometric measurements, 
recording 12-lead ECGs, undertaking venepuncture for biochemical and 
genetic analyses, and entering data into the research databases. Each member 
of staff completed a two month structured training program prior to working 
independently. Revalidation was required at 3 monthly intervals, and a record 
maintained in the training manual, for each member of staff.  
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2.3 STUDY PARTICIPANTS 
2.3.1 The London Life Sciences Population Study 
  I investigated 16,774 Indian Asians and 7,031 European participants of 
the London Life Sciences Population (LOLIPOP) study. LOLIPOP is an ongoing 
population based cohort study of Indian Asian and European men and women, 
aged 35-75 years, recruited from lists of 58 General Practitioners in West 
London, United Kingdom. Recruitment of participants commenced in 2001 and 
baseline collection was completed in 2008. Indian Asian ethnicity was identified 
as all four grandparents born on the Indian subcontinent (India, Pakistan, Sri 
Lanka and Bangladesh). Europeans had all four grandparents born in Europe. 
The LOLIPOP study was approved by a Research Ethics Committee, and all 
participants gave written informed consent.  
 
2.3.2 Duplicate diet study  
  I carried out a duplicate diet study in a sample of 115 Indian Asian and 
124 European men participating in the LOLIPOP study identified at random, 
and representative of males living in West London. Participants were free from 
known T2D or cardiovascular disease. All study participants were 
characterized according to LOLIPOP protocols described below. 
 
2.4 PARTICPANT CHARACTERIZATION 
2.4.1 Clinical questionnaire 
A standardized interviewer-administered questionnaire was used to 
collect data on medical history, family history, current prescribed medications, 
social history, alcohol and smoking habits and cardiovascular risk factors. In 
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addition data on birthplace of all four grandparents, religion, mother tongue, 
place of birth and years resident in the UK were recorded for each study 
participant.   
 
2.4.2 Assessment of physical activity 
Physical activity was assessed as leisure-time physical activity (LTPA); 
study participants were asked to quantify the frequency and duration of time 
spent (minutes) in moderate (3-6 METs, e.g. aerobics, brisk walking, cycling, 
football, jogging, swimming, skipping, tennis) and vigorous activities (>6 METs, 
e.g. circuit training, fast swimming, high impact aerobics, mountain biking, 
running, squash, skiing) during leisure time in the previous week. The total time 
(in minutes) spent in LTPA was calculated, and converted to MET-mins. 
Participants were categorized as physically active and inactive based on 
national guidance (≥450 MET-min/week)107.  
 
2.4.3 Physical assessment 
Physical measurements included height, weight, waist and hip 
circumference, and blood pressure.  
 
2.4.3.1 Height 
Height was measured using a stadiometer, mounted on a hard, flat 
surface. Patients were measured without shoes, standing with their back to the 
height rule, both feet together, and with head, buttocks and heels touching the 
wall. Patients were asked to look directly ahead, and the stadiometer bar 
moved down to touch the top of the head, pressing the hair flat. For patients 
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with turbans, the turban was removed. Height was recorded to the nearest 
0.1cm.  
 
2.4.3.2 Weight  
Weight was recorded using digital scales. The scales were mounted on 
a hard, flat surface. The patient was weighed after an overnight fast, wearing 
light clothing only. Weight was recorded to the nearest 0.1kg.  
 
2.4.3.3 Waist-to-Hip Ratio (WHR)  
WHR was measured after an overnight fast, with the patient undressed 
except for underwear, and standing erect, with feet together. Waist was defined 
as the point midway between iliac crest and lowest rib, identified by palpation, 
and waist circumference measured as the minimum circumference at this level. 
Hip circumference was defined as the maximum circumference over the greater 
trochanters and buttocks. Measurements were made using a non-stretchable 
measuring tape, applied around the body without twists, and gently touching 
skin, without compressing soft tissue. All measurements were recorded in 
centimetres, to the nearest 0.1cm.  
 
2.4.3.4 Blood Pressure  
Blood pressure was measured using an OMRON 705 CP blood pressure 
monitor. Blood pressure was measured in the right arm, with the subject in the 
supine position, after 10 minutes rest, in loose clothing, and in a warm room. 
The cuff was positioned level with heart, with the centre of bladder over the 
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brachial artery, and the lower edge of the cuff 2-3 cm above the antecubital 
fossa.  
 
2.4.4 Biochemical Measurements 
2.4.4.1 Sample collection  
Venous blood samples were collected by standard venepuncture 
technique. Venepuncture was performed with the patient lying on a couch for at 
least 10 minutes, at the antecubital fossa, with a tourniquet applied gently 
around the upper arm. Once the vein had been cannulated, the tourniquet was 
released. Samples were collected directly into pre-labelled vacuum filled 
sample tubes, with additive where appropriate, and once filled the sample 
tubes gently inverted 2-3 times.   
 
2.4.4.2 Routine biochemistry  
Blood was taken for fasting lipid profile, fasting glucose, fasting insulin, 
urea and electrolytes and HbA1c. Blood samples tests were analysed in the 
Clinical Chemistry laboratories at Ealing Hospital, using commercially available 
assays summarised in table 1.1. Whole blood was additionally collected and 
stored at -80oC for future genetic testing. 
 
2.4.5 Duplicate diet sampling 
Duplicate diet samples were collected over one day between 2001 and 
2003. Participants were instructed to collect duplicate portions of everything 
they ate and drank over 24-hours. Participants were provided with a diet record 
diary, leak-proof bottles and digital scales, and were taught by the research 
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dietician how to weigh, record and collect the duplicate diets. The dietician 
recorded the total weight of each duplicate collection, then homogenized it and 
stored three 30ml aliquots at -80oC for subsequent analysis.  
 
2.4.5.1 Chemical analysis of duplicate diet samples 
Duplicate diet samples were analysed in collaboration with the University 
of Surrey, Nutrition and Food Safety Laboratories, supervised by Professor 
Nazlin Howell, for:  
(i) Macronutrient composition (total fat, carbohydrate, protein, fibre), and 
(ii) Fatty acid subtypes (saturated, monounsaturated, polyunsaturated) 
(iii) Energy intake from individual macronutrients was calculated using the 
Atwater system210. 
(iv) Total energy was calculated by summing energy derived from all 
macronutrients in an individual duplicate diet collection. 
 
2.4.5.2 Determination of moisture content 
To prevent degradation of the food sample and to determine the 
moisture content, the samples were freeze-dried. Frozen samples in their 
containers were weighed and freeze-dried for about 4 – 6 days until a constant 
weight was obtained. The percentage moisture was calculated from the 
difference in weight. The freeze-dried samples were ground to a fine powder 
and kept at -20oC until further analysis.  
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2.4.5.3 Protein determination using the Kjeldahl method 
The dried food samples (1 gram) in duplicate, were digested with 
concentrated sulphuric acid (20 ml) and one Kjeldahl catalyst tablet (Sigma) at 
420oC. The digested sample was cooled, diluted with water and distilled with 
40% solution of sodium hydroxide in the distillation unit.  The released 
ammonia was dissolved in boric acid solution (25 ml) in a receiver flask. The 
nitrogen content in the solution was estimated by titration of the ammonium 
borate formed with 0.05 M hydrochloric acid, using methyl red indicator to 
determine the end-point of the reaction. Nitrogen content which was converted 
to protein concentration using a conversion of 6.25 (equivalent to 0.16 g 
nitrogen per gram of protein)211. 
 The following equation was used to determine the nitrogen 
concentration of a sample: 
% N = 100 × [titrant of sample (ml) – titrant of blank (ml)] x 0.0007 g of       
sample  
Protein (g) = N × factor specific for different products 
[N × 6.25 is normally used for unknown food proteins] 
Energy derived from protein was calculated by multiplying weight of protein 
(grams) by 4. 
 
2.4.5.4 Determination of total lipids using the Soxhlet method 
Total lipids were measured using Soxhlet extraction with a Soxtec 
system-HT212. Dried food samples (1 gram) were accurately weighed into 
extraction thimbles (in duplicate) and placed into the Soxtec system.  The lipid 
was extracted with 100 ml of petroleum ether b.p. 60-80oC for 2 hours into a 
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previously weighed extraction cup. The solvent was evaporated off and the oil 
collected and weighed.  The amount of oil in the sample was calculated by a 
difference in weight. Energy derived from fat was calculated by multiplying 
weight of fat (grams) by 9. 
 
2.4.5.5 Fatty acids analysis  
Fatty acids in the extracted lipids were analysed according to Saeed and 
Howell (1999)213. The fatty acids were trans-esterified and then analysed by 
gas chromatography. Diluted sodium methylate (2ml) was added to 200ml (or 
100mg) of lipid that was extracted from food samples by the Soxhlet method, 
vortexed for one minute, and left in the dark (wrapped tubes with foil) for one 
hour. To each tube, 2ml distilled water and 5ml chloroform was added and 
vortexed for another 5 minutes. Samples were centrifuged at 3000 x G for 5 
minutes. The upper layer was removed and discarded. To neutralise excess 
alkali  2ml of 1% citric acid solution was added into the chloroform bottom layer, 
vortexed for 5 minutes, centrifuged at 3000x G for 5 minutes and the 
chloroformic bottom layer was collected with a Pasteur pipette. The 
chloroformic extract was evaporated under a stream of nitrogen in a warm 
water bath (37°C) to dryness. The dry sample was used in gas chromatography 
for fatty acid analysis. 
Chromatographic analysis was carried out on an Agilent 6890N gas 
chromatograph fitted with a Supelco Omegawax, capillary column (30mm x 
0.32 mm 0.25 mm film thickness).  1µl of fatty acid methyl esters was injected 
into the gas Chromatograph, with a hydrogen flame ionization detector using 
hydrogen as a carrier gas at a flow rate of approximately 1ml/min.  Injection 
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was by a split injection system (50:1 split ratio). The injector temperature was 
250oC. Column temperature was set initially at 80oC (10 minutes), 180oC 
(15minutes), and the final temperature 220oC. The detector temperature was 
also set at 250oC.  Identification of peaks was by comparison of relative 
retention times with those of authentic standards (Supelco 37 component 
FAME MiX). 
 
2.4.5.6 Trans fatty acids determination 
Fatty acid methyl-esters were obtained as described above and the 
standard fatty acid methyl-ester (Supelco 37 component FAME Mix) 
chromatographed on a SP-2560 100mm x 0.25mm ID 0.20m film thickness214. 
The method for gas chromatography for trans fatty acids was supplied by 
Sigma Aldrich. The oven temperature was 140oC (5 minutes) increasing to 
240oC at 4oC/minute. The carrier gas was hydrogen with a flow rate of 
20cm/sec and the FID detector temperature was set at 260oC. Fatty acid 
methyl esters samples (1µl) were injected into the gas chromatograph, using a 
split injection system (100:1 split ratio) and an injector temperature of 250oC. 
Trans fatty acids were calculated from the standard (trans oleic C18:1n9t and 
trans linoleic acid C18:2n6t).  
 
2.4.5.7 Determination of carbohydrate content 
Carbohydrate content was analysed by the phenol/ sulphuric acid 
reaction method215. In preparation about 15-40mg dried samples were weighed 
into glass tubes, and 10ml of 1M hydrochloric acid was added to each tube and 
mixed well in an ultrasound bath at room temperature (22oC) for 1 hour. The 
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tubes were transferred to a boiling water bath for 2 hours, cooled, centrifuged 
and a suitable concentration was used to measure the total carbohydrate in the 
samples.  
Next a solution of analytical grade glucose in water (1mg/ml) was 
prepared. From this solution a serial dilution between 10-100μg/ml of glucose 
(0, 10, 30, 60, 90) was made and used as a standard to prepare a standard 
curve. 0.5ml of 5% phenol solution was added to 0.5ml of the sample, and the 
solution was mixed well and 2.5ml concentrated sulphuric acid was added and 
vortex mixed. The mixture was left for 10 minutes and transferred to a shaking 
water bath at 25-30oC for 30 minutes. The absorbance of the samples and 
different concentrations of standards were read in a spectrophotometer at 485 
nm against a blank. 
Energy derived from carbohydrate was calculated by multiplying weight 
of carbohydrate (grams) by 4. 
 
2.4.5.8 Fibre content 
The fibre content was calculated by difference from (100 – Total 
(moisture + protein + lipid + carbohydrate)). Energy derived from carbohydrate 
was calculated by multiplying weight of fibre (grams) by 2. 
 
2.5 GENETIC STUDIES 
I carried out a two-staged, genome-wide association (GWAS) and 
replication study amongst 58,587 participants of Indian Asian ancestry. GWAS 
was carried out amongst 5,561 Indian Asian cases with T2D and 14,458 Indian 
Asian controls from the LOLIPOP study216, the Pakistan Risk of Myocardial 
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Infarction Study (PROMIS)217 and the Singapore Indian Eye Study (SINDI)218. 
In stage two replication of top ranking loci from the GWAS were tested in 
13,170 T2D cases and 25,398 controls of Indian Asian ancestry.  
 
2.5.1 Genome-wide association discovery cohorts 
2.5.1.1 LOLIPOP Indian Asian T2D cases and controls.  
 LOLIPOP contributed 6,556 T2D cases and 6,472 controls for the 
GWAS. T2D cases were determined as those with a physician’s diagnosis of 
T2D, on anti-diabetic medication or with a fasting glucose >7mmol/L. Controls 
were Indian Asian individuals without a physician diagnosis of T2D and fasting 
plasma glucose levels less than 6.0mmol/L. 
 
2.5.1.2 Pakistan Risk of Myocardial Infarction study (PROMIS) 
PROMIS is an ongoing case-control study of acute myocardial infarction 
(MI) and other cardiometabolic traits in urban Pakistan, which, as of October 
2010, included ~7,500 MI cases and ~7,500 controls. MI cases have typical 
ECG changes, a positive troponin test, and MI symptoms within the previous 24 
hours. Controls are frequency-matched to cases by sex and age (in 5 year 
bands) and are visitors of patients attending the outpatient department, patients 
attending the outpatient department for routine non-cardiac complaints, or non-
blood related visitors of index MI cases. Non-fasting blood samples were 
collected from each participant; for MI cases this was within 24 hours of 
symptom onset. T2D was diagnosed based on physician diagnosis, prior use of 
oral hypoglycemics, and/or HbA1c≥6.5% (47.5 mmol/mol). Controls had no 
history of T2D, and had HbA1c<6.0% (42.1 mmol/mol). PROMIS contributed 
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2361 cases and 6817 controls to the GWAS. All laboratory analyses were 
conducted centrally at the Center for Non-Communicable Diseases (CNCD), 
Pakistan. PROMIS has been approved by the research ethics committee of the 
CNCD, Pakistan and research ethics committee of each of the institutions 
involved in participant recruitment.  
 
2.5.1.2 Singapore Indian Eye Study (SINDI) 
SINDI is a population-based, cross-sectional study of 3,400 men and 
women of Indian Asian ancestry (self reported), living in the South-Western part 
of Singapore, recruited as part of the Singapore Indian Chinese Cohort Eye 
Study. Age stratified random sampling was used to select 6,350 eligible 
participants, of which 3,400 participated in the study (75.6% response rate). 
T2D cases and controls were selected from the population based cross 
sectional study where T2D was defined as either a history of diabetes or HbA1c 
level greater than or equal to 6.5% (47.5 mmol/mol). Controls had no history of 
diabetes and HbA1c level <6.0% (42.1 mmol/mol). This yielded 977 Indian T2D 
cases and 1,169 controls which for the GWAS. 
 
2.5.2 Replication cohort descriptions  
Replication testing among Indian Asians was carried out in 13,170 cases 
and 25,398 control participants from the following studies: 
 
2.5.2.1 The COBRA Study 
COBRA is a population-based sample of adults in Karachi, Pakistan 
recruited in a cluster-randomized trial of strategies to control hypertension 
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(“Population Based Strategies for Effective Control of High Blood Pressure in 
Pakistan”, Trial registration number NCT00327574)219. A multi-stage cluster 
random sampling design was used to randomly select 12 geographical clusters 
in Karachi, the largest metropolitan city in Pakistan. A census was done, and a 
listing of all individuals from all households in the selected areas was made. All 
subjects aged 40 years or above and able to consent were invited to participate 
by trained community health workers. This included blood pressure 
measurement with a calibrated automated device (“Omron HEM-737 TM Blood 
Pressure Monitor”) in the sitting position after 5 minutes of rest, anthropometry 
(height, weight, waist and hip circumferences), laboratory tests for fasting 
plasma glucose (Synchron Cx-7/Delta, Beckman, US) and DNA extraction. T2D 
was defined as physician diagnosis on antidiabetic medications, or fasting 
blood glucose ≥7 mmol/L. Controls had no history of T2D, and had fasting 
glucose <7mmol/L. Ethical approval was obtained from the Ethics Review 
Committee at the Aga Khan University, Pakistan.  
 
2.5.2.2 Chennai Urban Rural Epidemiology Study (CURES) 
CURES is an ongoing epidemiology study of a representative sample of 
26,001 South Asians in Chennai (population ~5 million), recruited using a 
random sampling technique220. T2D was defined as self-reported diabetes on 
drug treatment, fasting glucose ≥7.8 or post-load glucose ≥11.1. Controls were 
selected as people with no history of T2D, fasting glucose <6.1 mmol/L and 2-
hour glucose <7.8 mmol/L. Written informed consent was obtained from all 
study subjects, and the protocol was approved by the Institutional Ethics 
Committee of the Madras Diabetes Research Foundation.  
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2.5.2.3 Diabetes Genetics in Pakistan (DGP) study 
Indigenous Pakistani subjects were recruited in collaboration with Baqai 
Institute of Diabetology and Endocrinology (BIDE), Karachi, Pakistan221. 
Subjects with T2D (physician diagnosed on treatment, N=840) were recruited 
either from hospitals within Mirpur District or from specifically organised 
Diabetes Awareness camps. Control subjects (N=1225) were recruited from 
community screening camps set up throughout Mirpur District. Normal glucose 
tolerance was defined as fasting whole blood glucose ≤5.6mmol/l. Genomic 
DNA was extracted from saliva using the Oragene® DNA sample collection kit 
and extraction protocol (DNA Genotek Inc., Ontario, Canada). Informed 
consent was obtained from all study participants and the study was approved 
by the BIDE Institutional Review Board.  
 
2.5.2.4 Mauritius cohort 
A population based survey was undertaken in 1998 that included 
participants who were 20 years and older, with a total of 6,291 participants 
examined222. Participants of self-reported South Asian ancestry were included 
in the present study. All subjects not taking diabetic medication had a 2-hour 
75-g oral glucose (glucose monohydrate) tolerance test (OGTT). Venous blood 
samples were drawn at baseline fasting and at 2 hours post ingestion of 
glucose and were centrifuged and separated immediately. Plasma glucose was 
measured using the YSI glucose analyzer (Yellow Springs Instruments, OH, 
USA). Glucose tolerance status was determined according to 1999 WHO 
criteria. Diabetes was diagnosed if subjects reported a history of diabetes and 
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were taking hypoglycaemic medication, or the fasting plasma glucose level was 
≥7.0 mmol/L and/or the 2-h value was ≥11.1 mmol/L. Normal glucose tolerance 
was assigned if the fasting plasma glucose level was <6.1 mmol/L and the 2-
hour value was <7.8 mmol/L.  
 
2.5.2.5 Ragama Health Study  
The Ragama Health Study is a population-based study of South Asian 
men and women aged 35-64 years living in the Ragama Medical Officer of 
Health (MOH) administrative area, near Colombo, Sri Lanka223. Consenting 
adults attended after a 12 hour fast with their available health records, and 
were interviewed by trained personnel to obtain information on medical, 
sociodemographic, and lifestyle variables. Blood pressure and anthropometric 
measurements were made. A 10-mL sample of venous blood was obtained 
from each subject, for measurement of fasting glucose and HbA1c; T2D was 
defined as physician diagnosis on treatment or fasting glucose >7mmol/L or 
HbA1c level more than 6.5% (47.5 mmol/mol). Controls had no history of T2D, 
fasting glucose <6.1 mmol/l, and HbA1c <6.0% (42.1 mmol/mol). Ethical 
approval for the study was obtained from the Ethics Committees of the Faculty 
of Medicine, University of Kelaniya and the National Center for Global Health 
and Medicine.  
 
2.5.2.6 Sikh Diabetes Study (SDS) 
Participants of SDS were recruited from Sikhs living in the Northern 
states of India, including Punjab, Haryana, Himachal Pradesh, Delhi, and 
Jammu and Kashmir224. T2D was defined as physician diagnosis on treatment, 
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a fasting plasma glucose level of ≥7.0mmol/L, or 2-hour post glucose load level 
of ≥11.1mmol/L, on more than one occasion with symptoms of T2D. Controls 
had no prior history of T2D and normal glucose tolerance (fasting glucose 
<6mmol/L, post glucose <7.8mmol/L). Subjects with impaired fasting glucose 
and/or impaired glucose tolerance were excluded from analysis. All participants 
provided a written informed consent for investigations. All SDS protocols and 
consent documents were reviewed and approved by the University of 
Oklahoma and the University of Pittsburgh Institutional Review Boards as well 
as the Human Subject Protection Committees at the participating hospitals and 
institutes in India.  
 
2.5.2.7 Singapore Consortium of Cohort Studies (SCCS) 
SCCS includes cases with T2D and controls recruited in Singapore. T2D 
cases are recruited from hospitals and polyclinics, namely Alexandra and 
Changi General Hospital and Ang Mo Kio, Jurong, Choa Chu Kang, Yishun and 
Pasir Ris Polyclinics. Controls are recruited from the general population. All 
participants complete a structured questionnaire, providing information on 
demographics, socio-economic status and medical history (including history of 
diabetes) and have measurement of anthropometric measures and blood 
pressure. Fasting blood samples are collected for blood glucose and lipid 
measurements. Participants gave broad consent for i) future biomedical 
research, ii) access to their medical records and iii) linkages to various 
registries. For the purpose of this study, only participants of self reported Indian 
Asian ancestry are included. T2D was defined as physician diagnosis on 
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treatment; controls had no prior history of diabetes and fasting glucose 
<6.1mmol/L.  
 
2.5.2.8 Sri Lankan Diabetes Studies 
Control subjects were participants in The Sri Lankan Diabetes 
Cardiovascular Study (SLDCS), a cross-sectional nationally–representative 
epidemiological investigation which recruited 4388 subjects (40% male)11. 
Among recruited subjects, 3372 had normal glucose tolerance based on the 
results of a 75g oral glucose tolerance test (OGTT), interpreted using ADA and 
WHO criteria. DNA collection was only initiated midway through the SLDCS 
collection, limiting the number of control samples available for genotyping to 
1576.  
T2D cases were mostly derived from the Sri Lankan Young Diabetes 
Study (SLYDS). A total of 992 patients with early onset diabetes (42.1% male) 
were recruited from the three largest hospitals in Sri Lanka in 2005-2006. All 
patients had been diagnosed with diabetes between the ages of 16 and 40 
years and were ≤45 years when they first joined the study. On the basis of 
clinical history (independence from insulin for at least 6 months after 
diagnosis), biochemistry and immunological testing (absence of anti-GAD 
antibodies), 890 were considered to have clinical T2D. The SLYDS case 
sample was augmented with 176 T2D cases from SLDCS. Additional exclusion 
criteria were applied to the combined cases set (GADA ≥ 14units/ml, age ≥80 
years, and missing sex information) to generate a total of 1066 T2D cases 
available for genotyping. Analyses of genotyping data excluded 330 samples 
based on a per-sample genotype call rate ≤90%. After these exclusions a total 
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of 841 T2D cases and 1471 controls were taken forward for association testing. 
PLINK was used to carry out the data analysis.  
 
2.5.2.9 United Kingdom Asian Diabetes Study (UKADS) 
UK-resident Indian Asians subjects with T2D (physician diagnosed, on 
treatment, n=892) were recruited to UKADS from Birmingham and Coventry, 
UK221. All subjects were of Punjabi ancestry, confirmed over three generations, 
and originated predominantly from Mirpur region of Azad Kashmir, Pakistan. 
Ethnically matched control subjects (n=449) were recruited from the same 
geographical areas through community screening. Normal glucose tolerance 
was defined as either fasting plasma glucose <6.1mmol/l and 2hr plasma 
glucose <7.8mmol/l on a 75g OGTT (where possible) or random blood glucose 
<7mmol/l. Genomic DNA was extracted from venous blood using the Nucleon® 
protocol (Nucleon Biosciences, Coatbridge, UK). Informed consent was 
obtained from all study participants and the study was approved by the 
Birmingham East, North and Solihull Research Ethics Committee.  
 
2.5.2.10 European T2D cases and controls  
Associations of SNPs with T2D in Europeans were tested in silico using 
results from the GWAS phase of the DIAGRAM+ study, which comprises 8,130 
cases with T2D and 38,987 controls of European ancestry195. T2D case or 
control status was defined using study-specific criteria. SNP associations were 
tested using an additive genetic model and combined across studies by inverse 
variance meta-analysis using a fixed effects model. 
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2.6 Genotyping 
2.6.1 Genome-wide association study 
For LOLIPOP study samples genotyping was carried out at 
KBiosciences, using the Illumina Hap610 BeadChip and Illumina Hap300 
BeadChip according to standard methodology. Each sample was whole-
genome amplified, fragmented, precipitated and resuspended in appropriate 
hybridization buffer. Denatured samples were hybridized on prepared 
HumanHap610 BeadChips for a minimum of 16 hours at 48°C. After 
hybridization, the BeadChips were processed for the single-base extension 
reaction, and staining and imaging on an Illumina Bead Array Reader. 
Normalized bead intensity data obtained for each sample were loaded into the 
Illumina Beadstudio 2.0 software, which converted fluorescence intensities into 
SNP genotypes. BeadChips, and genotypes were called using GenCall 
algorithms. For PROMIS and SINDI GWAS samples genotyping was carried 
using the Illumina Hap610 BeadChip, and genotypes were called using 
Illuminus and GenCall algorithms respectively.  
 
2.6.2 GWAS quality control 
Samples with a SNP call rate <95% were removed, as were SNPs with 
call rate <97%, minor allele frequency <1%, or Hardy-Weinberg equilibrium 
P<1.0×10−6. Hidden relatedness or duplicate samples were sought using 
identity-by-descent methods implemented in PLINK, and individuals with 
evidence for relatedness were excluded (pi hat≥0.5 in LOLIPOP and SINDI or 
pi hat≥0.37 in PROMIS to allow for the higher prevalence of consanguinity in 
Pakistanis). The primary analysis tested the association with T2D of the 
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568,976 autosomal SNPs that had been directly genotyped and passed quality 
control testing among the Indian Asian GWAS participants.  
Principal components analysis was used to identify population outliers 
by comparison to reference samples from the HapMap YRI, CHB, JPT and 
CEU panels and the Indian samples collected by Reich and colleagues225; 
samples with eigenvalues inconsistent with Indian Asian ancestry were 
removed. Principal components analysis was performed in Eigensoft v3.0 (ref. 
9) using a set of 100,864 SNPs common to all three studies and pruned to 
reduce pairwise LD; this SNP set was selected using the 'indep' option of 
PLINK with window size 50, step 3 and VIF = 1.3. 
 
2.6.3 Genotyping and quality control for replication testing 
Genotyping of the replication samples was performed by KASPAR (K-
Bioscience Ltd), Sequenom MassArray or TaqMan. Samples with <90% call 
rate were excluded, as were SNPs with call rate <95% or that deviated from 
Hardy-Weinberg equilibrium at P<2.5 × 10−3.  
 
2.7 Expression Quantitative Trait Loci resources 
  The HapMap3 resource comprises lymphoblastoid cell lines (LCL) from 
726 HapMap3 individuals (CEU: 109, CHB: 80, GIH: 82, JPT: 82, LWK: 82, 
MEX: 45, MKK: 138, and YRI: 108), with mRNA transcript levels measured 
using Illumina's whole genome expression array Sentrix Human-6 Expression 
BeadChip version 2. Log transformed expression signals were normalized as 
follows: quantile normalization across replicates of a single individual, followed 
by median normalization across all individuals of the eight populations. 
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Expression data from GIH, LWK, MEX, and MKK (populations with admixture) 
were subjected to correction for genetic structure. For each gene we tested for 
association between SNP genotype and normalized expression values using 
Spearman rank correlation (SRC), testing all SNPs mapping within a 2MB 
window centred on the gene's transcription start site (TSS). Statistical 
significance was evaluated through permutations of expression phenotypes 
relative to genotypes defining a significance threshold of 0.01.  
 The MuTHER resource includes LCLs, skin and adipose tissue derived 
simultaneously from a subset of well-phenotyped healthy female twins226. 
Whole-genome expression profiling of the samples, each with either two or 
three technical replicates, were performed using the Illumina Human HT-12 V3 
BeadChips (Illumina Inc) according to the protocol supplied by the 
manufacturer.  Log transformed expression signals were normalized separately 
per tissue as follows: quantile normalization was performed across technical 
replicates of each individual followed by quantile normalization across all 
individuals. Genotyping was done with a combination of Illumina arrays 
(HumanHap300, HumanHap610Q, 1MDuo and 1.2MDuo).  Untyped HapMap2 
SNPs were imputed using the IMPUTE software package (v2). The number of 
samples with genotypes and expression values per tissue is 778 LCL, 667 skin 
and 776 adipose, respectively. Association between all SNPs (MAF>5%, 
IMPUTE info >0.8) within a gene or within 1MB of the gene transcription start or 
end site and normalized expression values were performed with the 
GenABEL/ProbABEL packages using the polygenic linear model incorporating 
a kinship matrix in GenABEL followed by the ProbABEL mmscore score test 
with imputed genotypes. Age and experimental batch were included as 
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cofactors in the adipose and LCL analysis, while age, experimental batch and 
concentration were included as cofactors in the skin analysis.   
 
2.8 STATISTICAL METHODS  
For each study, statistical analyses were carried out according to a pre-
specified plan drawn up before the results were available. Continuous data are 
expressed as mean ± standard deviation (SD), and categorical data as %. A 
logarithmic transformation was used for positively skewed data. For these 
variables geometric means are presented along with approximate standard 
deviations derived using the variance transformation formula.  
For the population, genetic and diet studies, Student’s T-test, and 2-test 
were used to compare values of continuous and categorical variables 
respectively between groups. When comparing three or more groups, analysis 
of variance (ANOVA) and the 2-test were used for continuous and categorical 
variables respectively. Relationships with continuous variables were examined 
using correlation coefficients and linear regression. Logistic regression was 
used to examine the relationship between risk factors and T2D, making 
adjustment for potential confounding variables. Similar statistical methods were 
used for the diet study, but association with insulin resistance (HOMA-IR) were 
calculated. 
To calculate the magnitude of T2D risk attributable to a risk factor in 
population studies, population attributable risk (PAR%) was calculated using 
standard methodology. PAR% was calculated as [Pe(RR-1)x100]/[Pe(RR-1)+1], 
where RR is the relative risk and Pe the proportion of the population exposed. 
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Statistical significance was inferred at a P value of <0.05. For genetic 
studies, a correction for multiple tests was made; for known T2D genetic 
variants P<0.001 and for GWAS P<10-8 were used to infer statistical 
significance. Data were analysed using Statistical Package for the Social 
Sciences (SPSS) versions19.0.  
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Table 2.1: Assays used for biochemical analysis. 
 
 
 
Analyser 
 
Method 
 
Glucose Roche/ Hitachi cobas c 501 
 
Enzymatic, colorimetric method 
 
Insulin Cobas e 411 
 
Sandwich principle 
 
Cholesterol Roche/ Hitachi cobas c 501 
 
Enzymatic reference method with hexokinase 
 
Triglycerides Roche/ Hitachi cobas c 501 
 
Enzymatic colorimetric test 
 
HDL-cholesterol Roche/ Hitachi cobas c 501 
 
Homogeneous enzymatic colorimetric test 
 
HbA1c Bio-Rad VARIANTTM II TURBO 
 
High-performance liquid chromatography  
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CHAPTER 3 
INVESTIGATION OF THE CONTRIBUTION OF 
ADIPOSITY AND LEISURE TIME PHYSICAL ACTIVITY 
TO DIFFERENCES IN T2D, UNDIAGNOSED T2D AND 
PRE-DIABETES AMONGST INDIAN ASIANS 
COMPARED TO EUROPEANS 
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3.1 ABSTRACT 
Background 
Indian Asians are at increased risk of type-2 diabetes (T2D), insulin resistance 
and related metabolic disturbances compared to Europeans. The contribution 
of known lifestyle risk factors to the excess risk of T2D in Indian Asians is not 
well understood.  
 
Methods 
I investigated a representative population sample of 16,776 Indian Asian and 
7,031 European men and women (35 – 75 years) participating in the London 
Life Sciences Population (LOLIPOP) study. Baseline characterization for 
clinical, leisure time physical activity (LTPA), anthropometric and biochemical 
measures were done. Insulin resistance (HOMA-IR) and pancreatic –cell 
function (HOMA-B) were calculated using the Homeostasis Model of 
Assessment (HOMA) 2 calculator software. T2D, undiagnosed T2D and pre-
diabetes were defined using American Diabetes Association criteria. 
 
Results 
Indian Asians compared to Europeans had higher prevalence of T2D (21.1% 
vs 7.3%), undiagnosed T2D (6.1% vs 1.7%), pre-diabetes (32.8% vs 18.3), 
and higher HOMA-IR (1.4 vs 1.1), all P<0.001. T2D and HOMA-IR were 
directly associated with BMI and WHR (P<0.001) in Indian Asians and 
Europeans. LTPA was inversely correlated with T2D in Europeans (P<0.001), 
and HOMA-IR in both racial groups (P<0.001). In multivariate analysis T2D 
was 4.2-fold more common and HOMA-IR 29.7% higher in Indian Asians 
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compared to Europeans despite adjustment for age, sex, BMI, WHR, and 
LTPA (P<0.001).  
 
Conclusions 
The striking ~4-fold higher risk of T2D, undiagnosed T2D and pre-diabetes 
amongst Indian Asians compared to Europeans is not explained by known 
lifestyle risk factors. Understanding the increased susceptibility to T2D 
amongst Indian Asians, who comprise one quarter of the world’s population, is 
a global priority. 
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3.2 AIMS 
 To determine the burden of T2D and related glycaemic disturbances 
amongst Indian Asians compared to Europeans, and to investigate the 
contribution of adiposity and leisure time physical activity to differences in risk 
of T2D and associated glycaemic disturbances between the two racial groups. 
 
3.2.1 Specific aims 
1. To determine the prevalence of T2D, undiagnosed T2D and pre-diabetes 
amongst Indian Asian men and women compared European men and women 
participating in the LOLIPOP study. 
2. To investigate the contribution of adiposity to T2D and related glycaemic 
disorders amongst Indian Asians compared to Europeans. 
3. To evaluate the contribution of leisure time physical activity to T2D and 
related glycaemic disorders amongst Indian Asians compared to Europeans. 
4. To determine the extent to which lifestyle factors explain differences in T2D 
and associated glycaemic disorders amongst Indian Asians compared to 
Europeans.  
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3.3 INTRODUCTION  
Type-2 diabetes (T2D) is the fifth leading cause of death worldwide. T2D 
is a major risk factor for coronary heart disease, stroke, peripheral vascular 
disease and end-stage renal disease15,33. Current estimates suggest that T2D 
affects ~55 million Indian Asians worldwide227. This figure is expected to rise to 
~80 million by 2030, making Indian Asians the largest single population group 
with T2D globally. Increased T2D risk is most evident amongst Indian Asians 
who have moved from rural to urban settings, and those who have migrated 
overseas9,15.  
Based on small-scale observational studies, the prevalence of T2D is 
estimated as ~18% of Indian Asians compared to ~6% of Europeans15,228-230. 
However, little is known about the epidemiology and public health burden of 
T2D and its related metabolic disturbances amongst Indian Asian men and 
women. I therefore carried out a large-scale population based study of UK 
Indian Asians and Europeans to determine the prevalence of T2D, 
undiagnosed T2D and pre-diabetes in the two population groups. In addition I 
investigated the contribution of obesity and physical inactivity to the increased 
risk of T2D and related glycaemic disorders amongst Indian Asians.  
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3.4 METHODS AND MATERIALS 
3.4.1 Participants 
 I investigated 16,774 Indian Asians and 7,031 European participants of the 
London Life Sciences Population (LOLIPOP) study. LOLIPOP is an ongoing 
population based cohort study of Indian Asian and European men and women, 
aged 35-75 years, recruited from lists of 58 General Practitioners in West 
London, United Kingdom. Indian Asian ethnicity was identified as all four 
grandparents born on the Indian subcontinent (India, Pakistan, Sri Lanka and 
Bangladesh). Europeans had all four grandparents born in Europe. Response 
rates averaged 62% in Indian Asians and 61% in Europeans. Second 
generation Indian Asians were defined as those who were born in the UK. 
 
3.4.2 Participant characterization 
LOLIPOP participant characterization has been described in detail in 
chapter 2. Briefly, an interviewer-administered questionnaire was used to 
collect data on medical history, current prescribed medications, cardiovascular 
risk factors, leisure time physical activity (LTPA), country of birth, birth place of 
all four grandparents, language, and religion. Total time (in minutes per week) 
spent in LTPA was calculated and converted to MET-minutes per week. 
Participants were then categorized as physically active and inactive based on 
national guidance (≥450 MET-minutes/week)107.  
Physical measurements included height, weight, waist girth, hip 
circumference, and blood pressure. Following an 8-hour fast, blood was 
collected for biochemical analysis and whole blood was stored at -80oC for 
future genetic analyses.  
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T2D, undiagnosed T2D and pre-diabetes were defined using the 
American Diabetes Association criteria231: T2D as physician diagnosis of T2D or 
HbA1c ≥6.5% (47.5 mmol/mol); undiagnosed T2D as HbA1c ≥6.5% (47.5 
mmol/mol) without physician diagnosis of T2D; and pre-diabetes as HbA1c 
≥5.7% (38.8 mmol/mol) and <6.5% (47.5 mmol/mol), without physician diagnosis 
of T2D. Controls were individuals with no history of T2D and HbA1c <5.7% (38.8 
mmol/mol). Insulin resistance and pancreatic β-cell function were calculated 
using the Homeostasis Model of Assessment (HOMA) 2 calculator software 
licensed from Oxford University232.   
 
3.4.3 Statistical analyses 
SPSS version 19 was used for statistical analyses. Results are 
expressed as mean (standard deviation) or median (inter-quartile range) for 
continuous variables and as percentages for categorical variables. Continuous 
variables that were not normally distributed were log10 transformed, and 
geometric means and approximate standard deviations are presented. Initial 
univariate comparisons of continuous and categorical variables between 
Indian Asians and Europeans were carried out using the Student’s t-test and 
the 2-test respectively. The associations of BMI, waist circumference, WHR 
and LTPA with T2D were tested by logistic regression in Indian Asians and 
Europeans separately. Heterogeneity of effect between ethnic groups was 
tested by comparison of beta coefficients.  
Multivariate regression was carried out to examine the contribution of 
adiposity and LTPA to differences in T2D between Indian Asians and 
Europeans. The initial model comprised T2D as the dependant variable, and 
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age, sex and ethnicity as covariates. Stepwise adjustments were made for 
BMI, WHR, and LTPA. A similar approach was taken for undiagnosed T2D, 
pre-diabetes and HOMA-IR.  
To calculate changes in adiposity or LTPA required to equalise risk of 
T2D between Indian Asians and Europeans, I used multivariate regression 
model with T2D as the dependant variable and age, sex, WHR, BMI and total 
energy expended in LTPA (METs) as covariates. Beta-coefficients from this 
regression model were used to inform the following formula: 
Y   =  [Age  age] + [Sex  sex] + [Race  race] + [BMI  BMI] + [WHR  
WHR] + [LTPA  LTPA] + C 
Where:  
Y =  Risk of T2D 
BMI =  Body mass index (kg/m2) 
WHR =  Waist-to hip ratio 
LTPA =  Leisure time physical activity (METs-minutes per week) 
C =   Constant 
 
To calculate the magnitude of T2D risk attributable to BMI, WHR and 
LTPA amongst Indian Asians compared to Europeans, the T2D population 
attributable risk (PAR%) was estimated within each ethnic group using the 
following formula: 
 
[Pe(RR-1)x100]/[Pe(RR-1)+1] 
RR = Relative risk (estimated as the OR)  
Pe  = Proportion of the population exposed to each respective risk factor 
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3.5 RESULTS 
3.5.1 T2D, undiagnosed T2D and pre-diabetes amongst Indian Asians 
and Europeans 
 Clinical characteristics of LOLIPOP study participants are shown in tables 
3.1 and 3.2. The mean prevalence of T2D was 21.1% among Indian Asians 
and 7.3% among Europeans. Higher rates of T2D were present in Indian 
Asians than Europeans in each age group and in both men and women 
(figures 3.1 and 3.2). After adjustment for age and sex, the odds ratio (OR) 
for T2D was 4.21 (95% CI: 3.80 – 4.65, P<0.001) amongst Indian Asians 
compared to Europeans.  
  The prevalence of undiagnosed T2D was 6.1% and of pre-diabetes 
32.3% amongst Indian Asians, compared to 1.7% and 18.2% in Europeans 
respectively (both P<0.001 respectively; table 3.1 and 3.2, figures 3.3 and 
3.4). After adjusting for age and sex the ORs for undiagnosed T2D and pre-
diabetes were 4.65 (95% CI: 3.84 – 5.63, P<0.001) and 3.30 (95% CI: 3.07 – 
3.55, P<0.001) respectively amongst Indian Asians compared to Europeans.  
 
3.5.2 Comparison of fasting plasma levels of glucose and insulin, and 
HOMA-IR and HOMA-B amongst Indian Asians compared to Europeans 
  Fasting glucose, insulin, HOMA-IR and HOMA-B were higher amongst 
Indian Asians than Europeans (table 3.1, figure 3.4). The mean decline of 
HOMA-B with advancing age was 0.62% (95% CI: 0.54% – 0.70%) per year 
amongst non-diabetic Indian Asians compared to 0.08% (95% CI: 0.02% – 
0.18%) per year among non-diabetic Europeans. Adjusting for age and sex, 
HOMA-IR was 38.4% (95% CI: 35.3% – 41.5%, P<0.001) higher, and HOMA-
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B 8.9% (95% CI: 7.2% – 10.7%, P<0.001) higher amongst Indian Asians 
compared to Europeans. Differences in glucose, insulin, HOMA-IR and 
HOMA-B amongst Indian Asians compared to Europeans were greatest in the 
younger age groups (all P<0.001 for age*ethnicity interaction).  
 
3.5.6 T2D, undiagnosed T2D and pre-diabetes amongst major Indian 
Asian sub-groups and religious groups 
  Clinical characteristics of 2nd generation Indian Asians compared to 
Europeans are shown in table 3.3. The mean age of second generation Indian 
Asians was 37.3 years compared to 52.3 years among European LOLIPOP 
participants (P<0.001). The prevalence of T2D amongst 2nd generation Indian 
Asians was similar to rates observed in Europeans (table 3.4). Rates of T2D 
were highest amongst Bangladeshis and lowest amongst UK born, second 
generation Indian Asians (ANOVA, P<0.001). 
  Comparing major Indian Asian religious groups, the prevalence of T2D 
was highest amongst Muslims and lowest among Sikhs (25.2% vs 19.2%, 
P<0.001), though inter-faith differences of T2D rates did not reach statistical 
significance (ANOVA, P=0.47). Compared to Europeans, the prevalence of 
T2D was consistently higher among all major Indian Asian religious subgroups 
(table 3.5). 
  Rates of undiagnosed T2D and pre-diabetes were highest among Sri 
Lankans and lowest amongst individuals born in India (ANOVA P<0.001 for 
undiagnosed T2D and pre-diabetes respectively; table 3.4). Indian Asians 
born outside the UK consistently demonstrate higher levels of undiagnosed 
T2D and pre-diabetes than Europeans. The prevalence of undiagnosed T2D 
106 
 
was similar and rates of pre-diabetes higher amongst second generation 
Indian Asians than Europeans. Among the major religious groups, rates of 
undiagnosed T2D and pre-diabetes were highest amongst Muslims and 
Christians respectively (table 3.5), and were consistently elevated among all 
religious faith groups compared to Europeans. 
 
3.5.7 Contribution of adiposity and leisure time physical activity to risk of 
T2D, undiagnosed T2D, pre-diabetes and HOMA-IR amongst Indian 
Asians compared to Europeans 
BMI was similar and WHR higher amongst Indian Asians compared to 
Europeans (table 3.1). In univariate analyses BMI and WHR were associated 
with increased risk of T2D, undiagnosed T2D, pre-diabetes and with HOMA-
IR, in both population groups, though associations were generally weaker 
amongst Indian Asians than Europeans (table 3.6 – 3.9). In regression 
analysis the associations of BMI and WHR with T2D, undiagnosed T2D and 
pre-diabetes were independent and additive (table 3.10).  
Comparing Indian Asians to Europeans, rates of T2D were higher at 
every level of general and central obesity (figure 3.6). Differences in 
prevalence of T2D between the two populations were most marked in lean 
than in obese (Indian Asians versus European: BMI<25Kg/m2: OR 9.56, 95%: 
CI 7.05 – 12.87, P<0.001; BMI>40kg/m2: OR 1.74, 95% CI 0.98 – 2.34 
P=0.16; figure 3.6). The population risks of T2D attributable to overweight 
(BMI>25kg/m2) and central obesity (WHR>0.9) were similar amongst Indian 
Asians compared to Europeans (table 3.11, overweight: 40.6% versus 39.6%, 
P=0.45; central obesity: 63.3% versus 67.7%, P=0.52). 
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LTPA was lower amongst Indian Asians than Europeans (figure 3.7) 
and was inversely related to T2D in both population groups (age and sex 
adjusted Indian Asians (OR 0.88, 95% CI: 0.81 – 1.01, P=0.07), Europeans 
(OR 0.50, 95% CI 0.39 – 0.63, P<0.001). Comparison of LTPA between 
populations showed that Indian Asians were 57% less likely to perform more 
than 450MET-minutes/week of moderate to vigorous levels of LTPA than 
Europeans (OR 0.43, 95% CI: 0.40 – 0.46, P<0.001), after adjustment for age, 
sex and BMI). Odds ratio for T2D amongst Indian Asians compared to 
Europeans was greatest in the most physically active than the sedentary 
participants (Odds ratio for T2D Indian Asians versus Europeans: <200MET-
minutes/week: 3.43 (95% CI: 2.88 – 3.91), P<0.001; >800MET-minutes/week: 
5.62 (3.51 – 7.68), P<0.001; figure 3.6). LTPA was associated with reduced 
risk of undiagnosed T2D and pre-diabetes in Indian Asian and European 
women, but not in men.  
In subgroup analysis, levels of LTPA were lowest amongst 
Bangladeshis and highest amongst second generation Indian Asians (ANOVA 
P<0.001). In the latter, the proportion of individuals participating in at least 450 
MET-minutes per week was similar to rates observed among Europeans 
(table 3.12). Furthermore, levels of LTPA were lowest among Muslims and 
highest in the “other” faith groups (ANOVA P<0.001; table 3.13). Europeans 
consistently participated in higher levels of physical activity compared to the 
major Indian Asians religious groups.  
The population risk of T2D attributable to physical inactivity (considered 
as a binary variable; those who do and do not participate in greater than 450 
MET-minutes per week of LTPA) was similar in Indian Asians compared to 
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Europeans (20.8% versus 18.1%, P=0.34; table 3.11). In regression analysis 
LTPA (considered as a binary variable; those who do and do not participate in 
greater than 450 Met-minutes per week of LTPA) was associated with 10% 
and 18% reduction in HOMA-IR amongst Indian Asian men and women 
respectively (table 3.9). The corresponding changes in HOMA-IR among 
Europeans were 19% and 24% in men and women respectively. 
 
3.5.8 Determinants of increased risk of T2D amongst Indian Asians 
compared to Europeans  
  Following adjustment for age and sex Indian Asians had ~4-fold higher 
risk of T2D than Europeans (OR for T2D: 4.21, 95% CI: 3.8 0 – 4.65), P<0.001 
(table 3.14). The risk of T2D remained elevated despite adjustment for age, 
sex, BMI, WHR, LTPA (OR 4.05, 95% CI: 3.63 – 4.50, P<0.001). Findings 
were similar for undiagnosed T2D and pre-diabetes (table 3.15). 
 
3.5.9 Determinants of increased risk of T2D amongst 2nd generation 
Indian Asians compared to Europeans 
  Following adjustment for age and sex 2nd generation Indian Asians had 
~2.5-fold higher risk of T2D than Europeans (OR for T2D: 2.40, 95% CI: 1.76 – 
3.30), P<0.001 (table 3.14). The risk of T2D remained elevated despite 
adjustment for age, sex, BMI, WHR, LTPA (OR for T2D: 2.28, 95% CI: 1.64 – 
3.17, P<0.001). Findings were similar for undiagnosed T2D and pre-diabetes 
(table 3.15). 
 
109 
 
3.5.10 Determinants of increased HOMA-IR amongst Indian Asians 
compared to Europeans 
  Amongst Indian Asians, HOMA-IR was OR 29.7%, 95% CI: 27.4% – 
32.1%, P<0.001) higher than Europeans despite adjustment for age, sex, BMI, 
WHR and LTPA (table 3.17).  
 
3.5.11 Changes in adiposity or levels of LTPA required to equalise T2D 
risk between Indian Asians and Europeans 
  Beta coefficients used to calculate changes in levels of adiposity or 
LTPA required for Indian Asians to achieve risk of T2D comparable to 
Europeans are shown in table 3.17. For an Indian Asian man, aged 50 years, 
to have equivalent risk of a 50 year old European man (BMI 30kg/m2, WHR of 
0.9 who participates in 450 MET -minutes of LTPA per week), they would need 
reduce their BMI to 9.1 kg/m2 or reduce their WHR to 0.65 or increase levels 
of LTPA to 98,986 MET-minutes per week. 
 
3.5.12 Non-responders 
 Response rates averaged 62% in Indian Asians and 61% in Europeans. 
There were no material differences in age, gender, ethnicity and place of 
residence between responders and non-responders of the LOLIPOP study 
(figure 3.8).  
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3.6 DISCUSSION 
I show the risk of both pre-diabetes and T2D is a striking 4-fold higher 
amongst Indian Asian men and women, than in Europeans. Though adiposity, 
LTPA contribute to pre-diabetes and T2D in Indian Asians, they fail to account 
for the excess risk of both pre-diabetes and T2D amongst Indian Asians than 
Europeans. Our observations call for urgent research aimed at understanding 
susceptibility amongst Indian Asians to pre-diabetes and T2D. 
As in Europeans, I demonstrate that WHR and BMI are independent 
risk factors for T2D among Indian Asians, though effect sizes are smaller. I 
show a ~10-fold excess of T2D amongst lean Indian Asians than Europeans 
(BMI<25kg/m2), and similar risk of T2D among the morbidly obese. 
Differences in adiposity do not account for the 4-fold excess risk of T2D 
amongst Indian Asians compared to Europeans. My results challenge existing 
paradigms on the importance of adiposity to increased T2D risk among Indian 
Asians. 
In all populations studied including Indian Asians, there is growing 
evidence of a role for ectopic fat deposition and increased T2D risk233. 
Deposition of triglycerides within non-adipose tissue such as liver and 
pancreatic islet cells, disrupt glucose-insulin metabolism and contributes to the 
development of hepatic insulin resistance234 and -cell dysfunction64,65. In 
addition, adipose cell size, which is increased in Indian Asians, is positively 
correlated with T2D risk101. Failure of BMI and WHR to account for the 
increased risk of T2D amongst Indian Asians could represent reduced 
sensitivity of these simple measures of adiposity to fully capture the complex 
distribution of fat as well as extent of adipocyte cell hypertrophy in Indian 
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Asians. This may account for the underestimated effect of metabolically active 
adipose tissue on T2D risk observed among Indian Asians. Future 
investigations, employing state of the art imaging techniques, to fully 
characterize fat distribution and ectopic deposition, as well as adipocyte size, 
are required to delineate the contribution of adiposity to T2D risk among Indian 
Asians.   
Consistent with previous work, Indian Asians were 57% less likely than 
Europeans to participate in the minimum amount of LTPA according to current 
recommendations115. Bangladeshis, who have the highest rates of T2D, were 
the least likely to comply with these recommendations, while second 
generation Indian Asians participated in similar levels of LTPA to Europeans.  
Even among the most physically active, I show a striking ~6-fold excess of 
T2D amongst India Asians compared to Europeans, and adjustment for LTPA 
did not account for the excess risk of T2D and related glycaemic disorders 
between the two racial groups as a whole.  
A lack of association of LTPA with T2D among Indian Asians is 
surprising given that the interview-based questionnaire used comprised a 
comprehensive assessment of intensity, duration, frequency and type of leisure 
time physical activity. However, the validity of self-reported physical activity 
questionnaire as a measure of activity and energy expenditure has not 
specifically been evaluated in Indian Asian populations. Although I characterize 
LTPA, there is a lack of data on physical activity from occupation, 
transportation, or housework. In addition there is an absence of data on 
environmental factors that are known to limit physical activity, including 
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neighbourhood safety, crowding, and access to exercise facilities235; all the 
aforementioned may have confounded my association testing. 
Both insulin resistance and pancreatic β-cell dysfunction lead to 
impaired insulin secretion and are important in the pathogenesis of T2D1. I 
show that independent of lifestyle factors, HOMA-IR is 30% higher amongst 
non-diabetic Indian Asians compared to Europeans, and differences between 
the two racial groups are most pronounced in the young. In addition rate of 
decline of pancreatic β-cell function is ~8-fold greater among non-diabetic 
Indian Asians than non-diabetic Europeans. My findings make a case for 
increased genetic predisposition to insulin resistance and β-cell dysfunction 
underlying increased susceptibility to T2D in Indian Asians, and provide a 
rationale for future genome-wide association studies in Indian Asians using 
HOMA-IR and HOMA-B phenotypes.  
My data shows that through intense efforts to reduce weight and 
increase levels of physical activity, it is possible to reduce, but not eliminate, 
the considerable burden of T2D among Indian Asians to levels observed in 
Europeans. I calculate that Indian Asians would need to either reduce their 
BMI by 21kg/m2, or reduce WHR by 0.25, or increase levels of LTPA 222 
times the minimum weekly recommendation to achieve risk of T2D 
comparable with Europeans with BMI of 30kg/m2 and a WHR of 0.9 who 
performs 450 MET-minutes of LTPA per week. There is a public health 
mandate to rapidly introduce measures to reduce obesity and increase levels 
of physical activity among Indian Asians to lessen the burden of T2D and 
related complications. 
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In conclusion I show that the prevalence of T2D and related glycaemic 
disturbances are ~5 fold higher amongst Indian Asian men and women 
compared to Europeans. Failure of adiposity and LTPA to account for the high 
burden of glycaemic disorders amongst Indian Asians is a major obstacle to 
health promotion in this population. An international programme to identify 
dietary and genetic susceptibility factors underlying the increased prevalence 
of T2D and related glycaemic disturbances amongst Indian Asians is needed.  
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Figure 3.1: Prevalence of T2D (mean, 95% confidence intervals) amongst Indian Asian and European men and women. 2-
test was used to compare prevalence of T2D between Indian Asian and Europeans men and women; p<0.001 at each age 
category 
 
 
 
 114 
 
115 
 
Figure 3.2: Prevalence of pre-diabetes, known T2D and undiagnosed T2D amongst Indian Asian and European men and 
women.  
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Figure 3.3: Prevalence of pre-diabetes and undiagnosed T2D (mean, 95% confidence intervals) amongst Indian Asian and 
European men and women.  
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Figure 3.4: Levels of glucose, insulin, HOMA-B and HOMA-IR amongst Indian Asians and Europeans. Results are presented 
as mean (95% CI) by 5-year age group for: (i) all participants, (ii) non-diabetics, (iii) non-diabetic males, and (iv) non-diabetic 
females. 
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Figure 3.5: The prevalence of T2D stratified by (A) body mass index and (B) waist-to hip ratio amongst Indian Asians and 
Europeans. Shading represents 95% confidence bands. 
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Figure 3.6: Odds ratios for T2D amongst Indian Asian versus Europeans, stratified by (A) WHO classification of obesity, (B) WHO 
South Asian specific classification of obesity, (C) waist-to hip ratio (D) leisure time physical activity. WHO BMI criteria (kg/m2): 
Normal< 25; Overweight: 25.1 – 30; Obese: 30.1 – 35; Severely obese: 35.1 – 40, Morbidly obese> 40. South Asian WHO BMI 
criteria (kg/m2): Normal< 23.5; Overweight: 23.6 – 27.5; Obese: 27.6 – 32.5; Severely obese: 32.6 – 37.5, Morbidly obese>37.5.    
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Figure 3.7:  LTPA stratified by age amongst Indian Asians compared to Europeans. 2-test was used to compare LTPA 
between Indian Asian and Europeans. 
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Figure 3.8: Response rates stratified by (A) Hounslow wards and ethnicity; (B) Ealing wards and ethnicity; (C) age and ethnicity; 
and (D) age and gender. 
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Table 3.1: Characteristics of Indian Asian and European participants. Results are presented as mean (s.d.) for continuous 
variables or as percent for categorical variables. *Median and inter-quartile range given for leisure time physical activity (LTPA). 
Age and sex adjusted P-values are presented. 
 
 
  Indian Asians Europeans  P 
    
N 16,774 7,031 - 
Age (years) 50.5 (11.2) 52.3 (11.6) <0.001 
Male gender (%) 61.2 59.6 <0.001 
Body mass index (kg/m2) 27.4 (4.6) 27.5 (5.2) 0.66 
Waist-hip ratio 0.94 (0.08) 0.91 (0.08) <0.001 
    
Systolic blood pressure (mmHg) 130.8 (19.3) 130.6 (19.1) <0.001 
Diastolic blood pressure (mmHg) 80.4 (10.7) 79.3 (10.5) <0.001 
Hypertension (%) 27.8 19.2 <0.001 
    
LTPA (MET-min/week)* 0 (0 – 240) 160 (160 – 480) <0.001 
LTPA (% ≥450 MET-min/week) 15.3 28.8 <0.001 
Current smoker (%) 10.0 25.4 <0.001 
Alcohol (Units/ week) 4.6 (11.4) 12.4 (17.6) <0.001 
    
HbA1c (%) 6.0 (1.3) 5.5 (0.9) <0.001 
HbA1c (mmol/mol) 42.1 (9.5) 36.6 (6.5) <0.001 
Glucose (mmol/L) 5.8 (2.0) 5.4 (1.5) <0.001 
Insulin (IU/L) 10.5 (9.8) 7.6 (8.0) <0.001 
HOMA-IR  1.4 (1.2) 1.0 (1.0) <0.001 
HOMA-B (%) 96.9 (75.8) 87.7 (55.2) <0.001 122 
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Cholesterol (mmol/L) 5.2 (1.1) 5.4 (1.1) <0.001 
Triglycerides (mmol/L) 1.44 (1.00) 1.25 (0.92) <0.001 
HDL cholesterol  (mmol/L) 1.25 (0.33) 1.39 (0.40) <0.001 
LDL cholesterol (mmol/L) 3.06 (1.09) 3.21 (1.08) <0.001 
        
Pre-diabetes (%) 32.3 20.3 <0.001 
Undiagnosed T2D (%) 6.1 1.9 <0.001 
T2D (%) 21.1 7.3 <0.001 
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Table 3.2: Characteristics of Indian Asian and European participants stratified by gender. Results are presented as mean (s.d.) for 
continuous variables or as percent for categorical variables. 
 
 
 Indian Asians  Europeans 
 Men Women  Men Women 
      
N 10,269 6,505  4,187 2,844 
Age (years) 50.2 (11.5) 50.9 (10.5)  52.0 (11.7) 52.7 (11.5) 
BMI (kg/m2) 27.0 (4.1) 28.0 (5.2)  27.7 (4.6) 27.2 (5.9) 
WHR 0.96 (0.07) 0.92 (0.09)  0.94 (0.07) 0.87 (0.09) 
LTPA (%) 13.2 16.6  28.8 28.8 
      
Glucose (mmol/L) 5.7 (1.7) 5.3 (1.4)  5.3 (1.2) 5.1 (1.0) 
Insulin (IU/L) 10.8 (10.4) 10.0 (8.9)  7.8 (8.7) 7.2 (6.9) 
HOMA-B (%) 94.2 (79.2) 101.9 (1.29)  90.4 (50.9) 86.1 (57.7) 
HOMA-IR 1.4 (1.3) 1.3 (1.1)  1.0 (0.9)  1.0 (1.0) 
      
Cholesterol (mmol/L) 5.3 (1.1) 5.1 (1.0)  5.4 (1.1) 5.4 (1.1) 
HDL (mmol/L) 1.18 (0.30) 1.36 (0.34)  1.28 (0.34) 1.55 (0.42) 
LDL (mmol/L) 3.10 (1.14) 3.00 (1.00)  3.25 (1.08) 3.14 (1.08) 
Triglycerides (mmol/L) 1.57 (1.13) 1.26 (0.76)  1.37 (1.03) 1.09 (0.73) 
      
T2D (%) 22.7 18.6  8.5 5.5 
Undiagnosed T2D (%) 6.1 6.1  2.0 1.4 
Pre-diabetes (%) 28.9 37.5  17.0 21.4 
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Table 3.3: Characteristics of UK born (second generation) Indian Asian and European LOLIPOP participants. Results are 
presented as mean (s.d.) for continuous variables or as percent for categorical variables. 
 
 UK Indian Asians Europeans P 
    
N 1449 7031  
Age (years) 37.1 (4.8) 52.3 (11.6) <0.001 
Male gender (%) 66.0 59.6 <0.001 
BMI (kg/m2) 27.2 (5.1) 27.5 (5.2) 0.10 
WHR 0.91 (0.08) 0.91 (0.08) 0.91 
LTPA (%) 27.1 28.8 0.01 
    
HbA1c (%) 5.5 (0.8) 5.5 (0.9) 0.72 
HbA1c (mmol/mol) 40.2 (5.8) 40.2 (6.6) 0.72 
Glucose (mmol/L) 5.1 (1.0) 5.4 (1.5) <0.001 
Insulin (IU/L) 10.1 (9.8) 7.6 (8.0) <0.001 
HOMA-B (%) 113.8 (72.1) 87.7 (55.2) <0.001 
HOMA-IR 1.3 (1.2) 1.0 (1.0) <0.001 
    
Cholesterol (mmol/L) 5.3 (1.1) 5.4 (1.1) <0.001 
HDL (mmol/L) 1.28 (0.35) 1.25 (0.92) <0.001 
LDL (mmol/L) 3.17 (1.01) 3.21 (1.08) <0.001 
Triglycerides (mmol/L) 1.31 (1.04) 1.39 (0.40) <0.001 
     
Pre-diabetes (%) 24.3 20.3 <0.001 
Undiagnosed T2D (%) 2.1 1.7 0.67 
T2D (%) 5.9 7.3 0.06 
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Table 3.4: Prevalence of known T2D, undiagnosed T2D and pre-diabetes amongst Indian Asians stratified by country of birth. *2-
test used to compare prevalence with Europeans. 
 
 
 
Country of birth (n) 
Prevalence of 
T2D 
(%, 95% CI) 
P* 
 Prevalence of 
undiagnosed T2D 
(%, 95% CI) 
P* 
 Prevalence of  
pre-diabetes 
(%, 95% CI) 
P* 
         
Indian Asians         
India (8576) 22.2 (21.4 – 23.1) <0.001  6.3 (5.5 – 7.1) <0.001  39.6 (37.9 – 41.3) <0.001 
Pakistan (1982) 26.9 (25.0 – 28.9) <0.001  7.9 (7.3 – 8.5) <0.001  43.7 (42.5 – 44.9) <0.001 
Sri Lanka (653) 23.9 (20.6 – 27.2) <0.001  9.4 (8.0 – 10.9) <0.001  44.4 (41.8 – 47.0) <0.001 
Bangladesh (130) 27.7 (20.0 – 35.4) <0.001  7.8 (5.5 – 10.1) <0.001  43.5 (39.1 – 47.8) <0.001 
Other (4000) 20.6 (19.3 – 21.9) <0.001  8.7 (3.3 – 14.2) <0.001  48.9 (38.8 – 59.0) <0.001 
United Kingdom (1449) 5.9 (4.6 – 7.1) 0.06  2.1 (1.3 – 2.9) 0.67  24.8 (22.5 – 27.1) <0.001 
         
Europeans (7031) 7.3 (6.6 – 7.9) 
 
-  1.9 (1.6 – 2.3) 
 
-  20.3 (19.3 – 21.2) 
 
- 
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 Table 3.5: Prevalence of known T2D, undiagnosed T2D and pre-diabetes amongst Indian Asians stratified by religion. *2-test 
used to compare prevalence with Europeans. 
 
 
 
Religion (n) Prevalence of T2D (%, 95% CI) P* 
 Prevalence of 
undiagnosed T2D 
(%, 95% CI) 
P* 
 Prevalence of  
pre-diabetes 
(%, 95% CI) 
P* 
         
Indian Asians         
Hindu (4438) 22.0 (20.8 – 23.2) <0.001  8.1 (7.2 – 9.0) <0.001  42.7 (41.0 – 44.3) <0.001 
Sikh (8224) 19.2 (18.3 – 20.0) <0.001  6.1 (5.5 – 6.6) <0.001  38.6 (37.4 – 39.8) <0.001 
Muslim (3220) 25.2 (23.7 – 26.7) <0.001  8.8 (7.7 – 9.9) <0.001  44.1 (42.2 – 46.1) <0.001 
Christian (535) 24.1 (20.5 – 27.7) <0.001  7.9 (5.4 – 10.5) <0.001  45.1 (40.2 – 49.9) <0.001 
Other (357) 14.0 (10.4 – 17.6) <0.001  4.7 (2.4 – 7.0) <0.001  39.1 (33.6 – 44.5) <0.001 
         
Europeans (7031) 7.3 (6.6 – 7.9) 
 
-  1.9 (1.6 – 2.3) 
 
-  20.3 (19.3 – 21.2) 
 
- 
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Table 3.6: Gender stratified age adjusted logistic regression analysis for association of lifestyle risk factors with T2D amongst 
Indian Asians and Europeans. Odds ratios for age, WHR, BMI and waist are presented for one standard deviation change in the 
predictor variable. LTPA is presented as a binary variable (those who do and those who do not participate in greater than or equal 
to 450 MET-minutes/ week).  Phetero refers to P-value for heterogeneity of effect between Indian Asians and Europeans. (BMI= body 
mass index, WHR=waist-to hip ratio, LTPA= leisure time physical activity). 
 
 
 
Males 
      
 Indian Asians  Europeans   
 OR (95% CI) for T2D P OR (95% CI) for T2D P Phetero 
Age 2.16 (2.02 – 2.32) <0.001 2.07 (1.84 – 2.32) <0.001 0.49 
WHR 1.58 (1.50 – 1.66) <0.001 1.91 (1.70 – 2.14) <0.001 0.005 
BMI 1.39 (1.33 – 1.46) <0.001 1.89 (1.71 – 2.09) <0.001 <0.001 
Waist 1.42 (1.37 – 1.48) <0.001 1.99 (1.77 – 2.25) <0.001 <0.001 
LTPA 0.90 (0.79 – 1.03) 0.13 0.60 (0.45 – 0.80) <0.001 0.01 
      
Females 
      
 Indian Asians  Europeans   
 OR (95% CI) for T2D P OR (95% CI) for T2D P Phetero 
Age 1.97 (1.86 – 2.10) <0.001 2.33 (1.95 – 2.79) <0.001 0.35 
WHR 1.77 (1.65 – 1.90) <0.001 2.03 (1.73 – 2.37) <0.001 0.10 
BMI 1.55 (1.46 – 1.64) <0.001 2.21 (1.92 – 2.54) <0.001 <0.001 
Waist 1.56 (1.47 – 1.65) <0.001 2.61 (2.20 – 3.11) <0.001 <0.001 
LTPA  0.91 (0.74 – 1.11) 0.35 0.54 (0.34 – 0.85) <0.001 0.04 
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Table 3.7: Gender stratified age adjusted logistic regression analysis for association of lifestyle risk factors with undiagnosed T2D 
amongst Indian Asians and Europeans. Odds ratios for age, WHR, BMI and waist are presented for one standard deviation change 
in the predictor variable. LTPA is presented as a binary variable (those who do and those who do not participate in greater than or 
equal to 450 MET-minutes week).  Phetero refers to P-value for heterogeneity of effect between Indian Asians and Europeans. (BMI= 
body mass index, WHR=waist-to hip ratio, LTPA= leisure time physical activity). 
 
Males 
      
 Indian Asians  Europeans   
 
OR (95% CI) for 
Undiagnosed T2D P 
OR (95% CI) for 
Undiagnosed T2D P Phetero 
Age 1.54 (1.41 – 1.69) <0.001 1.77 (1.58 – 1.99) <0.001 0.06 
WHR 1.56 (1.44 – 1.70) <0.001 1.38 (1.28 – 1.50) <0.001 0.07 
BMI 1.53 (1.43 – 1.65) <0.001 1.62 (1.49 – 1.76) <0.001 0.88 
Waist 1.53 (1.41 – 1.67) <0.001 1.70 (1.54 – 1.87) <0.001 0.60 
LTPA 0.87 (0.70 – 1.10) 0.27 0.77 (0.54 – 1.08) 0.12 0.52 
      
Females 
      
 Indian Asians  Europeans   
 
OR (95% CI) for 
Undiagnosed T2D P 
OR (95% CI) for 
Undiagnosed T2D P Phetero 
Age 1.46 (1.35 – 1.59) <0.001 1.67 (1.34 – 2.10) <0.001 0.46 
WHR 1.82 (1.63 – 2.04) <0.001 2.88 (2.21 – 3.76) <0.001 0.001 
BMI 1.69 (1.55 – 1.84) <0.001 2.40 (1.93 – 2.98) <0.001 0.04 
Waist 1.51 (1.39 – 1.64) <0.001 2.90 (2.17 – 3.87) <0.001 0.003 
LTPA  0.69 (0.49 – 0.97) 0.03 0.56 (0.32 – 0.99) 0.047 0.25 
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Table 3.8: Age-adjusted logistic regression analysis for association of lifestyle risk factors with pre-diabetes amongst Indian Asian 
and Europeans men and women (BMI= body mass index, WHR=waist-to hip ratio, LTPA= leisure time physical activity). Odds 
ratios for age, WHR, BMI and waist are presented for one standard deviation change in the predictor variable. LTPA is presented 
as a binary variable (those who do and those who do not participate in greater than or equal to 450 MET-minutes/ week).  Phetero 
refers to P-value for heterogeneity of effect between Indian Asians and Europeans. 
 
Males 
   
 
   
 Indian Asians  Europeans   
 
OR (95% CI) for 
Pre-diabetes P 
OR (95% CI) for 
Pre-diabetes P Phetero 
Age 1.39 (1.33 – 1.45) <0.001 1.82 (1.66 – 1.99) <0.001 <0.001 
WHR 1.34 (1.28 – 1.41) <0.001 1.75 (1.60 – 1.91) <0.001 <0.001 
BMI 1.40 (1.33 – 1.47) <0.001 1.52 (1.40 – 1.65) <0.001 0.52 
Waist 1.39 (1.34 – 1.45) <0.001 1.74 (1.58 – 1.92) <0.001 <0.001 
LTPA 0.92 (0.82 – 1.04) 0.27 0.90 (0.76 – 1.08) 0.28 0.86 
      
Females 
      
 Indian Asians  Europeans   
 
OR (95% CI) for 
Pre-diabetes P 
OR (95% CI) for 
Pre-diabetes P Phetero 
Age 1.82 (1.71 – 1.93) <0.001 2.31 (2.06 – 2.58) <0.001 0.01 
WHR 1.45 (1.37 – 1.54) <0.001 1.73 (1.57 – 1.91) <0.001 <0.001 
BMI 1.61 (1.52 – 1.70) <0.001 1.64 (1.49 – 1.80) <0.001 0.23 
Waist 1.51 (1.45 – 1.57) <0.001 1.81 (1.66 – 1.97) <0.001 0.45 
LTPA 0.75 (0.64 – 0.88) 0.001 0.63 (0.51 – 0.77) <0.001 0.17 
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Table 3.9: Age-adjusted linear regression analysis for association of lifestyle risk factors with HOMA-IR amongst Indian Asian and 
Europeans men and women. Beta estimates are presented as percentage change in HOMA-IR for one standard deviation change 
in the predictor variable. 
Males 
       
 
Indian Asians 
Percentage change in HOMA-IR 
Estimate (95% CI) 
P 
 
Europeans 
Percentage change in HOMA-IR 
Estimate (95% CI) 
P Phetero 
Age -1.2 (-2.6 – 0.2) 0.09  11.4 (9.0 – 13.9) <0.0001 <0.001 
WHR 25.4 (23.8 – 27.0) <0.0001  38.5 (35.8 – 41.2) <0.0001 <0.001 
BMI 40.4 (37.9 – 43.0) <0.0001  51.6 (48.5 – 54.8) <0.0001 <0.001 
Waist 38.4 (36.8 – 40.1) <0.0001  53.0 (50.3 – 55.8) <0.0001 <0.001 
LTPA -10.3 (-13.4 – -7.0) <0.0001  -18.7 (-22.7 – -14.6) <0.0001 0.002 
       
       
Females 
       
 
Indian Asians 
Percentage change in HOMA-IR 
Estimate (95% CI) 
P 
 
Europeans 
Percentage change in HOMA-IR 
Estimate (95% CI) 
P Phetero 
Age 5.0 (3.2 – 6.8) <0.001  11.1 (8.3 – 14.0) <0.0001 0.001 
WHR 20.7 (18.7 – 22.7) <0.001  33.4 (30.4 – 36.5) <0.0001 <0.001 
BMI 33.1 (30.0 – 36.3) <0.001  46.0 (42.2 – 50.0) <0.0001 0.005 
Waist 30.4 (28.4 – 32.4) <0.001  45.4 (42.4 – 48.5) <0.0001 <0.001 
LTPA -18.7 (-22.7 – -14.6) <0.001  -23.8 (-27.8 – -19.6) <0.0001 0.09 
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Table 3.10: Associations of BMI and WHR for T2D, undiagnosed T2D and pre-diabetes amongst Indian Asians and Europeans. 
Results are based on a multivariate logistic regression model with disease state as the dependant variable and age, sex, BMI and 
WHR as independent variables. Odds ratios for BMI and WHR are presented for one standard deviation change in each variable. 
 
 
 
 
 Indian Asians   Europeans  
 OR (95%CI) P  OR (95%CI) P 
T2D      
BMI 1.29 (1.23 – 1.35) <0.001  1.35 (1.25 – 1.44) <0.001 
WHR 1.54 (1.47 – 1.62) <0.001  1.27 (1.18 – 1.37) <0.001 
      
Undiagnosed T2D      
BMI 1.49 (1.39 – 1.58) <0.001  1.78 (1.51 – 2.10) <0.001 
WHR 1.35 (1.25 – 1.45) <0.001  1.47 (1.30 – 1.66) <0.001 
      
Pre-diabetes      
BMI 1.32 (1.28 – 1.37) <0.001  1.35 (1.25 – 1.44) <0.001 
WHR 1.06 (1.02 – 1.11) 0.005  1.16 (1.11 – 1.22) <0.001 
      
 
 
132 
 
133 
 
Table 3.11: T2D attributable to adiposity and physical inactivity in European whites and Indian Asians. 
 
 
 
 
‡ The odds ratio of T2D for each risk factor. 
† Population attributable risk (%) was calculated as [Pe(RR-1)x100]/[Pe(RR-1)+1], where RR is the relative risk (estimated as the 
OR) and Pe is the proportion of the population exposed to each respective risk factor.  
 
 
 
 
 
 
Proportion of  
population exposed (%) 
 
 
 
 
 
Odds ratio 
for T2D‡ 
 
Population 
Attributable Risk (%)† 
 
 
Exposure 
 
Indian Asians Europeans Indian Asians Europeans 
      
BMI greater than 25kg/m2 68.5 65.5 2.00 40.6 39.6 
BMI greater than 30kg/m2 22.9 26.2 2.05 19.4 21.6 
WHR greater than 0.9 75.6 59.9 3.28 63.3 57.7 
LTPA less than 450 MET-minutes/ week 84.7 71.2 1.31 20.8 18.1 
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Table 3.12: Proportion of Indian Asians performing greater than or equal to 450 MET-minutes per week of LTPA stratified by 
country of birth. *2-test used to compare LTPA in individual Indian Asian sub-groups with Europeans. 
 
 
 
Country of birth (n) 
LTPA≥450 MET-min/week 
P* (%, 95% CI) 
 
Indian Asians  
 
    India (8576) 14.9 (13.8 – 16.0) <0.001 
    Pakistan (1982) 14.6 (13.8 – 15.3) <0.001 
    Bangladesh (653) 10.6 (9.2 – 12.0) <0.001 
    Sri Lanka (130) 16.1 (13.3 – 18.9) <0.001 
    Other (4000) 13.1 (7.3 – 18.9) <0.001 
    United Kingdom (1433) 26.9 (24.6 – 29.2) 0.14 
   
Europeans (7031) 28.8 (27.7 – 29.8) 
 
- 
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Table 3.13: Proportion of Indian Asians performing greater than or equal to 450 MET-minutes per week of LTPA stratified by self-
reported religion. *2-test used to compare LTPA in individual Indian Asian sub-groups with Europeans. 
 
 
 
Religion (n) 
LTPA≥450 MET-min/week 
P* (%, 95% CI) 
 
Indian Asians  
 
Hindu (4438) 18.1 (16.9 – 19.2) <0.001 
Sikh (8224) 15.0 (14.3 – 15.8) <0.001 
Muslim (3220) 10.9 (9.8 – 11.9) <0.001 
Christian (535) 19.3 (15.9 – 22.6) <0.001 
Other (357) 20.2 (16.0 – 24.3) <0.001 
   
Europeans (7031) 28.8 (27.7 – 29.8) 
 
- 
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Table 3.14: Multivariate regression analysis for association of Indian Asian ethnicity with T2D. Results are shown as OR (95%CI) 
for T2D amongst Indian Asians compared to Europeans before and after adjustment for known lifestyle risk factors. (BMI= body 
mass index, WHR=waist-to hip ratio, LTPA= leisure time physical activity). (A) In whole cohort (B) 2nd generation Indian Asians 
only. 
 
(A) 
 
 
 
(B) 
 
 Indian Asians vs Europeans OR (95% CI) for T2D P 
   
Age, Sex 4.21 (3.8 0 – 4.65) 0.001 
Age, Sex, BMI 4.66 (4.21 – 5.17) 0.001 
Age, Sex, BMI, WHR 4.03 (3.63 – 4.48) 0.001 
Age, Sex, BMI, WHR, LTPA 4.05 (3.63 – 4.50) 0.001 
   
 
2nd generation Indian Asians  
vs Europeans 
OR (95% C.I.) for T2D 
 
P 
   
Age 2.41 (1.77 – 3.30) <0.001 
Age, Sex 2.40 (1.76 – 3.28) <0.001 
Age, Sex, BMI 2.51 (1.82 – 3.48) <0.001 
Age, Sex, BMI, WHR 2.28 (1.64 – 3.17) <0.001 
Age, Sex, BMI, WHR, LTPA 2.28 (1.64 – 3.17) <0.001 
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Table 3.15: Multivariate regression analysis for association of Indian Asian ethnicity with undiagnosed T2D and pre-diabetes. 
Results are shown as OR (95%CI) for the respective glycaemic trait amongst Indian Asians compared to Europeans before and 
after adjustment for known lifestyle risk factors (BMI= body mass index, WHR=waist-to hip ratio, LTPA= leisure time physical 
activity). (A) In whole cohort (B) 2nd generation Indian Asians only. 
 
(A) 
 
 Indian Asians vs Europeans OR (95% C.I.) for undiagnosed T2D P 
Indian Asians vs Europeans 
OR (95% C.I.) for pre-diabetes P 
     
Age, Sex 4.65 (3.84 – 5.63) <0.001 3.30 (3.07 – 3.55) <0.001 
Age, Sex, BMI 5.20 (2.28 – 6.32) <0.001 3.51 (3.25 – 3.78) <0.001 
Age, Sex, BMI, WHR 4.63 (3.80 – 5.64) <0.001 3.32 (3.08 – 3.59) <0.001 
Age, Sex, BMI, WHR, LTPA 4.62 (3.79 – 5.63) <0.001 3.33 (3.08 – 3.59) <0.001 
     
 
(B) 
 
 
2nd generation Indian Asians  
vs Europeans 
OR (95% C.I.) for undiagnosed T2D 
P 
2nd generation Indian Asians  
vs Europeans 
OR (95% C.I.) for pre-diabetes 
P 
     
Age 2.48 (1.45 – 4.23) <0.001 3.68 (3.06 – 4.43) <0.001 
Age, Sex 2.46 (1.44 – 4.21) <0.001 3.68 (3.06 – 4.43) <0.001 
Age, Sex, BMI 2.49 (1.43 – 4.34) <0.001 3.82 (3.17 – 4.62) <0.001 
Age, Sex, BMI, WHR 2.19 (1.25 – 3.85) <0.001 3.65 (3.01 – 4.41) <0.001 
Age, Sex, BMI, WHR, LTPA 2.20 (1.25 – 3.85) <0.001 3.67 (3.03 – 4.44) <0.001 
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Table 3.16: Multivariate regression analysis for association of Indian Asian ethnicity with HOMA-IR. Results are shown as 
estimated percentage difference in HOMA-IR amongst Indian Asians compared to Europeans before and after adjustment for 
known lifestyle risk factors (BMI= body mass index, WHR=waist-to hip ratio, LTPA= leisure time physical activity). 
 
 
 
 Indian Asians vs Europeans  
 Percentage difference in HOMA-IR  
 Estimate (95% CI) P 
  
Age, Sex 38.4 (35.3 – 41.5) <0.001 
Age, Sex, BMI 38.4 (35.8 – 48.9) <0.001 
Age, Sex, BMI, WHR 31.2 (28.9 – 33.6) <0.001 
Age, Sex, BMI, WHR, LTPA 29.7 (27.4 – 32.1) <0.001 
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Table 3.17: Beta coefficients used to calculate changes in levels of adiposity or LTPA required for Indian Asians to achieve risk of 
T2D comparable Europeans with BMI of 30kg/m2 and a WHR of 0.9 who performs 450 MET-minutes of LTPA per week. 
 
 
 
Variable Beta coefficient 
  
Age 0.059 
  
Sex 0.215 
  
Race 1.382 
  
Body mass index 0.066 
  
Waist-to hip ratio 5.506 
  
Leisure time physical activity 1.390 10-5 
  
Constant -14.415 
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CHAPTER 4 
 
A DUPLICATE DIET STUDY TO INVESTIGATE THE 
CONTRIBUTION OF MAJOR DIETARY 
MACRONUTRIENTS TO INCREASED INSULIN 
RESISTANCE AMONGST INDIAN ASIANS COMPARED 
TO EUROPEANS 
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4.1 ABSTRACT 
Background 
Type-2 diabetes, insulin resistance and related metabolic disturbances are 
highly prevalent amongst Indian Asians compared to Europeans. Unhealthy 
diet is an important determinant of insulin resistance. I carried out direct 
chemical analysis of duplicate diet samples to investigate the contribution of 
dietary nutrients to differences in insulin resistance amongst Indian Asians 
compared to Europeans. 
 
Methods 
I carried out a duplicate diet study in a representative sample of 115 Indian 
Asian and 124 European men, aged between 35 and 75 years, participating in 
the LOLIPOP study. HOMA-IR was calculated using the Homeostasis Model of 
Assessment (HOMA) 2 calculator software. Duplicate diet samples were 
collected over one day between 2001 and 2003. Duplicate diet samples were 
weighed and then homogenized and stored at -80oC. Duplicate diet samples 
were analysed for macronutrient composition including total fat, carbohydrate, 
protein, fibre, and fatty acid subtypes.  
 
Results 
Among Indian Asians fasting plasma levels of insulin and HOMA-IR were 
higher, and fasting glucose levels and prevalence of impaired fasting glucose 
similar compared to Europeans. Intakes of protein, total fat and 
monounsaturated fatty acids were lower, carbohydrate higher, and fibre, 
polyunsaturated fatty acids, saturated fatty acids and trans fatty acids similar 
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amongst Indian Asians compared to Europeans. Dietary fibre was inversely 
related to HOMA-IR among Indian Asians (odds ratio [95% C.I.]: 0.67 [0.52 – 
0.86], P=0.002). After adjustment for age, HOMA-IR was 23.0% (3.6% - 46.0%) 
higher amongst Indian Asians than Europeans (P=0.02). In multivariate 
regression analysis HOMA-IR remained 24.7% higher amongst Indian Asians 
than Europeans despite adjustment for protein, carbohydrate, 
monounsaturated fatty acids and fibre (P=0.03), 
 
Conclusions 
Indian Asian diets are similar to European diets and differences in nutrition do 
not account for the ~25% higher risk of insulin resistance observed between 
racial groups.  
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4.3 GENERAL AIM 
  To investigate the contribution of dietary nutrients to differences in 
insulin resistance amongst Indian Asians compared to Europeans.  
 
4.3.1 SPECIFIC AIMS 
1. Carry out measurements of dietary macronutrients through chemical 
analysis of duplicate diet samples in Indian Asians and Europeans. 
2. Examine the relationship between nutrient intake and insulin resistance 
(HOMA-IR) in the two populations. 
3. Determine the extent to which dietary nutrients account for differences in 
insulin resistance amongst Indian Asian compared to Europeans.  
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4.2 INTRODUCTION 
Insulin resistance and related metabolic disturbances are highly 
prevalent amongst Indian Asians and contribute to their increased risk of T2D 
and cardiovascular disease compared to Europeans13. Although genetic factors 
are important determinants of insulin resistance195, environmental factors such 
as physical inactivity108, obesity72-74 and unhealthy diet119 are also considered 
to play a major role.  
Previous studies examining the relationship between dietary 
macronutrients and insulin resistance in Europeans point towards detrimental 
effects of fat intake, notably saturated131,147,148 and trans fat163, and a protective 
role for dietary fibre167. Effects of carbohydrates and protein on risk of insulin 
resistance and related metabolic disturbances are inconclusive165,173,174,236. 
Dietary patterns of Indian Asians differ to those of Europeans. Previous work 
among UK Indian Asians demonstrates consumption of total fat is higher, 
saturated fat similar, and intakes of polyunsaturated fat, fibre and carbohydrate 
higher compared to Europeans178. These differences in dietary nutrients would 
be expected to have a beneficial effect, and therefore do not explain the higher 
prevalence of insulin resistance and related metabolic disturbances amongst 
Indian Asians compared to Europeans.  
A major limitation of all previous studies comparing dietary patterns 
amongst Indian Asians and Europeans has been the use of imprecise methods 
such as food diaries (4 – 7 days), 24-hour recall and food frequency 
questionnaires120. Although many food-frequency questionnaires have been 
validated, they suffer from considerable measurement error that can profoundly 
affect the analysis and interpretation of studies in the relationship of nutrition 
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with disease states122. In addition diet-reporting tools are limited by food 
composition databases, which are recognised to be poorly representative of 
Indian Asian foods, and thus may not accurately reflect dietary habits123. 
The duplicate diet method is considered to be the most precise measure 
of actual dietary consumption237. Few duplicate diet studies have been carried 
out in any population, thus, little is known about dietary nutrients and their 
contribution to increased risk of insulin resistance in Indian Asians compared to 
Europeans. Therefore, I carried out direct chemical analysis of duplicate diet 
samples in a representative population sample of Indian Asians and Europeans 
to assess the contribution of dietary nutrients to insulin resistance and related 
metabolic disturbances.  
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4.4 METHODS AND MATERIALS 
4.4.1 Participants 
  I analyzed duplicate diet samples from a sample of 115 Indian Asian 
and 124 European men, aged 35 – 75 years, participating in the LOLIPOP 
study. All study participants were characterized according to LOLIPOP 
protocols. Participants with a history of T2D or cardiovascular disease were 
excluded from the study. HOMA-IR and HOMA-B were calculated using the 
Homeostasis Model of Assessment (HOMA) 2 calculator software licensed 
from Oxford University.  A binary variable for HOMA-IR was created by 
dividing individuals in the upper quartile of HOMA-IR, and those who were not. 
Impaired fasting glucose was defined as individuals with fasting glucose levels 
between 6.0 and 6.9mmol/L. 
 
4.4.2 Duplicate diet sampling 
Duplicate diet samples were collected over one day between 2001 and 
2003. Participants were instructed to collect duplicate portions of everything 
they ate and drank over a single 24-hour period. Participants were provided 
with a diet record diary, leak-proof bottles and digital scales, and were taught 
by the research dietician how to weigh, record and collect duplicate diets. The 
dietician recorded the total weight of each duplicate collection, then 
homogenized it and stored three 30ml aliquots at -80oC for subsequent 
analysis.  
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4.4.3 Dietary nutrient analysis 
 Duplicate diet samples were analysed in collaboration with the University 
of Surrey, Nutrition and Food Safety Laboratories, for: (i) macronutrient 
composition (total fat, carbohydrate, protein, fibre), and ii) fatty acid subtypes 
(saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), 
polyunsaturated fatty acids (PUFA) and trans fatty acids (TFA)). Detailed 
methodologies are provided in chapter 2. Energy intake for individual 
macronutrient was calculated using the Atwater system. Basal metabolic rate 
was estimated using the Harris–Benedict equation238. 
 
4.4.4 Statistical analysis 
Continuous data are expressed as mean ± standard deviation (SD), and 
categorical data as percentages (%). Logarithmic transformations were used 
for positively skewed data, and for these variables geometric means are 
presented with approximate standard deviations derived from the variance 
transformation formula.  
The Student’s T-test, and 2-test were used to compare continuous and 
categorical variables respectively. Relationships between dietary 
macronutrients and HOMA-IR, BMI and WHR were examined using correlation 
coefficients and linear regression. Logistic regression was used to evaluate the 
association of dietary macronutrients and HOMA-IR (defined as a binary 
variable) and impaired fasting glucose.  
Macronutrients that differed at baseline, or were associated with HOMA-
IR in either Indian Asians or Europeans were used as covariates in multivariate 
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regression analysis to investigate the extent to which dietary factors accounted 
for differences in HOMA-IR between Indian Asians and Europeans. 
 
4.4.5 Power 
This study has 80% power to identify correlations between nutrient intake 
and HOMA-IR of >0.2 at P<0.05, as well as a difference in correlation coefficient 
of >0.25 between the populations.  
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4.5 RESULTS 
4.5.1 Baseline characteristics 
Indian Asian participants were younger, had larger WHR, similar BMI 
and reduced body surface area compared to Europeans. Fasting plasma levels 
of insulin and HOMA-IR were higher, and fasting glucose levels, HOMA-B and 
prevalence of impaired fasting glucose were similar amongst Indian Asians 
compared to Europeans (table 4.1).  
Basal metabolic rate and weight of food consumed was lower, while total 
energy derived from diet similar amongst Indian Asians compared to 
Europeans. Intakes of protein, total fat and MUFA were lower, carbohydrate 
higher, and fibre, PUFA, SFA and TFA similar amongst Indian Asians 
compared to Europeans (table 4.2). 
 
4.5.2 Association of dietary of macronutrients with insulin resistance, 
impaired fasting glucose and insulin resistance 
In age-adjusted univariate regression analysis none of the 
macronutrients tested were associated with HOMA-IR amongst Indian Asians 
or Europeans, with no evidence for heterogeneity of effect between racial 
groups (table 4.3).  Considering HOMA-IR as a binary variable, dietary fibre 
was inversely related to HOMA-IR among Indian Asians (OR [95% C.I.]: 0.67 
[0.52 – 0.86], P=0.002) and intake of carbohydrate was positively correlated 
with insulin resistance among Europeans (OR [95% C.I.]: 1.09 [1.00 – 1.19], 
P=0.046; table 4.4). There was evidence for heterogeneity of effect for the 
association of dietary fibre and HOMA-IR between Indian Asians and 
Europeans (P=0.001). After adjustment for BMI, WHR and total energy the 
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odds ratio for the association of fibre with insulin resistance was 0.66 (95% CI: 
0.49 – 0.89), P=0.006. I found no association for dietary macronutrients with 
impaired fasting glucose, BMI or WHR (tables 4.5 – 4.7). 
After adjustment for age, HOMA-IR was 23.0% (95% CI: 3.6% – 46.0%) 
higher amongst Indian Asians than Europeans (P=0.02). Adjusting separately 
for individual dietary factors, none of the macronutrients accounted for the 
~20% higher HOMA-IR amongst Indian Asians compared to Europeans (table 
4.8). In multivariate regression analysis HOMA-IR remained 24.7% higher 
amongst Indian Asians than Europeans despite adjustment for protein, 
carbohydrate, MUFA and fibre (table 4.9, P=0.03), 
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4.6 DISCUSSION 
To my knowledge this is the first study to chemically characterise 
duplicate diet samples in a representative population sample of Indian Asians 
and Europeans to assess contribution of dietary nutrients to differences in 
insulin resistance. The principal finding is that dietary fibre has a protective 
effect on risk of insulin resistance among Indian Asians; however, differences in 
intakes of fibre and other major macronutrients do not account for the ~25% 
higher levels of HOMA-IR observed amongst Indian Asians compared to 
Europeans.  
Previous prospective studies based on food frequency questionnaires 
demonstrate that high intake of dietary fibre is associated with reduced 
incidence of T2D166,167. Furthermore dietary intervention studies report lower 
levels of fasting glucose and improved insulin sensitivity following introduction 
of fibre rich diets239-241. Studies examining composition of Indian Asian diets are 
few; from the data available UK Indian Asian diets have higher fibre content 
than Europeans, but dietary fibre does not correlate with 2 hour post-glucose 
insulin levels in this ethnic group178. In the current study, intake of fibre is 
similar between the two populations, and does not account for the 25% higher 
levels of HOMA-IR observed amongst Indian Asians compared to Europeans. 
Nonetheless, I show that low fibre intake is a risk factor for insulin resistance 
amongst Indian Asians, and the association is independent of total energy 
intake, BMI and WHR, implicating mechanisms other than obesity mediating 
the protective effect. To date, the mechanisms by which dietary fibres achieve 
their effects are largely unresolved, and there is no consensus as to whether it 
is soluble or insoluble fibres that exert protective effects. When measuring 
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insulin sensitivity using euglycaemic-hyperinsulinaemic clamps, consumption of 
insoluble dietary fibre increases whole-body glucose disposal independent of 
changes in body weight242-244. Other proposed mechanisms include beneficial 
effects on satiety and body weight, dilution of energy density, reduction of 
postprandial insulin levels, reduction of postprandial lipaemia and fasting blood 
lipids, interactions with incretins and other gastrointestinal hormones, reduction 
of low-grade inflammation, and effects mediated through colonic 
fermentation244.  
Human and animal studies investigating the contribution of diet to insulin 
resistance implicate increased fat intake, in particular saturated147  and trans 
fatty acids158. In this study I show total fat intake is lower and saturated and 
trans fat intakes similar amongst Indian Asians compared to Europeans. Lower 
intake of fat among Indian Asians is accounted for by low MUFA content of 
Indian Asian diets. Diets rich in MUFA are associated with improved insulin 
sensitivity and lower risk of T2D159. Intervention studies substituting MUFA for 
SFA have demonstrated beneficial effects on insulin sensitivity in glucose 
intolerant or healthy subjects, provided total fat intake is not high134,142. An 
isocaloric MUFA-rich diet prevents central fat redistribution and the 
postprandial decrease in peripheral adiponectin gene expression and insulin 
resistance induced by a carbohydrate-rich diet145. Potential mechanisms of 
action of MUFA relate to alterations in incretin responses and gastric 
emptying143, cytoprotective actions in pancreatic β-cells146 and an increase of 
basal glucose uptake through up regulation of glucose transporters GLUT1 and 
GLUT4 in cell membranes144. 
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4.6.1 Limitations 
This study has some limitations that merit discussion. Firstly the small 
sample size negatively impacts the power of the study to demonstrate 
differences in dietary nutrients and their impact on insulin resistance between 
the two racial groups. Women were excluded and dietary samples were 
collected on a single day; therefore my results may not represent usual diet. 
Although I chemically measure nutritional composition of dietary samples, 
many nutrient levels in blood or serum are physiologically controlled or interact 
with other nutrients and drugs so may not correlate well with intake.  
In this study I measured total carbohydrate intake, and consistent with 
previous work I show no association with insulin resistance in both Indian 
Asians and Europeans. Rather than total carbohydrate intake, data from 
longitudinal studies implicate low glycaemic index foods with reduced risk of 
insulin resistance and T2D245,246. Future experiments focused on characterizing 
diet samples for rapidly available glucose and slowly available glucose, a 
chemically based classification of dietary carbohydrates that takes into account 
the likely site, rate, and extent of digestion, will address this shortcoming247. 
Lastly we do not measure dietary micronutrients such as magnesium248 and 
vitamin C249, which are known to contribute to risk of insulin resistance and 
related metabolic disturbances.  
 
4.6.2 Conclusions 
This is the first study to chemically characterize diet composition in a 
representative sample of Indian Asian and European men. I show that Indian 
Asian diets are similar to European diets and differences in nutrition do not 
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account for the ~25% higher risk of insulin resistance observed between both 
racial groups. However, I show dietary fibre protects against risk of insulin 
resistance in Indian Asians, and Indian Asian diets are low in MUFA, a known 
risk factor for insulin resistance and related metabolic disturbances. There is a 
public health mandate to promote diets rich in fibre and MUFA to reduce the 
risk of insulin resistance and progression to T2D among Indian Asians.
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Table 4.1: Characteristics of Indian Asian and European men participating in the duplicate diet study. The results are presented as 
mean (s.d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Indian Asians Europeans P 
 
N 115 124  
Age (years) 49.3 (8.0) 52.4 (7.0) 0.002 
    
Systolic BP (mmHg) 129.1 (20.9) 129.9 (21.2) 0.75 
Diastolic BP (mmHg) 81.2 (12.8) 81.4 (111.0) 0.93 
    
Waist-hip ratio 0.96 (0.07) 0.94 (0.07) 0.04 
Body mass index (kg/m2) 26.9 (3.7) 26.5 (3.7) 0.54 
Height (cm) 171.2 (5.9) 175.8 (7.5) <0.001 
Weight (kg) 79.0 (12.5) 81.9 (12.5) 0.05 
Body surface area (m2) 1.93 (0.17) 1.99 (1.17) 0.004 
    
Glucose (mmol/L) 5.4 (0.5) 5.3 (0.6) 0.05 
Insulin (IU/L) 8.8 (5.8) 7.5 (5.5) 0.02 
HOMA-B (%) 91.6 (57.3) 85.3 (56.7) 0.18 
HOMA-IR 1.3 (0.9) 1.0 (0.9) 0.03 
Impaired fasting glucose (%) 26.1 25.8 0.96 
    
Cholesterol (mmol/L) 5.44 (1.04) 5.63 (0.97) 0.17 
HDL-cholesterol (mmol/L) 1.15 (0.23) 1.25 (0.37) 0.008 
Triglycerides (mmol/L) 1.54 (1.03) 1.42 (0.98) 0.23 
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Table 4.2: Dietary intakes amongst Indian Asian and European men participating in the duplicate diet study. Results are presented 
as mean (s.d.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Indian Asians Europeans P 
 
N 115 124  
Basal metabolic rate (cal/day) 1539.7 (195.2) 1584.9 (200.6) 0.005 
Weight of sample (g) 2455.0 (633.4) 2858.3 (749.6) <0.001 
Energy (cal) 2026.2 (544.8) 2083.1 (522.4) 0.56 
Energy per unit body surface area (cal/m2) 1055.6 (293.5) 1051.4 (272.8) 0.89 
Water (g) 1992.4 (542.0) 2405 (703.5) <0.001 
 
Intake of macronutrients (% of total energy)  
 
Protein  16.7 (4.6) 17.8 (4.9) 0.02 
Carbohydrate  47.8 (8.6) 43.0 (8.6) <0.001 
Fibre 4.5 (1.8) 4.9 (2.2) 0.17 
Total lipids  35.6 (9.8) 39.1 (9.7) 0.009 
Saturated fatty acids  11.2 (5.0) 11.8 (4.6) 0.08 
Monounsaturated fatty acids  14.6 (5.4) 18.5 (5.6) <0.001 
Polyunsaturated fatty acids 8.5 (4.5) 8.4 (4.1) 0.81 
Trans fatty acids 0.4 (1.1) 0.3 (1.1) 0.13 
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Table 4.3: Age-adjusted regression analysis for association of dietary factors with HOMA-IR (characterised as individuals within 
and not within the upper quartile of HOMA-IR levels). Results are presented as percentage change in HOMA-IR per unit increase in 
the predictor variable. Ph refers to test for heterogeneity between Indian Asians and Europeans. (Macronutrients given as 
percentage of total energy; SFA=saturated fatty acids, MUFA=monounsaturated fatty acids, PUFA=polyunsaturated fatty acid, 
TFA= trans fatty acid). 
 
 
 
Indian Asians 
Percentage change in HOMA-IR 
Estimate (95% CI) P 
 Europeans 
Percentage change in HOMA-IR 
Estimate (95% CI) P 
 
Phetero 
        
Carbohydrate -0.04 (-1.38 – 1.32) 0.95  -0.23 (-1.57 – 1.13) 0.73  0.42 
Protein 0.10 (-2.58 – 2.84) 0.94  1.86 (-0.41 – 4.18) 0.16  0.17 
Total lipid 0.01 (-1.33 – 1.37) 0.98  -0.23 (-1.57 – 1.13) 0.71  0.40 
SFA -0.59 (-2.81 – 1.68) 0.61  1.62 (-1.09 – 4.41) 0.20  0.11 
PUFA -0.92 (-3.13 – 1.34) 0.49  -2.50 (-5.11 – 0.18) 0.09  0.19 
MUFA -0.69 (-2.90 – 1.58) 0.55  -0.03 (-2.26 – 2.25) 0.98  0.34 
TFA -0.77 (-2.40 – 1.20) 0.42  0.79 (-0.95 – 2.87) 0.39  0.12 
Fibre -4.28 (-10.14 – 1.96) 0.17  -1.14 (-6.78 – 4.83) 0.73  0.23 
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Table 4.4: Age-adjusted logistic regression analysis for association of dietary factors with HOMA-IR (characterised as individuals 
within and not within the upper quartile of HOMA-IR levels). Results are presented as odds ratio (95% C.I.) for insulin resistance for 
individual macronutrients and total energy. Ph refers to test for heterogeneity between Indian Asians and Europeans. 
(Macronutrients given as percentage of total energy; SFA=saturated fatty acids, PUFA=polyunsaturated fatty acids, 
MUFA=monounsaturated fatty acid, TFA= trans fatty acids). 
 
 
 
Indian Asians 
OR (95% CI) for  
HOMA-IR P 
 Europeans 
OR (95% CI) for  
HOMA-IR P 
 
Phetero 
        
Carbohydrate 0.97 (0.93 – 1.02) 0.28  1.01 (0.96 – 1.07) 0.66  0.16 
Protein 0.99 (0.89 – 1.09) 0.99  1.09 (1.00 – 1.19) 0.04  0.06 
Total lipid 1.03 (0.98 – 1.07) 0.28  0.99 (0.95 – 1.04) 0.78  0.16 
SFA 0.99 (0.92 – 1.07) 0.81  1.04 (0.95 – 1.14) 0.39  0.21 
PUFA 0.98 (0.90 – 1.08) 0.74  0.94 (0.84 – 1.05) 0.25  0.25 
MUFA 1.00 (0.93 – 1.08) 0.98  1.00 (0.93 – 1.07) 0.99  0.49 
TFA 0.94 (0.91 – 1.11) 0.26  1.00 (0.93 – 1.33) 0.99  0.20 
Fibre 0.67 (0.52 – 0.86) 0.002  1.20 (0.90 – 1.29) 0.90  0.001 
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Table 4.5: Age-adjusted logistic regression analysis for association of dietary factors with impaired fasting glucose (IFG). Results 
are presented as odds ratio (95% C.I.) for insulin resistance for individual macronutrients and total energy. Ph refers to test for 
heterogeneity between Indian Asians and Europeans. (Macronutrients given as percentage of total energy; SFA=saturated fatty 
acids, MUFA=monounsaturated fatty acids, PUFA=polyunsaturated fatty acid, TFA= trans fatty acid). 
 
 
 
Indian Asians 
OR (95% CI) for IFG P 
 Europeans 
OR (95% CI) for IFG P 
 
Phetero 
        
Carbohydrate 1.01 (0.97 – 1.06) 0.61  0.99 (0.94 – 1.03) 0.55  0.22 
Protein 1.00 (0.91 – 1.10) 0.97  0.92 (0.83 – 1.02) 0.92  0.13 
Total lipid 0.99 (0.95 – 1.04) 0.65  1.03 (0.98 – 1.07) 0.19  0.12 
SFA 0.97 (0.89 – 1.05) 0.97  0.97 (0.89 – 1.06) 0.53  0.47 
PUFA 1.04 (0.95 – 1.14) 0.40  1.07 (0.97 – 1.18) 0.15  0.34 
MUFA 0.99 (0.92 – 1.07) 0.79  1.08 (1.00 – 1.16) 0.05  0.06 
TFA 0.95 (0.91 – 1.16) 0.70  1.16 (0.96 – 2.58) 0.22  0.07 
Fibre 0.92 (0.72 – 1.16) 0.48  0.86 (0.76 – 1.13) 0.47  0.46 
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Table 4.6: Age adjusted regression analysis for association of dietary factors with BMI. Results are presented as unit change in 
BMI per unit increase in predictor variable. Ph refers to test for heterogeneity between Indian Asians and Europeans. 
(Macronutrients given as percentage of total energy; SFA=saturated fatty acids, MUFA=monounsaturated fatty acids, 
PUFA=polyunsaturated fatty acid, TFA= trans fatty acid). 
 
 
 
Indian Asians 
Beta estimate (95% CI) P 
 Europeans 
Beta estimate (95% CI) P 
 
Phetero 
        
Carbohydrate -0.05 (-0.14 – 0.03) 0.37  -0.09 (-0.16 – -0.01) 0.39  0.27 
Protein 0.10 (-0.06 – 0.27) 0.60  0.05 (-0.09 – 0.19) 0.49  0.31 
Total lipid 0.02 (-0.05 – 0.10) 0.56  0.06 (-0.01 – 0.13) 0.10  0.24 
SFA 0.01 (-0.13 – 0.15) 0.90  0.14 (-0.01 – 0.28) 0.06  0.11 
PUFA 0.09 (-0.07 – 0.25) 0.26  -0.02 (-0.18 – 0.14) 0.84  0.18 
MUFA 0.01 (-0.12 – 0.14) 0.92  0.10 (-0.01 – 0.22) 0.09  0.14 
TFA -0.01 (-0.10 – 1.66) 0.94  0.26 (-0.06 – 3.53) 0.29  0.24 
Fibre -0.13 (-0.51 – 0.26) 0.52  0.03 (-0.28 – 0.34) 0.86  0.27 
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Table 4.7: Age adjusted regression analysis for association of dietary factors with WHR. Results are presented as unit change in 
WHR per unit increase in predictor variable. Ph refers to test for heterogeneity between Indian Asians and Europeans. 
(Macronutrients given as percentage of total energy; SFA=saturated fatty acids, MUFA=monounsaturated fatty acids, 
PUFA=polyunsaturated fatty acid, TFA= trans fatty acid). 
 
 
 
Indian Asians 
Beta estimate (95% CI) P 
 Europeans 
Beta estimate (95% CI) P 
 
Phetero 
        
Carbohydrate -0.0010 (-0.0030 – 0.0010) 0.47  -0.0010 (-0.0030 – 0.0010) 0.12  0.50 
Protein 0.0030 (0.0010 – 0.0050) 0.05  0.0020 (0.0000 – 0.0040) 0.11  0.24 
Total lipids -0.0002 (-0.0021 – 0.0018) 0.82  0.0004 (-0.0016 – 0.0023) 0.56  0.36 
SFA -0.0010 (-0.0030 – 0.0010) 0.37  0.0010 (-0.0010 – 0.0030) 0.27  0.08 
MUFA 0.0010 (-0.0010 – 0.0030) 0.39  0.0004 (-0.0016 – 0.0024) 0.79  0.34 
PUFA -0.0010 (-0.0030 – 0.0010) 0.22  0.0010 (-0.0010 – 0.0030) 0.50  0.08 
TFA -0.0023 (-0.0074 – 0.0032) 0.40  0.0002 (-0.0038 – 0.0044) 0.51  0.23 
Fibre -0.0050 (-0.0109 – 0.0009) 0.19  0.0005 (-0.0054 – 0.0064) 0.86  0.10 
        
 
161 
 
162 
 
Table 4.8: Age adjusted univariate linear regression analysis for association of Indian Asian ethnicity with HOMA-IR amongst 
participants of the duplicate diet study. Results are shown as percentage increase in HOMA-IR amongst Indian Asians compared to 
Europeans after adjustment for age and individual dietary factors. 
 
 
 
Indian Asians vs Europeans 
Percentage difference in HOMA-IR 
Estimate (95% CI) 
P 
   
Age 20.2 (2.2 – 41.4) 0.03 
Age, Protein 22.2 (2.9 – 45.0) 0.02 
Age, Carbohydrate 21.3 (1.8 – 44.7) 0.04 
Age, Total fat 19.9 (0.6 – 43.0) 0.04 
 Age, Saturated fatty acids 23.3 (3.9 – 46.4) 0.02 
 Age, Trans fatty acids 19.4 (0.6 – 41.7) 0.048 
       Age, Polyunsaturated fatty acids 23.6 (4.1 – 46.7) 0.02 
          Age, Monounsaturated fatty acids 21.6 (1.5 – 45.7) 0.03 
Age, Fibre 22.7 (3.4 – 45.7) 0.02 
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Table 4.9: Multivariate linear regression analysis for association of Indian Asian ethnicity with HOMA-IR amongst participants of the 
duplicate diet study. Results are shown as percentage increase in HOMA-IR amongst Indian Asians compared to Europeans before 
and after adjustment for dietary factors (CHO= carbohydrates, MUFA= monounsaturated fatty acids).  
 
 
 
 
Indian Asians vs Europeans 
Percentage difference in HOMA-IR 
Estimate (95% CI) 
P 
   
Age 23.0 (3.6 – 46.0) 0.02 
Age, Fibre 22.7 (3.4 – 45.7) 0.02 
Age, Fibre, CHO 20.5 (0.6 – 44.3) 0.04 
Age, Fibre, CHO, Protein 22.2 (2.0 – 46.4) 0.03 
Age, Fibre, CHO, Protein, MUFA 24.7 (2.7 – 51.5) 0.03 
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CHAPTER 5 
THE CONTRIBUTION OF KNOWN TYPE-2 DIABETES 
GENETIC VARIANTS TO THE INCREASED RISK OF 
T2D AMONGST INDIAN ASIANS COMPARED TO 
EUROPEANS 
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5.1 ABSTRACT 
Background 
Genome-wide association studies (GWAS) have reported common variants at 
49 loci to be associated with T2D in individuals of European and East Asian 
descent. I investigated whether differences in risk allele frequencies and or 
odds ratios for T2D at these loci contribute to the 4-fold increased risk of T2D 
amongst Indian Asians, compared to European whites. 
 
Methods and materials 
Indian Asians were participants of the South Asian Type-2 Diabetes (SAT2D) 
Consortium, which comprises London Life Sciences Population (LOLIPOP) 
study, Pakistan Risk of Myocardial Infarction (PROMIS) study, and Singapore 
Indian Eye (SINDI) study (5561 T2D cases, 14,458 controls). All participants 
were genotyped on the Illumina 317k or 610k arrays. Results for Europeans 
were obtained from the Diabetes Genetics Replication and Meta-analyses 
consortium (DIAGRAM+) consortium, a study of 8,138 T2D cases and 38,987 
controls of European ancestry. I compared allele frequencies and odds ratios of 
the 49 T2D SNPs identified in GWA, between Indian Asians and Europeans. A 
genetic risk score (GRS) was generated by summing the total number of risk 
alleles in each study participant. 
 
Results 
I demonstrate association of 6 previously reported T2D SNPS amongst Indian 
Asians, independent of adiposity (P<0.05 after correction for multiple tests). Of 
the 12 T2D SNPs identified in East Asian populations, only KCNQ1 and 
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C2CD4A/B were associated with T2D amongst Indian Asians (P<0.05). Risk 
allele frequencies were similar and odds ratios of T2D SNPs were lower 
amongst Indian Asians compared to Europeans. 3 T2D genetic loci were 
inversely associated with HOMA-B and no T2D genetic loci were associated 
with HOMA-IR after correction for multiple testing (P<0.001). Among Indian 
Asian’s participating in LOLIPOP, one unit increase of the GRS was associated 
with 6% increase in T2D risk. In ROC curve analysis, addition of GRS to a 
model comprising age, sex, BMI and WHR increased the area under the curve 
by 0.011 in Indian Asians (P<0.001). 
 
Conclusions 
Known T2D genetic risk factors do not account for the 4-fold increased risk of 
T2D amongst Indian Asians compared to Europeans. These findings raise the 
possibility that increased risk of T2D amongst Indian Asians is the result of 
genetic susceptibility factors that are specific to Asians. 
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5.2 AIMS 
To investigate the contribution of previously reported T2D common 
genetic variants to the increased risk of T2D amongst Indian Asian compared 
to Europeans. 
 
5.2.1 Specific aims 
1. To test the association of known T2D SNPs with T2D amongst Indian 
Asians.  
2. To compare risk allele frequencies and odds ratios of known T2D genetic 
variants between Indian Asians and Europeans. 
3. To generate a genetic risk score to examine the composite effect of known 
T2D common genetic variants on risk of T2D amongst Indian Asians 
compared to Europeans participating in LOLIPOP. 
4. To examine whether the relationship of known genetic variants with T2D 
(singly or composite) is influenced by WHR or BMI amongst Indian Asians 
participating in LOLIPOP. 
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5.3 INTRODUCTION 
 T2D is the fifth leading cause of death worldwide. The risk of T2D is high 
in Indian Asians, who comprise ~20% of the global burden of T2D7. Although 
adiposity, physical inactivity and unhealthy diet make an important contribution 
to T2D risk in Indian Asians, a strong genetic component is widely accepted. 
Recent genome-wide association studies (GWAS), carried out primarily in 
European and East Asians populations, have reported common variants at 49 
loci to be associated with T2D56. The role of these T2D common genetic 
variants to T2D risk in Indian Asians and their contribution to the 4-fold excess 
risk amongst Indian Asians compared to Europeans is not known.  
 I investigated whether differences in risk allele frequency and or odds 
ratios for T2D at these loci contribute to the 4-fold excess risk of T2D amongst 
Indian Asians, compared to European whites. 
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5.4 METHODS AND MATERIALS 
5.4.1 Participants 
 I investigated 5,561 Indian Asian T2D cases and 14,458 Indian Asian 
controls from the South Asian Type-2 Diabetes consortium (SAT2D) comprising 
participants from the London Life Sciences Population (LOLIPOP) study216, the 
Pakistan Risk of Myocardial Infarction Study (PROMIS)217 and Singapore 
Indian Eye (SINDI) Study218. Results for Europeans were made available by the 
Diabetes Genetics Replication and Meta-analyses consortium (DIAGRAM+), a 
collaboration of 8 case-control studies comprising 8,138 T2D cases and 38,987 
controls of European ancestry195.  
 
5.4.2 Selection of T2D variants  
I accessed the National Human Genome Research Institute (NHGRI) 
catalogue250 on 12.01.2012 and identified 49 SNPs previously reported in 
association with T2D at genome-wide significance (P<5x10-8) amongst 
individuals of European or East Asian ancestry. Where SNPs were not 
available on the Illumina platform, best available proxy SNPs were used (table 
5.1). These were identified using SNAP (Broad institute; 
www.broadinstitute.org/mpg/snap). 
 rs6815464 in MAEA was not available on the Illumina platform and there 
were no suitable proxy SNPS available. Therefore MAEA locus excluded from 
my analyses. 
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5.4.3 Genotyping 
  Data on previously reported T2D SNPs for Indian Asians was obtained 
from SAT2D GWAS, which is described in chapter 2. Briefly, in stage one, 
GWA scans were done in 5,561 Indian Asian T2D cases and 14,458 Indian 
Asian controls, using Illumina genotyping arrays. Samples with call rates <95% 
were excluded as were SNPs with call rates <97%, Hardy-Weinburg P<10-6 or 
minor allele frequency (MAF) <1%. Imputation of genotypes not directly 
measured was performed on stage one GWAS data, using MACH (Markov 
Chain Haplotyping) and autosomal SNPs polymorphic in all three (CEU, YRI 
and JPT+CHB) HapMap populations. Pooled founder haplotypes from all three 
HapMap populations (phased haplotypes, release 21) were used as reference 
for imputation to better capture local patterns of haplotype variations in SAT2D 
participations. Comparisons of imputed and experimentally derived genotypes, 
yielded an estimated imputation error rate of 2.86% per allele and an estimated 
average r2 of 89.78%. 
 
5.4.4 Statistical analysis  
 Single marker odds ratios (ORs) were calculated under an additive risk 
model using logistic regression. I tested associations for 48 SNP markers with 
T2D. Principal components were included as covariates to adjust for population 
substructure; no other covariates were used in the regression analyses. 
Results from the separate studies were combined by fixed effects inverse 
variance meta-analysis implemented in METAL, and with output association 
test results adjusted for genomic control inflation factor. Statistical significance 
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for association of T2D SNPs with T2D was inferred at P<0.001 after correction 
for multiple testing (48 tests). 
  Risk allele frequencies and effect sizes were compared between Indian 
Asians and European whites using the 2-squared test, and the Students T-test 
respectively. The Sign test was used to investigate concordance of risk allele 
frequencies and effect sizes of known T2D SNPs in our populations with those 
derived from the European genome wide scan. 
To determine the combined effect of known T2D risk alleles among 
Indian Asians compared to Europeans, I used directly genotyped data from 
6557 Indian Asian and 927 European T2D cases and controls participating in 
LOLIPOP. 22 SNPs genotyped on the Illumina platform were available for 
analysis; for the other 23 T2D loci suitable proxy SNPs was used (table 5.1). At 
MAEA, DUSP8 and KCNQ1 (discovered in Europeans) no suitable proxy SNPs 
were available and these were excluded from my analysis. I assessed the 
cumulative effect of known T2D SNPs by summing the total number of risk 
alleles in each LOLIPOP study participant. I grouped individuals into categories 
based on total number of risk alleles, with each category treated as an 
independent variable in the logistic regression model. To assess the 
discriminatory power of the genetic risk score for T2D and undiagnosed T2D, I 
plotted receiver operating characteristic (ROC) curves and calculated 
corresponding areas under the curve (AUCs) for a logistic regression model 
including conventional risk factors (age, gender, BMI, WHR) and another 
including genetic risk score plus the conventional risk factors.  
I used regression analysis (logistic regression for categorical variables, 
and linear regression for quantitative variables) to determine the association of 
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known T2D SNPs with glycaemic traits (glucose, insulin, HOMA-IR and HOMA-
B) and anthropometric measurements (BMI and WHR) amongst LOLIPOP 
study participants.  
To evaluate the role of gene-environment interactions, I carried out 
further logistic regression analyses, using T2D as the independent variable and 
each individual SNP as dependant variables, making adjustments for BMI and 
WHR respectively. 
 
5.4.5 Power 
Power calculations were carried on Quanto 1.2.3 ((http:// 
hydra.usc.edu/gxe). Based on an additive genetic model, this study had 80% 
power to detect an odds ratio of 1.10 given an a minor allele frequency >20% 
per allele copy at P<10-4.  
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5.5 RESULTS 
5.5.1 Clinical characteristics 
 Clinical characteristics of study participants are presented in table 5.2. 
In each cohort T2D cases were older, had larger BMI and WHR and higher 
blood pressure. Total cholesterol and HDL cholesterol were lower, and 
triglycerides, fasting glucose and HbA1c higher amongst T2D cases compared 
to controls. 
 
5.5.2 Replication of known T2D variants amongst Indian Asians in SAT2D 
 The odds ratio for individual variants ranged from 0.94 (ZFAND3 0.94 
[95 CI: 0.88 – 1.01]) to 1.25 (TCF7L2 1.25 [95 CI: 1.19 – 1.32]) amongst Indian 
Asians. Of the 48 SNPs tested I replicated association of TCF7L2, CDKN2AB, 
GCKR, SLC30A8, IGD2BP2, and CDC123 with T2D (P<0.001) amongst Indian 
Asians. I further demonstrated nominal associations for SNPs near or within 
KCNQ1 (identified in East Asians), ADCY5, TP53INP1, HHEX, KCNQ1 
(identified in Europeans), HNF1B, IRS1, CDKAL1, WFS1, CHCD9, MTNR1B, 
UBE2E2, FTO, TSPAN8, JAZF1, ADAMTS9, C2CD4A/B, PRC1, HMGA2 and 
ADCY5 (0.001<P<0.05) with T2D (figure 5.1 and table 5.3).  Of the 12 T2D 
SNPs identified in East Asian populations, only KCNQ1 and C2CD4A/B were 
nominally associated with T2D amongst Indian Asians (0.001< P <0.05). 
 
5.5.3 Comparison of known T2D genetic variants between Indian Asians 
and Europeans 
 Risk allele frequencies for T2D common genetic variants were higher at 
23 loci and lower at 25 loci amongst Indian Asians compared to Europeans. 
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Considered together, risk allele frequencies for T2D SNPs were similar 
between both racial groups (sign test; P=0.66, figure 5.2). Odds ratios for T2D 
genetic variants were higher at 8 loci and lower at 40 loci amongst Indian 
Asians compared to Europeans. Collectively, odds ratios of T2D SNPs were 
significantly lower amongst Indian Asians compared to Europeans (sign test; 
P=0.0003, figure 5.3). Similarly SNPs identified in populations of East Asian 
ancestry, risk allele frequencies were similar and odds ratios were lower 
amongst Indian Asians than Europeans (sign test; P=0.62 and P=0.01 
respectively). 
  41 SNPs demonstrated direction of effect consistent with those 
observed in Europeans. SNPs near or within THADA, PSMD6, ZBED3, 
ZFAND3, KLF14, PTPRD, and SRR had discordant direction of effect amongst 
Indian Asians compared to Europeans, though heterogeneity of effect between 
population groups was observed only for KLIF14. There was no evidence of 
heterogeneity of effect between both genders for T2D genetic variants (table 
5.4). Besides GCKR, effect sizes for T2D variants were similar between the 
three Indian Asian cohorts (table 5.5).  
 
5.5.4 Combined analysis of 46 T2D common genetic variants with risk of 
T2D among Indian Asian and European participants from LOLIPOP 
 The GRS followed a normal distribution in both Indian Asians and 
Europeans (figure 5.4). The mean GRS was higher amongst Indian Asians 
compared to Europeans (52.9 [95% CI: 52.8 – 53.0] vs 51.7 [95% CI: 51.4 – 
52.0, P<0.001). For each unit increase in GRS, risk of T2D increased by 1.06-
fold among Indian Asians (OR: 1.06 [95 CI: 1.03 – 1.09], P<0.001), compared 
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to 1.07-fold among Europeans (OR: 1.07 [95 CI: 1.03 – 1.11], P<0.001), after 
adjustment for age and sex. Indian Asian participants in the highest quartile 
had an odds ratio for T2D of 1.94 (95% CI: 1.66 – 2.27), P<0.001, compared to 
Indian Asians in the lowest quartile of the GRS. The odds ratio for T2D for 
Europeans in the highest genetic risk score quartile compared to Europeans in 
the lowest quartile was 2.76 (95% CI: 1.36 – 5.61), P<0.001. 
In ROC curve analysis the area under the curve (AUC) for the GRS and 
T2D was 0.568 (P<0.001). The AUC for conventional risk factors (including 
age, sex, BMI and WHR) and T2D was 0.706 (P<0.001), which increased 
marginally to 0.717 following addition of the GRS (P<0.001) (figure 5.5 A and 
B). For undiagnosed T2D the area under the curve (AUC) for GRS was 0.542 
(P<0.001). The AUC for conventional risk factors and undiagnosed T2D was 
0.632, which increased to 0.641 following addition of the GRS (figure 5.5 C 
and D). 
 
5.5.5 Association of known T2D genetic variants with pancreatic -cell 
function and insulin resistance  
I examined the effect of T2D susceptibility alleles on HOMA-B and 
HOMA-IR in 4534 non-diabetic Indian Asians and 846 non-diabetic European 
participants from LOLIPOP. Amongst Indian Asians, coefficients for association 
between T2D risk alleles and decreasing HOMA-B were positive for 21 of the 
46 loci examined, and increasing HOMA-IR were positive for 12 of the 46. Risk 
alleles at 9 loci (NOTCH2, UBE2E2, ADCY5, ZFAND3, DGKB, GCK, GLIS3, 
CDKN2A, AND TCLF7L2) were associated with reduced β-cell function (table 
5.6 and figure 5.6, P<0.05), and three loci (MTNR1B, GCKR and PRC1) were 
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associated with increased insulin resistance (table 5.7 and figure 5.6, P<0.05). 
ZFAND3 and TCF7L2 were inversely associated with insulin resistance 
(P<0.05). After correction for multiple testing TCF7L2, GCK and ADCY were 
associated with HOMA-B and no locus was associated with HOMA-IR among 
Indian Asians. 
 
5.5.6 Association of known T2D variants with adiposity amongst Indian 
Asians 
I investigated whether the relationship of known T2D SNPs with T2D 
might be mediated through adiposity. I examined the association of T2D SNPs 
with BMI and WHR among LOLIPOP study participants. Amongst Indian 
Asians, coefficients for association between the T2D risk allele and increasing 
BMI were positive for 19 of the 46 loci examined (table 5.8). Only FTO was 
significantly associated with increased BMI (P<9.1x10-5), while T2D risk alleles 
at 6 loci (NOTCH2, BCL11A, IRS1, ADCY5, IGF2BP2 AND HMGA2) were 
associated with lower BMI (P<0.05). With regards WHR (table 5.9), coefficients 
for association between the T2D risk allele and increasing WHR were positive 
for 18 loci, and T2D risk allele at IGF2BP2 was significantly associated with 
reducing WHR (P<0.001). 
Lastly, the association of previously reported T2D SNPs with T2D was 
not materially influenced by additional adjustment for BMI and separately WHR 
amongst Indian Asians participating in LOLIPOP (table 5.10). 
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5.6 DISCUSSION 
This study supports a role for some common genetic variants identified 
from GWAS studies in the pathogenesis of T2D amongst Indian Asians. 
However, there was no systematic increase in either risk allele frequency or 
effect size of previously reported T2D loci amongst Indian Asians compared to 
Europeans; therefore known T2D genetic susceptibility factors do not explain the 
4-fold increased risk of T2D observed amongst Indian Asians compared to 
Europeans.  
Possible reasons for the failure to replicate many of the associations of 
previously identified T2D risk alleles among Indian Asians may relate to 
limitations of sample size and power. Effect sizes for T2D SNPs among Indian 
Asians were generally smaller than those observed in the initial studies that 
identified these variants. It is possible that the effect estimates of the initial 
discoveries were over-estimates (winner's curse); therefore use of replication 
odds ratios from those initial GWA studies may have provided fairer comparison. 
Other potential reasons include allelic heterogeneity and differences in patterns 
of linkage disequilibrium between these SNPs and functional variants at these 
loci in different ethnic populations. Precedence for Indian Asian-specific variation 
comes from the discovery of a common variant in MYBPC3 that is closely 
associated with cardiomyopathy and heart failure, and which is specific to 
populations from the Indian subcontinent251. Alternatively, gene-environment 
interactions may operate in the pathogenesis of T2D and that differences in the 
level of environmental risk factors in different populations may alter the impact of 
susceptibility loci on T2D risk252,253. Whether our observations of lower odds 
ratios amongst Indian Asians reflect differences in study design, true 
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heterogeneity of effect or gene-environment interactions remains to be 
determined. 
Although the GRS marginally improved identification of individuals at risk 
of T2D, its use as a tool for risk stratification is questioned. Undoubtedly, GWAS 
have provided important insights into genetic mechanisms underpinning T2D as 
well as other complex traits. However, as in other populations, the discriminatory 
value of previously reported T2D SNPs to identify Indian Asians at increased risk 
of T2D is limited.  
Since overweight and obesity are major risk factors for T2D74, I 
investigated whether the relationship of the known T2D SNPs with T2D might be 
mediated through adiposity. I found the association of T2D SNPs with T2D is not 
materially influenced by additional adjustment for measures of obesity amongst 
Indian Asians in LOLIPOP. Adiposity therefore does not mediate the 
relationships between known T2D SNPs and T2D in Indian Asians. 
Amongst Indian Asians I show that direction of effect for most T2D genetic 
variants with HOMA-B is consistent with that reported for Europeans. Thus, as in 
Europeans, known T2D loci primarily influence pancreatic β-cell dysfunction 
rather than insulin resistance among Indian Asians254. This contrasts with 
previous work, which suggest that insulin resistance and related metabolic 
disturbances are more prevalent amongst Indian Asians than Europeans, and 
contribute to their increased risk of cardiovascular disease13. Rather than insulin 
resistance, my analyses highlight a role for genetic predisposition to pancreatic 
β-cell failure as an important determinant for the development of T2D among 
Indian Asians. Future efforts to delineate the functional significance of known 
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T2D variants on pancreatic β -cell function will improve understanding of disease 
mechanisms, and provide novel targets for novel pharmacological targets. 
Current estimates indicate that known T2D risk alleles account for ~10% of 
genetic heritability195, therefore suggesting further genetic influences remain to 
be discovered. Given the high rates of T2D amongst Indian Asians, unaccounted 
for by established environmental and genetic risk factors, it is likely that 
population-specific genetic variants or undiscovered shared common genetic 
polymorphisms may explain their increased risk. Recent GWA studies in T2D 
provide clear evidence of the value of extending the search for complex-trait 
associations beyond the current focus in Europeans, to populations with different 
genetic structure200-203. This strategy has the potential for discovery of ethnic-
specific susceptibility loci that may otherwise go undetected in studies based 
exclusively in Europeans. Furthermore, the emergence of high throughput, next 
generation sequencing technology promises to facilitate identification of all but 
the rarest genetic polymorphisms from within the Indian genome255. Identification 
of population-specific genetic influences may lead to improved accountability of 
the 4-fold excess risk of T2D observed in Indian Asians compared to European 
whites. 
In conclusion, previously reported T2D risk alleles do not account for the 4-
fold increased risk of T2D amongst Indian Asians compared to Europeans. 
Future Indian Asian-specific GWA studies together with third generation 
sequencing efforts will provide further insights in to the genetic architecture 
underlying T2D in this high-risk ethnic group. 
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Figure 5.1: Forest plot of odds ratios for T2D of known T2D loci amongst Indian Asians. Red depicts T2D SNPs identified amongst 
East Asians 
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 Figure 5.2: Scatter plot of risk allele frequencies of known T2D loci amongst Indian Asians and Europeans 
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Figure 5.3: Scatter plot of odds ratios for T2D of known T2D loci amongst Indian Asians and Europeans 
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Figure 5.4: Distribution of genetic risk score amongst Indian Asians and Europeans participating in LOLIPOP 
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Figure 5.5: ROC curves for discrimination between T2D cases and controls, and patients with undiagnosed T2D and controls. 
Graphs show plots based on (A) conventional risk factors (age, sex, BMI, WHR) among T2D cases and controls, (B) conventional 
risk factors and genetic risk score amongst T2D cases and controls, (C) conventional risk factors (age, sex, BMI, WHR) among 
undiagnosed T2D cases and controls, (B) conventional risk factors and genetic risk score amongst undiagnosed T2D cases and 
controls 
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Figure 5.6: Plot of HOMA-B (an index of beta cell function; x axis) and HOMA-IR (an index of insulin sensitivity; y axis). Each point 
refers to a single T2D association signal, with colours denoting the strength of the association to (A) HOMA-B (B) HOMA-IR. Red 
P<10−3; blue 0.001<P<0.01; green 0.01<P<0.05; grey, P>0.05 
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Table 5.1:  SNPs or best available proxy SNPs tested amongst LOLIPOP study participants. Grey shade denotes proxy SNPs. 
 
Locus Chm SNP Source R2 D' 
PROX1 1 rs340874 MAGIC    
NOTCH2 1 rs2641348 Proxy for rs10923931 0.850 1 
BCL11A 2 rs243021 DIAGRAM+   
IRS1 2 rs7578326 DIAGRAM+   
GCKR 2 rs780094 MAGIC    
THADA 2 rs7578597 Proxy for rs11899863 0.901 1 
RBMS1 2 rs407746 Proxy for rs7593730 1 1 
IGF2BP2 3 rs1470579 DIAGRAM+   
PSMD6 3 rs831571 Published  
ADCY5 3 rs2877716 Proxy for rs11708067 0.807 0.945 
PPARG 3 rs13089415 Proxy for rs13081389 1 1 
ADAMTS9 3 rs4411878 Proxy for rs4607103 0.950 1 
UBE2E2 3 rs7612463 Proxy for rs6780569 0.292 0.629 
WFS1 4 rs10012946 Proxy for rs1801214 1 1 
MAEA 4 rs6815464 No proxy SNP available  
ZBED3 5 rs7708285 Proxy for rs4457053 0.927 1 
ZFAND3 6 rs9470794 Published  
CDKAL1 6 rs7754840 Proxy for rs10440833 0.628 0.898 
KCNK16 6 rs3734618 Proxy for rs1535500 1 1 
GCK 7 rs4607517 MAGIC    
GCC1-PAX4 7 rs6467136 Published  
DGKB 7 rs2191348 Proxy for rs2191349 1 1 
JAZF1 7 rs1635852 Proxy for rs849134 1 1 
KLF14 7 rs13234407 Proxy for rs972283 0.967 1 
TP53INP1 8 rs896854 DIAGRAM+   
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SLC30A8 8 rs13266634 Proxy for rs3802177 1 1 
CDKN2A/B 9 rs10965250 DIAGRAM+    
CHCD9 9 rs10512085 Proxy for rs13292136 0.869 1 
PTPRD 9 rs17584499 Published  
GLIS3 9 rs7041847 Published  
HHEX 10 rs5015480 DIAGRAM+   
TCF7L2 10 rs7903146 DIAGRAM+   
MTNR1B 11 rs1387153 DIAGRAM+   
CENTD2 11 rs1552224 DIAGRAM+   
KCNJ11 11 rs5215 DIAGRAM+   
KCNQ1 11 rs2237892 Proxy for rs231362 0.186 1 
DUSP8 11 rs2334499 No proxy SNP available  
KCNQ1 11 rs163184 No proxy SNP available  
HMGA2 12 rs2612067 Proxy for rs1531343 1 1 
TSPAN8 12 rs4760915 Proxy for rs4760790 1 1 
HNF1A 12 rs7965349 Proxy for rs7957197 0.873 0.934 
PRC1 15 rs8042680 DIAGRAM+   
AP3S2 15 rs2028299 Published  
C2CD4A/B 15 rs7172432 Published  
ZFAND6 15 rs4778582 Proxy for rs11634397 0.965 1 
FTO 16 rs3751812 Proxy for rs9939609 1 1 
SRR 17 rs391300 Published  
HNF1B 17 rs4430796 Published  
PEPD 19 rs436248 Proxy for rs3786897 0.640 0.814 
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Table 5.2: Characteristics of study participants. †P<0.05 for comparisons between T2D cases and controls. 
 
 LOLIPOP 610k LOLIPOP 317k SINDI PROMIS LOLIPOP Europeans 
 T2D Controls T2D Controls T2D Controls T2D Controls T2D Controls 
N 1783 4773 440 1699 977 1169 2361 6817 81 846 
Age 59.4 (9.2) 53.9 (10.7)† 54.1 (10.1) 46.8 (10.1) † 60.7 (9.9) 55.7 (9.7) † 55.0 (9.4) 52.9 (10.5) † 60.7 (8.7) 55.7 (9.8) † 
Gender (% male) 82.9 84.8 100.0 100.0 54.4 48.4† 76.5 83.0† 82.7 72.2 
           
Systolic BP (mmHg) 140. 6 (20.4) 133.5 (18.9) † 139.8 (20.6) 132.0 (20.2) † 140.0 (19.7) 131.7 (19.2) † 129.9 (21.5) 127.1 (20.5) † 139.1 (16.3) 132.7 (19.1) † 
Diastolic BP (mmHg) 80.7 (10.9) 82.4 (10.7) † 84.0 (11.7) 82.5 (12.1) † 77.1 (10.1) 77.2 (9.9) † 81.6 (11.9) 80.8 (11.6) † 81.4 (9.4) 81.0 (10.3)  
Weight (kg) 78.1 (14.0) 75.6 (13.0) † 80.0 (15.9) 78.4 (13.9) † 70.9 (14.0) 66.7 (12.5) † 71.0 (12.5) 69.1 (13.2) † 92.3 (19.1) 80.6 (15.4) † 
BMI (kg/m2) 28.1 (4.6) 26.8 (4.2) † 27.6 (4.7) 26.6 (4.2) † 27.1 (5.1) 25.3 (4.4) † 26.0 (4.0) 25.3 (3.9) † 31.0 (51) 27.2 (4.5) † 
Waist (cm) 100.8 (11.5) 96.6 (10.9) † 100.0 (12.2) 96.3 (11.4) † -- -- 92.0 (12.0) 90.1 (11.7) † 106.3 (13.8) 94.7 (12.4) † 
WHR 0.99 (0.07) 0.95 (0.07) † 0.99 (0.07) 0.95 (0.07) † - - 0.95 (0.06) 0.94 (0.07) † 0.97 (0.06) 0.92 (0.08) † 
           
Cholesterol (mmol/L) 4.65 (1.20) 5.21 (1.12) † 4.94 (1.09) 5.46 (1.04) † 4.86 (1.11) 5.36 (0.98) † 4.81 (1.39) 4.74 (1.29) † 5.12 (1.27) 5.61 (1.03) † 
HDL chol (mmol/L) 1.16 (0.30) 1.22 (0.30) † 1.17 (0.29) 1.247 (0.31) † 1.02 (0.30) 1.10 (0.31) † 0.88 (0.25) 0.89 (0.25) † 1.15 (0.29) 1.40 (0.39) † 
Triglycerides 
(mmol/L) 1.94 (1.55) 1.77 (1.12)
 † 1.82 (0.86) 1.65 (0.82) † 2.09 (1.22) 1.85 (1.13) † 2.51 (1.58) 2.20 (1.36) † 1.82(1.64) 1.26 (0.89) † 
Glucose (mmol/L) 8.6 (3.1) 5.2 (0.60) † 8.9 (2.9) 5.1 (0.6) † 9.71 (4.44) 5.38 (1.06) † 13.31 (5.47) 6.89 (2.91) † 8.48 (3.69) 5.12 (0.52) † 
HbA1c (mmol/mol) 57.7 (12.4) 41.1 (4.0) † 58.4 (13.2) 40.1 (3.7) † 55.5 (11.0) 40.2 (2.0) † 65.0 (14.9) 42.4 (3.3) † 52.7 (13.3) 38.7 (3.1) † 
           
Genotyping array Illumina 610Quad Illumina Hap317 Illumina 610Quad Illumina 660Quad Illumina 610Quad 
Calling algorithm GenCall GenCall GenCall Illuminus GenCall 
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Table 5.3: Association of SNPs reported to be associated with T2D in other populations, with T2D amongst Indian Asians from 
SAT2D, and Europeans from the GWA phase of DIAGRAM+. N: effective sample size. RAF: risk allele frequency: IA = Indian 
Asians, Eu = Europeans. Dir: +=concordant Indian Asians and DIAGRAM+, -1=discordant Indian Asians and DIAGRAM+. 
Phetero is for comparison of effect size between Indian Asians and Europeans. Grey shade identifies SNPs discovered in East 
Asian populations. 
 
 
SNP Chr Pos Nearest gene 
Alleles RAF Europeans Indian Asians    
Alt Risk Eu IA OR P OR P Dir Phetero 
rs10923931 1 120230001 NOTCH2 G T 0.12 0.18 1.14 (1.07 – 1.21) 6.50E-05 1.01 (0.95 – 1.07) 8.3E-01 + 5.5E-03 
rs340874 1 210547651 PROX1 T C 0.51 0.55 1.07 (1.02 – 1.11) 2.00E-03 1.02 (0.98 – 1.07) 3.1E-01 + 2.0E-01 
rs780094 2 27652888 GCKR T C 0.62 0.74 1.01 (0.97 – 1.05) 6.00E-01 1.19 (1.11 – 1.29) 4.1E-06 + 1.2E-04 
rs11899863 2 43530470 THADA T C 0.93 0.96 1.17 (1.09 – 1.25) 1.00E-05 0.96 (0.80 – 1.15) 6.3E-01 - 4.4E-02 
rs243021 2 60496470 BCL11A G A 0.46 0.51 1.09 (1.05 – 1.14) 8.10E-06 1.05 (1.00 – 1.10) 3.6E-02 + 1.9E-01 
rs7593730 2 160996961 RBMS1 T C 0.8 0.8 1.07 (1.02 – 1.13) 6.50E-03 1.01 (0.95 – 1.07) 7.8E-01 + 1.1E-01 
rs7578326 2 226846158 IRS1 G A 0.64 0.77 1.12 (1.07 – 1.17) 8.70E-07 1.08 (1.03 – 1.14) 4.4E-03 + 4.2E-01 
rs13081389 3 12264800 PPARG G A 0.96 0.93 1.24 (1.14 – 1.35) 2.00E-07 1.07 (0.97 – 1.19) 1.7E-01 + 2.8E-02 
rs6780569 3 23173488 UBE2E2 A G 0.95 0.74 1.11 (1.04 – 1.18) 1.50E-03 1.07 (1.02 – 1.13) 8.9E-03 + 4.4E-01 
rs831571 3 64023337 PSMD6  T C 0.76 0.79 1.02 (0.97  – 1.07) 4.00E-01 0.97 (0.92 – 1.02) 2.5E-01 - 4.0E-01 
rs6795735 3 64680405 ADAMTS9 T C 0.54 0.28 1.09 (1.04 – 1.13) 8.40E-05 1.06 (1.01 – 1.12) 2.4E-02 + 5.1E-01 
rs11708067 3 124548468 ADCY5 G A 0.78 0.78 1.10 (1.05 – 1.16) 1.70E-04 1.10 (1.04 – 1.17) 1.4E-03 + 9.8E-01 
rs1470579 3 187011782 IGF2BP2 A C 0.29 0.42 1.14 (1.09 – 1.19) 2.20E-09 1.12 (1.07 – 1.17) 2.5E-06 + 5.8E-01 
rs6815464 4 1299901 MAEA  G C 0.91 - 1.19 (1.05 – 1.36) 7.00E-03 - -  - 
rs1801214 4 6421094 WFS1 C T 0.73 0.68 1.13 (1.08 – 1.18) 3.20E-08 1.08 (1.02 – 1.13) 7.2E-03 + 1.6E-01 
rs4457053 5 76460705 ZBED3 A G 0.26 0.22 1.16 (1.10 – 1.23) 4.20E-08 0.97 (0.88 – 1.08) 6.3E-01 - 3.0E-03 
rs10440833 6 20796100 CDKAL1 T A 0.25 0.26 1.25 (1.20 – 1.31) 1.80E-22 1.08 (1.02 – 1.14) 4.9E-03 + 2.8E-05 
rs9470794 6 38214822 ZFAND3  T C 0.23 0.11 0.97 (0.90 – 1.04) 2.00E-10 0.94 (0.88 – 1.01) 7.8E-02 - 8.9E-01 
rs1535500 6 39392028 KCNK16  G T 0.05 - 1.00 (0.96  –1.04) 9.00E-01 1.04 (0.99 – 1.09) 2.5E-01 + 2.5E-01 
rs2191349 7 14837549 DGKB G T 0.47 0.62 1.07 (1.03 – 1.11) 1.20E-03 1.05 (1.00 – 1.11) 3.5E-02 + 6.7E-01 
rs849134 7 27969462 JAZF1 G A 0.53 0.69 1.13 (1.08 – 1.17) 2.80E-09 1.06 (1.01 – 1.12) 2.3E-02 + 6.5E-02 
rs4607517 7 44008908 GCK G A 0.2 0.13 1.03 (0.97 – 1.09) 3.10E-01 1.01 (0.95 – 1.08) 7.1E-01 + 7.3E-01 
rs6467136 7 126952194 GCC1-PAX4  A G 0.09 0.56 0.99 (0.95 – 1.03) 5.00E-11 1.00 (0.96 – 1.05) 9.4E-01  8.2E-01 
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rs972283 7 129924109 KLF14 A G 0.55 0.61 1.10 (1.06 – 1.15) 1.80E-06 0.98 (0.94 – 1.03) 4.6E-01 - 2.7E-04 
rs896854 8 96029687 TP53INP1 C T 0.48 0.41 1.10 (1.06 – 1.15) 1.20E-06 1.08 (1.03 – 1.13) 1.8E-03 + 4.5E-01 
rs3802177 8 118254206 SLC30A8 A G 0.75 0.76 1.15 (1.10 – 1.21) 1.50E-08 1.13 (1.07 – 1.19) 2.4E-05 + 5.7E-01 
rs7041847 9 4277466 GLIS3  G A 0.62 0.55 1.04 (1.00 – 1.08) 6.00E-02 1.04 (0.99 – 1.09) 1.2E-01 + 5.3E-01 
rs17584499 9 8869118 PTPRD C T 0.25 0.25 1.03 (0.96 – 1.10) 3.80E-01 0.98 (0.93 – 1.04) 5.5E-01 - 2.8E-01 
rs10965250 9 22123284 CDKN2A/B A G 0.81 0.87 1.20 (1.13 – 1.27) 1.20E-10 1.20 (1.10 – 1.30) 2.6E-05 + 9.6E-01 
rs13292136 9 79181682 CHCD9 T C 0.93 0.86 1.20 (1.11 – 1.29) 1.50E-06 1.10 (1.03 – 1.17) 7.5E-03 + 8.0E-02 
rs12779790 10 12368016 CDC123 A G 0.23 0.17 1.09 (1.04 – 1.15) 6.80E-04 1.12 (1.05 – 1.20) 5.9E-04 + 4.9E-01 
rs5015480 10 94455539 HHEX T C 0.57 0.45 1.18 (1.13 – 1.23) 1.30E-15 1.08 (1.03 – 1.13) 2.1E-03 + 3.3E-03 
rs7903146 10 114748339 TCF7L2 C T 0.25 0.31 1.40 (1.34 – 1.46) 2.20E-51 1.25 (1.19 – 1.32) 3.4E-19 + 1.1E-03 
rs2334499 11 1653425 DUSP8 C T 0.44 0.28 1.08 (1.04 – 1.13) 1.20E-04 1.02 (0.97 – 1.07) 4.2E-01 + 7.8E-02 
rs231362 11 2648047 KCNQ1 A G 0.52 0.73 1.11 (1.06 – 1.16) 6.40E-06 1.09 (1.03 – 1.15) 3.0E-03 + 5.9E-01 
rs163184 11 2803645 KCNQ1 T G 0.44 0.53 1.09 (1.04 – 1.13) 6.80E-05 1.08 (1.03 – 1.13) 1.2E-03 + 8.4E-01 
rs5215 11 17365206 KCNJ11 T C 0.41 0.37 1.09 (1.05 – 1.14) 1.60E-05 1.04 (0.99 – 1.09) 1.1E-01 + 1.1E-01 
rs1552224 11 72110746 CENTD2 C A 0.88 0.83 1.13 (1.07 – 1.19) 7.00E-06 1.04 (0.98 – 1.10) 2.2E-01 + 4.2E-02 
rs1387153 11 92313476 MTNR1B C T 0.28 0.39 1.12 (1.07 – 1.17) 1.00E-06 1.07 (1.02- – 1.12) 8.7E-03 + 1.3E-01 
rs1531343 12 64461161 HMGA2 G C 0.1 0.18 1.20 (1.12 – 1.29) 1.70E-07 1.07 (1.01 – 1.13) 3.4E-02 + 1.0E-02 
rs4760790 12 69921061 TSPAN8 G A 0.23 0.34 1.11 (1.06 – 1.16) 3.60E-06 1.06 (1.01 – 1.11) 1.8E-02 + 1.6E-01 
rs7957197 12 119923406 HNF1A A T 0.85 0.95 1.14 (1.08 – 1.19) 4.60E-07 1.14 (0.97 – 1.34) 1.2E-01 + 9.9E-01 
rs7172432 15 60183681 C2CD4A/B G A 0.52 0.61 1.07 (1.03 – 1.12) 1.10E-03 1.05 (1.01 – 1.11) 2.6E-02 + 6.4E-01 
rs11634397 15 78219277 ZFAND6 A G 0.6 0.53 1.11 (1.06 – 1.16) 5.10E-06 1.05 (1.00 – 1.12) 7.5E-02 + 1.8E-01 
rs8042680 15 89322341 PRC1 C A 0.22 0.63 1.10 (1.06 – 1.15) 8.20E-06 1.06 (1.01 – 1.11) 2.8E-02 + 2.0E-01 
rs11642841 16 52402988 FTO C A 0.45 0.32 1.13 (1.08 – 1.18) 3.40E-08 1.07 (1.02 – 1.14) 1.2E-02 + 1.7E-01 
rs391300 17 2163008 SRR T C 0.64 0.51 1.00 (0.96 – 1.04) 9.50E-01 0.99 (0.94 – 1.03) 6.1E-01 - 6.7E-01 
rs4430796 17 33172153 HNF1B A G 0.53 0.37 1.14 (1.08 – 1.20) 1.50E-06 1.07 (1.02 – 1.13) 4.1E-03 + 1.1E-01 
rs3786897 19 38384848 PEPD  G A 0.2 0.71 1.02 (0.98  – 1.06) 4.00E-01 1.04 (0.99 – 1.10)   8.5E-01 + 8.5E-01 
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Table 5.4: Tests for heterogeneity of effect (Phetero) between male and female SAT2D participants at the previously reported 
T2D loci. 
 
 
      Male  Female   
SNP Chr Position Nearest gene Reference 
Alleles 
(A/R) OR (95% CI) P OR (95% CI) P Phetero 
           
rs10923931 1 120230001 NOTCH2 DIAGRAM G/T 0.99 (0.93 – 1.06) 0.79 1.06 (0.94 – 1.21) 0.33 0.32 
rs340874 1 210547651 PROX1 Published T/C 1.03 (0.98 – 1.09) 0.21 0.99 (0.90 – 1.09) 0.87 0.46 
rs780094 2 27652888 GCKR Published T/C 1.18 (1.08 – 1.28) 1.5E-04 1.25 (1.07 – 1.47) 0.01 0.49 
rs11899863 2 43530470 THADA DIAGRAM T/C 0.98 (0.80 – 1.21) 0.86 0.87 (0.59 – 1.28) 0.49 0.59 
rs243021 2 60496470 BCL11A DIAGRAM G/A 1.06 (1.01 – 1.12) 0.02 1.00 (0.91 – 1.11) 0.93 0.30 
rs7593730 2 160996961 RBMS1 Published T/C 1.01 (0.95 – 1.08) 0.70 0.99 (0.88 – 1.12) 0.92 0.78 
rs7578326 2 226846158 IRS1 DIAGRAM G/A 1.08 (1.02 – 1.15) 0.01 1.10 (0.97 – 1.23) 0.14 0.84 
rs13081389 3 12264800 PPARG DIAGRAM G/A 1.04 (0.93 – 1.16) 0.49 1.24 (0.98 – 1.57) 0.07 0.19 
rs6780569 3 23173488 UBE2E2 Published A/G 1.10 (1.04 – 1.17) 1.6E-03 0.98 (0.88 – 1.10) 0.76 0.08 
rs6795735 3 64680405 ADAMTS9 DIAGRAM T/C 1.05 (0.99 – 1.11) 0.12 1.12 (1.00 – 1.25) 0.05 0.32 
rs11708067 3 124548468 ADCY5 Published G/A 1.11 (1.04 – 1.19) 1.5E-03 1.06 (0.94 – 1.20) 0.36 0.52 
rs1470579 3 187011782 IGF2BP2 DIAGRAM A/C 1.16 (1.10 – 1.22) 5.1E-08 0.99 (0.90 – 1.10) 0.87 0.007 
rs1801214 4 6421094 WFS1 DIAGRAM C/T 1.11 (1.04 – 1.17) 8.9E-04 0.97 (0.87 – 1.09) 0.60 0.05 
rs4457053 5 76460705 ZBED3 DIAGRAM A/G 1.00 (0.90 – 1.12) 0.96 0.83 (0.64 – 1.08) 0.16 0.19 
rs10440833 6 20796100 CDKAL1 DIAGRAM T/A 1.07 (1.01 – 1.14) 0.03 1.12 (1.00 – 1.25) 0.05 0.50 
rs2191349 7 14837549 DGKB Published G/T 1.06 (1.00 – 1.12) 0.05 1.04 (0.94 – 1.16) 0.43 0.82 
rs849134 7 27969462 JAZF1 DIAGRAM G/A 1.07 (1.01 – 1.14) 0.02 1.02 (0.91 – 1.14) 0.74 0.42 
rs4607517 7 44008908 GCK Published G/A 0.98 (0.91 – 1.06) 0.59 1.14 (0.99 – 1.32) 0.07 0.07 
rs972283 7 129924109 KLF14 DIAGRAM A/G 0.97 (0.92 – 1.03) 0.36 1.01 (0.91 – 1.12) 0.89 0.58 
rs896854 8 96029687 TP53INP1 DIAGRAM C/T 1.09 (1.03 – 1.15) 1.4E-03 1.04 (0.94 – 1.14) 0.49 0.38 
rs3802177 8 118254206 SLC30A8 DIAGRAM A/G 1.13 (1.06 – 1.20) 8.9E-05 1.11 (0.99 – 1.25) 0.09 0.78 
rs17584499 9 8869118 PTPRD Published C/T 1.00 (0.94 – 1.07) 0.93 0.92 (0.83 – 1.03) 0.15 0.20 
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rs10965250 9 22123284 CDKN2A/B DIAGRAM A/G 1.19 (1.08 – 1.30) 2.6E-04 1.24 (1.03 – 1.51) 0.03 0.65 
rs13292136 9 79181682 CHCD9 DIAGRAM T/C 1.09 (1.02 – 1.18) 0.02 1.11 (0.96 – 1.28) 0.17 0.88 
rs12779790 10 12368016 CDC123 DIAGRAM A/G 1.16 (1.08 – 1.25) 1.1E-04 1.01 (0.87 – 1.16) 0.93 0.08 
rs5015480 10 94455539 HHEX DIAGRAM T/C 1.05 (0.99 – 1.10) 0.09 1.19 (1.08 – 1.31) 6.4E-04 0.03 
rs7903146 10 114748339 TCF7L2 DIAGRAM C/T 1.30 (1.23 – 1.38) 1.2E-20 1.09 (0.98 – 1.22) 0.10 0.005 
rs2334499 11 1653425 DUSP8 Published C/T 1.04 (0.98 – 1.10) 0.22 0.97 (0.87 – 1.08) 0.57 0.28 
rs231362 11 2648047 KCNQ1 DIAGRAM A/G 1.08 (1.01 – 1.15) 0.02 1.12 (1.00 – 1.26) 0.06 0.58 
rs163184 11 2803645 KCNQ1 DIAGRAM T/G 1.06 (1.00 – 1.11) 0.04 1.17 (1.06 – 1.29) 2.1E-03 0.08 
rs5215 11 17365206 KCNJ11 DIAGRAM T/C 1.05 (1.00 – 1.11) 0.07 1.00 (0.90 – 1.10) 0.97 0.37 
rs1552224 11 72110746 CENTD2 DIAGRAM C/A 1.03 (0.96 – 1.11) 0.35 1.06 (0.93 – 1.21) 0.37 0.73 
rs1387153 11 92313476 MTNR1B DIAGRAM C/T 1.08 (1.02 – 1.14) 4.6E-03 1.02 (0.92 – 1.12) 0.76 0.29 
rs1531343 12 64461161 HMGA2 DIAGRAM G/C 1.07 (1.00 – 1.14) 0.05 1.06 (0.94 – 1.21) 0.35 0.97 
rs4760790 12 69921061 TSPAN8 DIAGRAM G/A 1.05 (0.99 – 1.11) 0.08 1.10 (0.99 – 1.22) 0.07 0.45 
rs7957197 12 119923406 HNF1A DIAGRAM A/T 1.11 (0.93 – 1.33) 0.26 1.24 (0.88 – 1.76) 0.22 0.57 
rs7172432 15 60183681 C2CD4A/B Published G/A 1.06 (1.01 – 1.12) 0.03 1.03 (0.94 – 1.14) 0.51 0.66 
rs11634397 15 78219277 ZFAND6 DIAGRAM A/G 1.04 (0.98 – 1.11) 0.22 1.11 (0.98 – 1.27) 0.11 0.37 
rs8042680 15 89322341 PRC1 DIAGRAM C/A 1.06 (1.00 – 1.11) 0.05 1.06 (0.95 – 1.17) 0.31 1.00 
rs11642841 16 52402988 FTO DIAGRAM C/A 1.05 (0.99 – 1.12) 0.09 1.15 (1.02 – 1.29) 0.02 0.22 
rs391300 17 2163008 SRR Published T/C 0.99 (0.94 – 1.04) 0.68 0.98 (0.89 – 1.08) 0.73 0.91 
rs4430796 17 33172153 HNF1B DIAGRAM A/G 1.09 (1.03 – 1.15) 2.8E-03 1.03 (0.93 – 1.14) 0.60 0.35 
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Table 5.5: Tests for heterogeneity of effect (Phetero) between the three SAT2D cohorts at the previously reported T2D loci. 
 
 
     LOLIPOP 610 LOLIPOP 317 PROMIS SINDI  
SNP Nearest gene Ref 
Alleles 
(A/R) OR P OR P OR P OR P Phetero 
             
rs10923931 NOTCH2 DIAG G/T 0.97 (0.87 – 1.08) 0.59 0.95 (0.78 – 1.15) 0.58 1.03 (0.95 – 1.13) 0.48 1.05 (0.91 – 1.22) 0.51 0.78 
rs340874 PROX1 Pub T/C 1.02 (0.94 – 1.10) 0.67 1.12 (0.96 – 1.30) 0.16 1.05 (0.98 – 1.12) 0.17 0.91 (0.81 – 1.03) 0.13 0.33 
rs780094 GCKR Pub T/C 1.15 (1.04 – 1.26) 4E-03 1.48 (1.23 – 1.79) 2.0E-05 1.02 (0.95 – 1.11) 0.53 1.13 (0.98 – 1.32) 0.10 6.0E-03 
rs11899863 THADA DIAG T/C NA NA NA NA 0.96 (0.80 – 1.15) 0.66 NA NA NA 
rs243021 BCL11A DIAG G/A 1.09 (1.00 – 1.18) 0.04 1.03 (0.88 – 1.19) 0.74 1.00 (0.94 – 1.07) 0.89 1.14 (1.01 – 1.29) 0.04 0.41 
rs7593730 RBMS1 Pub T/C 1.02 (0.92 – 1.13) 0.69 1.15 (0.95 – 1.40) 0.15 1.01 (0.93 – 1.09) 0.85 0.93 (0.81 – 1.07) 0.33 0.50 
rs7578326 IRS1 DIAG G/A 1.11 (1.01 – 1.22) 0.02 1.09 (0.91 – 1.29) 0.36 1.07 (0.99 – 1.16) 0.09 1.05 (0.89 – 1.22) 0.57 0.93 
rs13081389 PPARG DIAG G/A 1.10 (0.94 – 1.29) 0.23 NA NA 1.06 (0.93 – 1.20) 0.39 NA NA 0.69 
rs6780569 UBE2E2 Pub A/G 1.08 (0.99 – 1.19) 0.10 1.09 (0.92 – 1.31) 0.31 1.06 (0.99 – 1.15) 0.11 1.05 (0.92 – 1.20) 0.45 0.99 
rs6795735 ADAMTS9 DIAG T/C 1.01 (0.92 – 1.10) 0.89 1.10 (0.93 – 1.30) 0.28 1.07 (0.99 – 1.15) 0.09 1.16 (1.00 – 1.35) 0.04 0.53 
rs11708067 ADCY5 Pub G/A 1.13 (1.02 – 1.25) 0.02 1.28 (1.05 – 1.56) 0.01 1.07 (0.98 – 1.16) 0.11 1.04 (0.88 – 1.22) 0.67 0.40 
rs1470579 IGF2BP2 DIAG A/C 1.13 (1.04 – 1.23) 3E-03 1.09 (0.93 – 1.27) 0.28 1.13 (1.06 – 1.21) 3.1E-04 1.08 (0.95 – 1.22) 0.23 0.93 
rs1801214 WFS1 DIAG C/T 1.11 (1.02 – 1.22) 0.02 0.94 (0.79 – 1.12) 0.49 1.09 (1.01 – 1.17) 0.03 1.05 (0.91 – 1.22) 0.49 0.47 
rs4457053 ZBED3 DIAG A/G 0.98 (0.88 – 1.08) 0.63 NA NA NA NA NA NA NA 
rs10440833 CDKAL1 DIAG T/A 1.02 (0.93 – 1.11) 0.74 0.96 (0.81 – 1.15) 0.69 1.13 (1.05 – 1.22) 1.6E-03 1.14 (0.99 – 1.32) 0.07 0.25 
rs2191349 DGKB Pub G/T 1.10 (1.01 – 1.19) 0.03 1.08 (0.93 – 1.27) 0.31 1.01 (0.95 – 1.09) 0.70 1.08 (0.95 – 1.22) 0.26 0.64 
rs849134 JAZF1 DIAG G/A 1.11 (1.01 – 1.21) 0.02 1.15 (0.97 – 1.36) 0.12 1.02 (0.94 – 1.09) 0.68 1.09 (0.94 – 1.25) 0.26 0.48 
rs4607517 GCK Pub G/A 1.14 (1.01 – 1.29) 0.04 0.98 (0.77 – 1.24) 0.84 0.95 (0.86 – 1.05) 0.29 1.01 (0.84 – 1.21) 0.95 0.25 
rs972283 KLF14 DIAG A/G 1.04 (0.95 – 1.13) 0.38 0.96 (0.81 – 1.12) 0.58 0.94 (0.88 – 1.01) 0.09 1.01 (0.89 – 1.15) 0.84 0.47 
rs896854 TP53INP1 DIAG C/T 1.08 (0.99 – 1.17) 0.07 1.08 (0.93 – 1.25) 0.33 1.09 (1.02 – 1.17) 0.01 1.02 (0.90 – 1.16) 0.75 0.91 
rs3802177 SLC30A8 DIAG A/G 1.11 (1.01 – 1.22) 0.03 1.13 (0.95 – 1.35) 0.17 1.15 (1.06 – 1.24) 7.4E-04 1.07 (0.93 – 1.24) 0.35 0.92 
rs17584499 PTPRD Pub C/T 1.01 (0.92 – 1.11) 0.86 1.19 (0.85 – 1.67) 0.31 0.97 (0.90 – 1.05) 0.43 0.95 (0.83 – 1.09) 0.48 0.37 
rs10965250 CDKN2A/B DIAG A/G 1.11 (0.98 – 1.26) 0.09 NA NA 1.26 (1.14 – 1.40) 1.7E-05 NA NA 0.13 
rs13292136 CHCD9 DIAG T/C 1.08 (0.96 – 1.22) 0.19 1.09 (0.88 – 1.36) 0.43 1.13 (1.03 – 1.25) 0.01 1.04 (0.87 – 1.24) 0.68 0.90 
rs12779790 CDC123 DIAG A/G 1.12 (1.00 – 1.25) 0.04 1.23 (0.99 – 1.52) 0.07 1.10 (1.00 – 1.21) 0.06 1.14 (0.96 – 1.35) 0.14 0.87 
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rs5015480 HHEX DIAG T/C 1.11 (1.03 – 1.21) 0.01 0.97 (0.83 – 1.13) 0.68 1.04 (0.97-1.11) 0.27 1.20 (1.06 – 1.35) 4.6E-03 0.20 
rs7903146 TCF7L2 DIAG C/T 1.22 (1.12 – 1.33) 1E-05 1.51 (1.29 – 1.76) 2.9E-07 1.25 (1.16-1.34) 1.5E-09 1.21 (1.06 – 1.39) 3.9E-03 0.17 
rs2334499 DUSP8 Pub C/T 1.03 (0.94 – 1.13) 0.54 1.04 (0.89 – 1.23) 0.60 1.06 (0.98-1.14) 0.12 0.87 (0.76 – 0.99) 0.04 0.27 
rs231362 KCNQ1 DIAG A/G 1.10 (1.00 – 1.20) 0.06 1.23 (0.97 – 1.56) 0.09 1.08 (1.00-1.17) 0.05 1.04 (0.90 – 1.19) 0.62 0.66 
rs163184 KCNQ1 DIAG T/G 1.11 (1.02 – 1.20) 0.01 1.03 (0.89 – 1.20) 0.70 1.06 (1.00-1.14) 0.07 1.11 (0.98 – 1.25) 0.09 0.81 
rs5215 KCNJ11 DIAG T/C 1.11 (1.02 – 1.21) 0.01 0.98 (0.84 – 1.15) 0.83 1.00 (0.93-1.07) 0.97 1.02 (0.90 – 1.16) 0.73 0.35 
rs1552224 CENTD2 DIAG C/A 1.14 (1.02 – 1.26) 0.02 1.09 (0.89 – 1.33) 0.40 0.99 (0.91-1.08) 0.80 0.97 (0.83 – 1.14) 0.71 0.32 
rs1387153 MTNR1B DIAG C/T 1.09 (1.00 – 1.18) 0.05 1.08 (0.92 – 1.26) 0.35 1.07 (1.00-1.14) 0.07 1.01 (0.89 – 1.14) 0.93 0.88 
rs1531343 HMGA2 DIAG G/C 1.03 (0.93 – 1.14) 0.60 1.22 (1.00 – 1.48) 0.05 1.08 (0.99-1.17) 0.10 1.05 (0.89 – 1.22) 0.58 0.57 
rs4760790 TSPAN8 DIAG G/A 1.04 (0.96 – 1.13) 0.36 0.92 (0.78 – 1.08) 0.32 1.13 (1.06-1.22) 5.2E-04 0.98 (0.87 – 1.11) 0.76 0.10 
rs7957197 HNF1A DIAG A/T NA NA NA NA 1.14 (0.98-1.34) 0.10 NA NA NA 
rs7172432 C2CD4A/B Pub G/A 1.08 (1.00 – 1.18) 0.06 1.00 (0.86 – 1.16) 0.98 1.06 (0.99-1.13) 0.10 1.01 (0.89 – 1.14) 0.89 0.79 
rs11634397 ZFAND6 DIAG A/G 1.07 (0.98 – 1.17) 0.12 NA NA 1.04 (0.97-1.12) 0.27 NA NA 0.64 
rs8042680 PRC1 DIAG C/A 1.05 (0.97 – 1.14) 0.21 1.04 (0.89 – 1.21) 0.65 1.08 (1.00-1.15) 0.04 1.00 (0.87 – 1.16) 0.99 0.89 
rs11642841 FTO DIAG C/A 0.95 (0.86 – 1.05) 0.31 1.07 (0.88 – 1.30) 0.49 1.17 (1.08-1.27) 8.1E-05 1.05 (0.91 – 1.22) 0.49 0.04 
rs391300 SRR Pub T/C 0.93 (0.86 – 1.01) 0.09 1.01 (0.86 – 1.17) 0.94 1.02 (0.95-1.09) 0.57 1.00 (0.89 – 1.13) 0.97 0.54 
rs4430796 HNF1B DIAG A/G 1.14 (1.05 – 1.24) 2E-03 1.15 (0.95 – 1.37) 0.14 1.07 (1.00-1.15) 0.05 0.93 (0.81 – 1.06) 0.26 0.20 
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Table 5.6: Association of SNPs reported to be associated with T2D or best available proxy SNP, with HOMA-B amongst Indian 
Asians and Europeans participating in LOLIPOP. Phetero is for comparison of effect size between Indian Asians and Europeans. 
 
 
   Indian Asians   Europeans       
Locus Chm SNP HOMA B Beta (95%CI) P  HOMA B Beta (95%CI) P   P hetero 
NOTCH2 1 rs2641348 -0.05 (-0.08 – -0.01) 0.01  -0.014 (-0.115 – 0.099) 0.81  0.59 
PROX1 1 rs340874 -0.02 (-0.04 – 0.01) 0.20  -0.014 (-0.099 – 0.079) 0.7  0.52 
GCKR 2 rs780094 0.00 (-0.03 – 0.03) 0.90  0.042 (-0.048 – 0.141) 0.23  0.76 
THADA 2 rs7578597 -0.02 (-0.06 – 0.02) 0.27  -0.096 (-0.185 – 0.002) 0.05  0.65 
BCL11A 2 rs243021 -0.02 (-0.05 – 0.00) 0.11  0.047 (0.001 – 0.095) 0.11  0.92 
RBMS1 2 rs407746 -0.01 (-0.04 – 0.03) 0.69  -0.054 (-0.132 – 0.031) 0.2  0.63 
IRS1 2 rs7578326 0.01 (-0.02 – 0.04) 0.61  0.052 (-0.017 – 0.126) 0.16  0.94 
PPARG 3 rs13089415 -0.01 (-0.06 – 0.05) 0.73  0.064 (-0.071 – 0.218) 0.37  0.78 
UBE2E2 3 rs7612463 -0.03 (-0.07 – 0.00) 0.04  0.094 (0.000 – 0.197) 0.1  0.97 
PSMD6 3 rs831571 0.00 (-0.03 – 0.04) 0.90  0.040 (-0.046 – 0.133) 0.36  0.75 
ADAMTS9 3 rs4411878 0.01 (-0.02 – 0.04) 0.41  0.030 (-0.050 – 0.118) 0.45  0.64 
ADCY5 3 rs2877716 -0.07 (-0.10 – -0.04) 2.5x10-5  -0.045 (-0.116 – 0.031) 0.24  0.56 
IGF2BP2 3 rs1470579 0.01 (-0.02 – 0.03) 0.64  -0.071 (-0.151 – 0.017) 0.05  0.70 
MAEA 4 rs6815464 NA NA  NA NA  NA 
WFS1 4 rs10012946 -0.01 (-0.04 – 0.02) 0.54  -0.038 (-0.101 – 0.029) 0.25  0.61 
ZBED3 5 rs7708285 0.01 (-0.02 – 0.05) 0.53  -0.005 (-0.074 – 0.070) 0.92  0.58 
CDKAL1 6 rs7754840 -0.03 (-0.06 – 0.00) 0.10  -0.021 (-0.089 – 0.053) 0.55  0.53 
ZFAND3 6 rs9470794 -0.06 (-0.10 – -0.01) 0.01  -0.002 (-0.109 – 0.117) 0.97  0.64 
KCNK16 6 rs3734618 0.00 (-0.02 – 0.03) 0.75  -0.016 (-0.080 – 0.053) 0.63  0.60 
DGKB 7 rs2191348 -0.03 (-0.06 – 0.00) 0.03  0.005 (-0.061 – 0.075) 0.91  0.66 
JAZF1 7 rs1635852 -0.01 (-0.04 – 0.02) 0.41  -0.018 (-0.062 – 0.027) 0.58  0.54 
GCK 7 rs4607517 -0.08 (-0.13 – -0.04) 5.0x10-5  -0.014 (-0.107 – 0.089) 0.79  0.66 
GCC1-PAX4 7 rs6467136 0.00 (-0.02 – 0.03) 0.90  0.028 (-0.039 – 0.100) 0.43  0.71 
KLF14 7 rs13234407 0.00 (-0.02 – 0.03) 0.90     0.54 
TP53INP1 8 rs896854 0.00 (-0.04 – 0.04) 0.79  0.028 (-0.065 – 0.130) 0.57  0.66 
SLC30A8 8 rs13266634 -0.03 (-0.06 – 0.00) 0.06  -0.056 (-0.122 – 0.015) 0.12  0.57 
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GLIS3 9 rs7041847 -0.03 (-0.06 – -0.01) 0.03  -0.041 (-0.099 – 0.022) 0.2  0.53 
PTPRD 9 rs17584499 0.01 (-0.02 – 0.05) 0.40  0.026 (-0.059 – 0.117) 0.55  0.58 
CDKN2A/B 9 rs10965250 -0.05 (-0.09 – -0.01) 0.02  -0.043 (-0.125 – 0.048) 0.33  0.52 
CHCD9 9 rs429573 0.01 (-0.02 – 0.04) 0.55  -0.007 (-0.072 – 0.063) 0.84  0.58 
HHEX 10 rs5015480 0.00 (-0.03 – 0.03) 0.99  -0.009 (-0.095 – 0.084) 0.77  0.54 
TCF7L2 10 rs7903146 -0.06 (-0.09 – -0.03) 1.4x10-4  -0.047 (-0.114 – 0.024) 0.18  0.53 
DUSP8 11 rs2334499 NA NA  NA NA  NA 
KCNQ1 11 rs2237892 0.02 (-0.08 – 0.13) 0.68  0.007 (-0.109 – 0.137) 0.93  0.54 
KCNQ1 11 rs163184 NA NA  NA NA  NA 
KCNJ11 11 rs5215 0.00 (-0.03 – 0.03) 0.99  -0.049 (-0.112 – 0.017) 0.15  0.67 
CENTD2 11 rs1552224 -0.01 (-0.04 – 0.03) 0.70  -0.060 (-0.145 – 0.033) 0.21  0.64 
MTNR1B 11 rs1387153 -0.02 (-0.04 – 0.01) 0.29  -0.002 (-0.072 – 0.072) 0.96  0.57 
HMGA2 12 rs2612067 -0.03 (-0.06 – 0.01) 0.12  -0.005 (-0.107 – 0.109) 0.94  0.58 
TSPAN8 12 rs4760915 -0.02 (-0.05 – 0.01) 0.22  0.007 (-0.063 – 0.082) 0.84  0.62 
HNF1A 12 rs7965349 -0.01 (-0.07 – 0.06) 0.83  0.062 (-0.021 – 0.152) 0.16  0.83 
C2CD4A/B 15 rs7172432 -0.01 (-0.04 – 0.01) 0.34  -0.045 (-0.108 – 0.022) 0.17  0.61 
ZFAND6 15 rs4778582 0.02 (-0.01 – 0.05) 0.15  -0.034 (-0.097 – 0.034) 0.33  0.71 
AP3S2 15 rs2028299 0.01 (-0.03 – 0.05) 0.45  0.000 (-0.091 – 0.099) 0.99  0.53 
PRC1 15 rs8042680 0.01 (-0.02 – 0.03) 0.59  0.038 (-0.035 – 0.115) 0.33  0.78 
FTO 16 rs3751812 0.01 (-0.02 – 0.04) 0.55  -0.007 (-0.072 – 0.063) 0.84  0.58 
SRR 17 rs391300 0.00 (-0.02 – 0.03) 0.75  0.002 (-0.063 – 0.073) 0.96  0.51 
HNF1B 17 rs4430796 0.01 (-0.01 – 0.04) 0.35  -0.009 (-0.070 – 0.055) 0.76  0.63 
PEPD 19 rs436248 -0.02 (-0.05 – 0.01) 0.13   0.057 (-0.600 – 1.789) 0.91   0.55 
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Table 5.7: Association of SNPs reported to be associated with T2D or best available proxy SNP, with HOMA-IR amongst 
Indian Asians and Europeans participating in LOLIPOP. Phetero is for comparison of effect size between Indian Asians and 
Europeans. 
 
    Indian Asians     Europeans       
Locus Chm SNP HOMA IR Beta (95%CI) P   HOMA IR Beta (95%CI) P   P hetero 
NOTCH2 1 rs2641348 -0.03 (-0.07 – 0.00) 0.08  -0.07 (-0.18 – 0.07) 0.39  0.57 
PROX1 1 rs340874 0.01 (-0.02 – 0.04) 0.69  0.02 (-0.07 – 0.11) 0.68  0.55 
GCKR 2 rs780094 0.04 (0.01 – 0.08) 0.01  0.10 (0.00 – 0.20) 0.03  1.00 
THADA 2 rs7578597 -0.03 (-0.07 – 0.01) 0.20  -0.05 (-0.17 – 0.09) 0.37  0.54 
BCL11A 2 rs243021 -0.02 (-0.05 – 0.01) 0.14  0.05 (-0.04 – 0.15) 0.16  0.85 
RBMS1 2 rs407746 -0.01 (-0.04 – 0.03) 0.73  -0.01 (-0.09 – 0.09) 0.91  0.50 
IRS1 2 rs7578326 -0.01 (-0.04 – 0.02) 0.71  0.07 (-0.02 – 0.17) 0.06  0.97 
PPARG 3 rs13089415 0.01 (-0.04 – 0.07) 0.69  0.12 (-0.06 – 0.34) 0.18  0.93 
UBE2E2 3 rs7612463 -0.03 (-0.07 – 0.00) 0.08  0.05 (-0.09 – 0.20) 0.56  0.77 
PSMD6 3 rs831571 -0.01 (-0.05 – 0.02) 0.57  0.10 (0.00 – 0.20) 0.07  0.99 
ADAMTS9 3 rs4411878 0.02 (-0.01 – 0.05) 0.15  0.05 (-0.04 – 0.15) 0.39  0.72 
ADCY5 3 rs2877716 -0.03 (-0.32 – 0.40) 0.11  0.02 (-0.07 – 0.11) 0.7  0.56 
IGF2BP2 3 rs1470579 0.00 (-0.03 – 0.03) 0.92  -0.05 (-0.13 – 0.05) 0.42  0.63 
MAEA 4 rs6815464 NA NA  NA NA  NA 
WFS1 4 rs10012946 0.00 (-0.03 – 0.03) 0.95  -0.01 (-0.10 – 0.08) 0.79  0.55 
ZBED3 5 rs7708285 0.00 (-0.04 – 0.04) 0.99  -0.05 (-0.13 – 0.05) 0.31  0.63 
CDKAL1 6 rs7754840 -0.01 (-0.04 – 0.02) 0.56  0.01 (-0.08 – 0.10) 0.81  0.58 
ZFAND3 6 rs9470794 -0.05 (-0.10 – 0.00) 0.04  0.02 (-0.11 – 0.17) 0.65  0.69 
KCNK16 6 rs3734618 0.00 (-0.03 – 0.03) 0.83  -0.05 (-0.13 – 0.05) 0.24  0.63 
DGKB 7 rs2191348 -0.01 (-0.04 – 0.02) 0.38  0.05 (-0.04 – 0.15) 0.22  0.84 
JAZF1 7 rs1635852 0.00 (-0.03 – 0.03) 0.93  0.01 (-0.07 – 0.11) 0.73  0.56 
GCK 7 rs4607517 -0.03 (-0.08 – 0.03) 0.34  -0.05 (-0.17 – 0.09) 0.39  0.54 
GCC1-PAX4 7 rs6467136 0.02 (-0.01 – 0.06) 0.12  -0.02 (-0.11 – 0.07) 0.61  0.66 
KLF14 7 rs13234407 0.02 (-0.01 – 0.05) 0.16  0.05 (-0.04 – 0.15) 0.34  0.72 
TP53INP1 8 rs896854 0.02 (-0.02 – 0.06) 0.46  -0.02 (-0.11 – 0.07) 0.59  0.64 
SLC30A8 8 rs13266634 0.00 (-0.04 – 0.04) 0.96  -0.05 (-0.13 -– 0.05) 0.32  0.63 
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GLIS3 9 rs7041847 -0.02 (-0.05 – 0.01) 0.20  -0.09 (-0.17 – 0.00) 0.04  0.65 
PTPRD 9 rs17584499 0.02 (-0.02 – 0.05) 0.38  0.05 (-0.04 – 0.15) 0.37  0.74 
CDKN2A/B 9 rs10965250 -0.03 (-0.07 – 0.01) 0.16  -0.09 (-0.17 – 0.00) 0.08  0.62 
CHCD9 9 rs429573 0.00 (-0.03 – 0.03) 0.83  -0.05 (-0.13 – 0.05) 0.32  0.64 
HHEX 10 rs5015480 0.00 (-0.04 – 0.03) 0.80  0.02 (-0.07 – 0.12) 0.64  0.63 
TCF7L2 10 rs7903146 -0.05 (-0.08 – -0.02) 0.002  0.00 (-0.08 – 0.10) 0.96  0.67 
DUSP8 11 rs2334499 NA NA  NA NA  NA 
KCNQ1 11 rs2237892 0.05 (-0.06 – 0.17) 0.38  0.05 (-0.09 – 0.20) 0.58  0.51 
KCNQ1 11 rs163184 NA NA  NA NA  NA 
KCNJ11 11 rs5215 0.02 (-0.01 – 0.06) 0.13  -0.05 (-0.13 – 0.05) 0.38  0.70 
CENTD2 11 rs1552224 -0.01 (-0.05 – 0.03) 0.57  -0.26 (-0.35 – -0.15) 0.6  0.76 
MTNR1B 11 rs1387153 0.04 (0.01 – 0.07) 0.02  0.00 (-0.09 – 0.09) 0.9  0.68 
HMGA2 12 rs2612067 -0.03 (-0.06 – 0.02) 0.20  -0.02 (-0.14 – 0.12) 0.74  0.51 
TSPAN8 12 rs4760915 -0.01 (-0.04 – 0.02) 0.56  0.00 (-0.08 – 0.10) 0.91  0.56 
HNF1A 12 rs7965349 -0.02 (-0.08 – 0.05) 0.59  0.05 (-0.04 – 0.15) 0.37  0.76 
C2CD4A/B 15 rs7172432 0.00 (-0.03 – 0.03) 0.83  -0.05 (-0.13 – 0.05) 0.32  0.64 
ZFAND6 15 rs4778582 0.02 (-0.01 – 0.06) 0.12  -0.05 (-0.13 – 0.05) 0.41  0.70 
AP3S2 15 rs2028299 -0.01 (-0.05 – 0.04) 0.65  0.00 (-0.13 – 0.14) 0.96  0.52 
PRC1 15 rs8042680 0.03 (0.00 – 0.07) 0.04  0.10 (0.00 – 0.20) 0.02  1.00 
FTO 16 rs3751812 0.02 (-0.01 – 0.05) 0.20  0.00 (-0.09 – 0.09) 0.96  0.60 
SRR 17 rs391300 0.00 (-0.03 – 0.04) 0.73  0.07 (-0.02 – 0.17) 0.07  0.98 
HNF1B 17 rs4430796 0.01 (-0.02 – 0.04) 0.67  0.02 (-0.07 – 0.12) 0.56  0.59 
PEPD 19 rs436248 -0.01 (-0.04 – 0.02) 0.41   0.00 (-0.09 – 0.09) 0.97   0.55 
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Table 5.8: Association of SNPs reported to be associated with T2D or best available proxy SNP, with BMI amongst Indian Asians 
and Europeans participating in LOLIPOP. Phetero is for comparison of effect size between Indian Asians and Europeans.  
 
 
   Indian Asians  Europeans   
Locus Chm SNP BMI Beta (95%CI) P  BMI Beta (95%CI) P   Phetero 
NOTCH2 1 rs2641348 -0.26 (-0.45 – -0.07) 0.006  -0.28 (-0.99 – 0.43) 0.44  0.48 
PROX1 1 rs340874 -0.10 (-1.47 – 1.27) 0.17  0.05 (-0.38 – 0.48) 0.83  0.42 
GCKR 2 rs780094 0.06 (-0.11 – 0.23) 0.45  0.51 (0.08 – 0.94) 0.02  0.03 
THADA 2 rs7578597 0.05 (0.03 – 0.07) 0.61  0.10 (-0.57 – 0.77) 0.78  0.44 
BCL11A 2 rs243021 -0.17 (-0.32 – -0.02) 0.02  0.39 (-0.02 – 0.80) 0.07  0.01 
RBMS1 2 rs407746 -0.02 (-0.20 – 0.16) 0.83  -0.09 (-0.62 – 0.44) 0.74  0.40 
IRS1 2 rs7578326 -0.27 (-0.44 – -0.10) 0.002  -0.01 (-0.09 – 0.07) 0.96  0.50 
PPARG 3 rs13089415 -0.22 (-0.49 – 0.05) 0.12  0.33 (-0.53 – 1.19) 0.46  0.12 
UBE2E2 3 rs7612463 -0.13 (-0.31 – 0.05) 0.16  -0.10 (-0.79 – 0.59) 0.79  0.47 
PSMD6 3 rs831571 0.02 (-0.16 – 0.20) 0.85  0.18 (-0.36 – 0.72) 0.51  0.29 
ADAMTS9 3 rs4411878 -0.04 (-0.18 – 0.10) 0.63  -0.25 (-0.76 – 0.26) 0.34  0.22 
ADCY5 3 rs2877716 -0.21 (-0.38 – -0.04) 0.02  -0.10 (-0.59 – 0.39) 0.69  0.34 
IGF2BP2 3 rs1470579 -0.20 (-0.35 – -0.05) 0.007  -0.05 (-0.50 – 0.40) 0.82  0.27 
MAEA 4 rs6815464 NA NA  NA NA  NA 
WFS1 4 rs10012946 0.02 (-0.14 – 0.18) 0.78  -0.09 (-0.52 – 0.34) 0.68  0.32 
ZBED3 5 rs7708285 0.32 (0.14 – 0.50) 0.73  -0.28 (-0.75 – 0.19) 0.25  0.01 
CDKAL1 6 rs7754840 0.01 (-0.15 – 0.17) 0.88  0.20 (-0.25 – 0.65) 0.38  0.22 
ZFAND3 6 rs9470794 -0.15 (-0.39 – 0.08) 0.2  0.54 (-0.20 – 1.28) 0.15  0.04 
KCNK16 6 rs3734618 0.05 (-0.10 – 0.20) 0.68  -0.04 (-0.45 – 0.37) 0.84  0.34 
DGKB 7 rs2191348 -0.02 (-0.17 – 0.13) 0.83  0.23 (-0.18 – 0.64) 0.29  0.13 
JAZF1 7 rs1635852 -0.04 (-0.20 – 0.12) 0.63  0.04 (-0.37 – 0.45) 0.86  0.36 
GCK 7 rs4607517 -0.01 (-0.26 – 0.24) 0.94  -0.84 (-1.48 – -0.20) 0.01  0.01 
GCC1-PAX4 7 rs6467136 -0.07 (-0.21 – 0.08) 0.37  0.09 (-0.34 – 0.51) 0.4  0.25 
KLF14 7 rs13234407 -0.01 (-0.16 – 0.14) 0.92  0.00 (-0.43 – 0.43) 0.99  0.48 
TP53INP1 8 rs896854 0.08 (-0.13 – 0.29) 0.43  0.18 (-0.41 – 0.77) 0.55  0.38 
SLC30A8 8 rs13266634 -0.01 (-0.16 – 0.14) 0.92  -0.62 (-1.07 – -0.17) 0.008  0.01 
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GLIS3 9 rs7041847 0.12 (-0.03 – 0.27) 0.10  0.02 (-0.39 – 0.43) 0.94  0.33 
PTPRD 9 rs17584499 0.01 (-0.16 – 0.17) 0.94  0.41 (-0.16 – 0.98) 0.15  0.09 
CDKN2A/B 9 rs10965250 -0.16 (-0.16 – -0.16) 0.14  0.15 (-0.42 – 0.72) 0.60  0.14 
CHCD9 9 rs429573 0.03 (-0.12 – 0.18) 0.74  0.06 (-0.39 – 0.51) 0.78  0.45 
HHEX 10 rs5015480 -0.06 (-0.22 – 0.10) 0.42  -0.15 (-0.60 – 0.30) 0.50  0.36 
TCF7L2 10 rs7903146 -0.15 (-0.31 – 0.01) 0.06  -0.12 (-0.57 – 0.33) 0.62  0.45 
DUSP8 11 rs2334499 NA NA  NA NA  NA 
KCNQ1 11 rs2237892 0.23 (-0.30 – 0.76) 0.39  0.18 (-0.60 – 0.96) 0.66  0.46 
KCNQ1 11 rs163184 NA NA  NA NA  NA 
KCNJ11 11 rs5215 -0.01 (-0.16 – 0.14) 0.90  -0.47 (-0.90 – -0.04) 0.04  0.02 
CENTD2 11 rs1552224 -0.09 (-0.28 – 0.10) 0.36  -0.51 (-1.12 – 0.10) 0.10  0.10 
MTNR1B 11 rs1387153 0.03 (-0.12 – 0.18) 0.68  -0.01 (-0.46 – 0.44) 0.98  0.44 
HMGA2 12 rs2612067 -0.23 (-0.42 – -0.04) 0.02  -0.42 (-1.11 – 0.27) 0.23  0.30 
TSPAN8 12 rs4760915 0.11 (-0.04 – 0.26) 0.18  -0.02 (-0.49 – 0.46) 0.95  0.31 
HNF1A 12 rs7965349 -0.22 (-0.55 – 0.11) 0.19  0.39 (-0.14 – 0.92) 0.16  0.03 
C2CD4A/B 15 rs7172432 0.02 (-0.13 – 0.17) 0.76  -0.05 (-0.48 – 0.38) 0.83  0.38 
ZFAND6 15 rs4778582 0.03 (-0.12 – 0.18) 0.74  0.06 (-0.39 – 0.51) 0.78  0.45 
AP3S2 15 rs2028299 0.19 (-0.03 – 0.41) 0.08  -0.35 (-0.96 – 0.26) 0.25  0.05 
PRC1 15 rs8042680 0.04 (-0.11 – 0.19) 0.56  0.51 (0.06 – 0.96) 0.96  0.03 
FTO 16 rs3751812 0.31 (0.16 – 0.46) 9.110-5  0.29 (-0.12 – 0.70) 0.171  0.46 
SRR 17 rs391300 0.05 (-0.09 – 0.19) 0.72  0.30 (-0.15 – 0.75) 0.18  0.15 
HNF1B 17 rs4430796 -0.09 (-0.24 – 0.06) 0.23  0.18 (-0.23 – 0.59) 0.39  0.11 
PEPD 19 rs436248 -0.15 (-0.31 – 0.01) 0.07  0.02 (-0.40 – 0.44) 0.91  0.23 
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Table 5.9: Association of SNPs reported to be associated with T2D or best available proxy SNP, with WHR amongst Indian Asians 
and Europeans participating in LOLIPOP. Phetero is for comparison of effect size between Indian Asians and Europeans. 
 
   Indian Asians  Europeans   
Locus Chm SNP WHR Beta (95%CI) P   WHR Beta (95%CI) P    P hetero 
NOTCH2 1 rs2641348 -0.001 (-0.005  – 0.003) 0.67  0.003 (-0.007 – 0.013) 0.56  0.23 
PROX1 1 rs340874 -0.002 (-0.004  – 0.000) 0.05  -0.002 (-0.008 – 0.004) 0.47  0.50 
GCKR 2 rs780094 0.002 (0.000 – 0.004) 0.14  0.004 (-0.002 – 0.010) 0.27  0.26 
THADA 2 rs7578597 -0.001 (-0.005 – 0.003) 0.58  -0.003 (-0.013 – 0.007) 0.54  0.36 
BCL11A 2 rs243021 -0.003 (-0.005 – -0.001) 0.01  0.004 (-0.002 – 0.010) 0.22  0.01 
RBMS1 2 rs407746 -0.001 (-0.003 – 0.001) 0.73  0.005 (-0.003 – 0.013) 0.19  0.07 
IRS1 2 rs7578326 -0.002 (-0.004 – 0.000) 0.12  0.004 (-0.002 – 0.010) 0.18  0.03 
PPARG 3 rs13089415 -0.001 (-0.005 – 0.003) 0.58  -0.006 (-0.018 – 0.006) 0.36  0.21 
UBE2E2 3 rs7612463 0.001 (-0.001 – 0.003) 0.47  -0.001 (-0.011 – 0.009) 0.92  0.35 
PSMD6 3 rs831571 0.000 (-0.001 – 0.002) 0.74  0.003 (-0.005 – 0.011) 0.42  0.27 
ADAMTS9 3 rs4411878 -0.036 (-0.181 – 0.109) 0.63  0.001 (-0.007 – 0.009) 0.90  0.31 
ADCY5 3 rs2877716 -0.002 (-0.004 – 0.000) 0.07  0.001 (-0.007 – 0.009) 0.90  0.23 
IGF2BP2 3 rs1470579 -0.003 (-0.005 – -0.001) 0.006  -0.003 (-0.009 – 0.003) 0.33  0.50 
MAEA 4 rs6815464 NA NA  NA NA  NA 
WFS1 4 rs10012946 0.001 (-0.001 – 0.003) 0.34  0.001 (-0.005 – 0.007) 0.89  0.50 
ZBED3 5 rs7708285 -0.001 (-0.003 – 0.001) 0.32  -0.006 (-0.012 – 0.000) 0.11  0.06 
CDKAL1 6 rs7754840 0.000 (-0.002 – 0.002) 0.81  0.010 (0.004 – 0.016) 0.01  8.010-4 
ZFAND3 6 rs9470794 0.002 (-0.002 – 0.006) 0.28  -0.001 (-0.011 – 0.009) 0.8  0.29 
KCNK16 6 rs3734618 0.001 (-0.001 – 0.003) 0.41  -0.001 (-0.007 – 0.005) 0.77  0.26 
DGKB 7 rs2191348 0.001 (-0.001 – 0.003) 0.63  0.003 (-0.003 – 0.009) 0.27  0.26 
JAZF1 7 rs1635852 0.000 (-0.002 – 0.002) 0.96  0.001 (-0.005 – 0.007) 0.79  0.38 
GCK 7 rs4607517 0.000 (-0.004 – 0.004) 0.88  -0.008 (-0.018 – 0.002) 0.09  0.06 
GCC1-PAX4 7 rs6467136 0.001 (-0.001 – 0.003) 0.60  0.002 (-0.004 – 0.008) 0.63  0.38 
KLF14 7 rs13234407 -0.002 (-0.004 – 0.000) 0.15  0.001 (-0.005 – 0.007) 0.69  0.17 
TP53INP1 8 rs896854 0.001 (-0.003 – 0.005) 0.50  0.001 (-0.007 – 0.009) 0.86  0.50 
SLC30A8 8 rs13266634 0.000 (-0.002 – 0.002) 0.81  -0.011 (-0.017 – -0.005) 0.001  1.010-5 
GLIS3 9 rs7041847 0.001 (-0.001 – 0.003) 0.41  -0.003 (-0.009 – 0.003) 0.38  0.10 
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PTPRD 9 rs17584499 -0.003 (-0.005 – -0.001) 0.06  0.000 (-0.008 – 0.008) 0.99  0.23 
CDKN2A/B 9 rs10965250 -0.163 (-0.379 – 0.053) 0.14  0.151 (-0.417 – 0.719) 0.60  0.16 
CHCD9 9 rs429573 0.002 (-0.002 – -0.006) 0.20  -0.004 (-0.012 – 0.004) 0.33  0.09 
HHEX 10 rs5015480 0.001 (-0.001 – 0.003) 0.57  -0.006 (-0.012 – 0.000) 0.07  0.01 
TCF7L2 10 rs7903146 0.000 (-0.002 – 0.002) 0.81  -0.001 (-0.007 – 0.005) 0.77  0.34 
DUSP8 11 rs2334499 NA NA  NA NA  NA 
KCNQ1 11 rs2237892 -0.002 (-0.010 – 0.006) 0.63  0.002 (-0.010 – 0.014) 0.72  0.29 
KCNQ1 11 rs163184 NA NA  NA NA  NA 
KCNJ11 11 rs5215 0.001 (-0.001 – 0.003) 0.56  -0.004 (-0.010 – 0.002) 0.17  0.06 
CENTD2 11 rs1552224 0.000 (-0.004 – 0.004) 0.96  -0.020 (-0.028 – -0.012) 4.010-4  410-7 
MTNR1B 11 rs1387153 0.001 (-0.001 – 0.003) 0.32  0.001 (-0.005 – 0.007) 0.84  0.50 
HMGA2 12 rs2612067 -0.001 (-0.005 – 0.003) 0.38  0.003 (-0.007 – 0.013) 0.5  0.23 
TSPAN8 12 rs4760915 0.001 (-0.001 – 0.003) 0.64  0.001 (-0.005 – 0.007) 0.68  0.50 
HNF1A 12 rs7965349 -0.002 (-0.008 – 0.004) 0.46  0.003 (-0.005 – 0.011) 0.41  0.16 
C2CD4A/B 15 rs7172432 0.001 (-0.001 – 0.003) 0.42  0.000 (-0.006 – 0.006) 0.93  0.41 
ZFAND6 15 rs4778582 0.000 (-0.002 – 0.002) 0.77  0.003 (-0.003 – 0.009) 0.41  0.20 
AP3S2 15 rs2028299 0.002 (-0.002 – 0.006) 0.20  -0.004 (-0.012 – 0.004) 0.33  0.09 
PRC1 15 rs8042680 0.002 (0.000 – 0.004) 0.12  0.001 (-0.005 – 0.007) 0.75  0.38 
FTO 16 rs3751812 0.002 (0.000 – 0.004) 0.09  -0.001 (-0.007 – 0.005) 0.74  0.17 
SRR 17 rs391300 0.001 (-0.001 – 0.003) 0.63  0.004 (-0.002 – 0.010) 0.25  0.17 
HNF1B 17 rs4430796 0.000 (-0.002 – 0.002) 0.41  0.001 (-0.005 – 0.007) 0.69  0.43 
PEPD 19 rs436248 -0.001 (-0.003 – 0.001) 0.45   -0.006 (-0.012 – 0.000) 0.06   0.06 
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Table 5.10: Association of SNPs reported to be associated with T2D or best available proxy SNP, with T2D amongst Indian Asians 
and Europeans participating in LOLIPOP. Associations with T2D are also presented following adjustment for BMI and separately for 
WHR. Phetero is for comparison of adjusted with unadjusted effect sizes. 
 
Locus Chm SNP T2D P  Adjustment for BMI  P Phetero  Adjustment for WHR  P Phetero 
NOTCH2 1 rs2641348 1.02 (0.83 – 1.30) 0.77  1.04 (0.94 – 1.15) 0.5 0.37  1.02 (0.92 – 1.13) 0.68 0.47 
PROX1 1 rs340874 0.97 (0.79 – 1.12) 0.49  0.86 (0.80 – 0.93) 0.7 0.01  0.99 (0.91 – 1.07) 0.791 0.39 
GCKR 2 rs780094 1.15 (1.13 – 1.69) 0.002  1.15 (1.05 – 1.26) 0.002 0.50  1.14 (1.04 – 1.25) 0.004 0.45 
THADA 2 rs7578597 0.97 (0.73 – 1.20) 0.59  0.96 (0.86 – 1.08) 0.51 0.46  0.98 (0.87 – 1.09) 0.7 0.46 
BCL11A 2 rs243021 1.07 (0.98 – 1.39) 0.09  1.08 (1.00 – 1.17) 0.044 0.41  1.09 (1.01 – 1.18) 0.03 0.36 
RBMS1 2 rs407746 0.99 (0.77 – 1.21) 0.76  0.99 (0.90 – 1.09) 0.8 0.48  0.99 (0.90 – 1.09) 0.82 0.48 
IRS1 2 rs7578326 1.15 (1.13 – 1.69) 0.002  1.18 (1.08 – 1.29) <0.001 0.34  1.17 (1.07 – 1.29) 0.001 0.38 
PPARG 3 rs13089415 1.09 (0.87 – 1.72) 0.237  1.12 (0.97 – 1.30) 0.13 0.40  1.11 (0.96 – 1.30) 0.16 0.43 
UBE2E2 3 rs7612463 1.06 (0.92 – 1.44) 0.2  1.08 (0.98 – 1.18) 0.14 0.44  1.06 (0.96 – 1.17) 0.23 0.49 
PSMD6  3 rs831571 1.06 (0.92 – 1.41) 0.25  1.06 (0.96 – 1.16) 0.27 0.49  1.05 (0.96 – 1.16) 0.28 0.48 
ADAMTS9 3 rs4411878 1.04 (0.92 – 1.31) 0.91  1.01 (0.93 – 1.09) 0.85 0.27  1.01 (0.93 – 1.09) 0.81 0.30 
ADCY5 3 rs2877716 1.18 (1.17 – 1.80) 0.001  1.20 (1.09 – 1.32) <0.001 0.38  1.20 (1.09 – 1.32) <0.001 0.39 
IGF2BP2 3 rs1470579 1.13 (1.12 – 1.60) 0.002  1.16 (1.07 – 1.25) <0.001 0.36  1.17 (1.08 – 1.27) <0.001 0.31 
MAEA  4 rs6815464 NA NA  NA NA NA  NA NA NA 
WFS1 4 rs10012946 1.13 (1.04 – 0.11) 0.003  1.14 (1.04 – 1.24) 0.003 0.49  1.13 (1.04 – 1.23) 0.005 0.48 
ZBED3 5 rs7708285 0.97 (0.88 – 0.16) 0.97  0.96 (0.88 – 1.06) 0.45 0.48  0.97 (0.88 – 1.07) 0.59 0.46 
CDKAL1 6 rs7754840 1.02 (0.93 – 0.14) 0.661  1.02 (0.94 – 1.11) 0.66 0.49  1.02 (0.94 – 1.12) 0.62 0.48 
ZFAND3  6 rs9470794 0.96 (0.85 – 0.16) 0.56  0.97 (0.87 – 1.10) 0.68 0.45  0.95 (0.83 – 1.07) 0.38 0.41 
KCNK16  6 rs3734618 0.94 (0.87 – 0.17) 0.11  0.93 (0.86 – 1.01) 0.08 0.46  0.93 (0.86 – 1.00) 0.06 0.42 
DGKB 7 rs2191348 1.15 (1.06 – 0.11) 0.001  1.16 (1.07 – 1.25) <0.001 0.44  1.15 (1.06 – 1.25) 0.001 0.49 
JAZF1 7 rs1635852 1.17 (1.08 – 0.11) <0.001  1.18 (1.08 – 1.28) <0.001 0.45  1.17 (1.08 – 1.28) <0.001 0.47 
GCK 7 rs4607517 1.12 (0.99 – 0.12) 0.078  1.13 (0.99 – 1.29) 0.07 0.48  1.13 (0.99 – 1.29) 0.07 0.48 
GCC1-PAX4  7 rs6467136 1.03 (0.95 – 0.14) 0.47  1.03 (0.95 – 1.12) 0.42 0.47  1.02 (0.95 – 1.11) 0.54 0.47 
KLF14 7 rs13234407 1.05 (0.97 – 0.13) 0.18  0.00 (0.00 – 0.00) 0 0.09  1.07 (0.99 – 1.16) 0.11 0.38 
TP53INP1 8 rs896854 1.05 (0.94 – 0.14) 0.42  1.04 (0.93 – 1.16) 0.52 0.45  1.04 (0.93 – 1.17) 0.45 0.49 
SLC30A8 8 rs13266634 1.10 (1.00 – 0.12) 0.04  1.10 (1.00 – 1.20) 0.04 0.49  1.10 (1.01 – 1.21) 0.03 0.47 
GLIS3  9 rs7041847 1.07 (0.99 – 0.13) 0.08  1.06 (0.98 – 1.15) 0.147 0.42  1.07 (0.99 – 1.16) 0.11 0.48 203  
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PTPRD 9 rs17584499 0.98 (0.89 – 0.15) 0.58  0.96 (0.88 – 1.04) 0.32 0.38  1.00 (0.91 – 1.09) 0.91 0.38 
CDKN2A/B 9 rs10965250 0.99 (0.89 – 0.15) 0.83  0.97 (0.87 – 1.09) 0.62 0.42  0.97 (0.87 – 1.09) 0.62 0.42 
CHCD9 9 rs10512058 1.11 (1.00 – 0.12) 0.06  1.10 (0.98 – 1.23) 0.11 0.43  1.08 (1.00 – 1.17) 0.05 0.48 
HHEX 10 rs5015480 1.08 (1.00 – 0.12) 0.04  1.09 (1.01 – 1.18) 0.03 0.46  1.08 (1.00 – 1.17) 0.05 0.48 
TCF7L2 10 rs7903146 1.20 (1.10 – 0.10) <0.001  1.22 (1.12 – 1.33) <0.001 0.37  1.21 (1.11 – 1.32) <0.001 0.43 
DUSP8 11 rs2334499 NA NA  NA NA NA  NA NA NA 
KCNQ1 11 rs2237892 1.22 (0.91 – 0.11) 0.18  1.21 (0.90 – 1.62) 0.22 0.48  1.25 (0.93 – 1.69) 0.14 0.46 
KCNQ1 11 rs163184 NA NA  NA NA NA  NA NA NA 
KCNJ11 11 rs5215 1.10 (1.01 – 0.12) 0.02  1.10 (1.02 – 1.20) 0.02 0.46  1.10 (1.01 – 1.19) 0.03 0.49 
CENTD2 11 rs1552224 1.15 (1.03 – 0.11) 0.01  1.16 (1.05 – 1.29) 0.005 0.42  1.16 (1.04 – 1.29) 0.007 0.45 
MTNR1B 11 rs1387153 1.07 (0.99 – 0.13) 0.1  1.07 (0.98 – 1.15) 0.12 0.48  1.06 (0.98 – 1.15) 0.15 0.46 
HMGA2 12 rs2612067 1.00 (0.90 – 0.15) 0.92  1.01 (0.92 – 1.12) 0.79 0.40  1.00 (0.91 – 1.11) 0.95 0.46 
TSPAN8 12 rs4760915 1.03 (0.95 – 0.14) 0.46  1.02 (0.94 – 1.11) 0.58 0.45  1.02 (0.94 – 1.11) 0.57 0.46 
HNF1A 12 rs7965349 1.12 (0.94 – 0.12) 0.19  1.16 (0.97 – 1.38) 0.11 0.41  1.16 (0.97 – 1.38) 0.11 0.41 
C2CD4A/B 15 rs7172432 1.07 (0.99 – 0.13) 0.07  1.07 (0.99 – 1.16) 0.09 0.48  1.06 (0.98 – 1.15) 0.13 0.43 
ZFAND6 15 rs4778582 1.03 (0.95 – 0.14) 0.53  1.02 (0.94 – 1.10) 0.62 0.46  1.03 (0.95 – 1.11) 0.52 0.49 
AP3S2  15 rs2028299 0.99 (0.89 – 0.15) 0.83  0.97 (0.87 – 1.09) 0.62 0.42  0.97 (0.87 – 1.09) 0.62 0.42 
PRC1 15 rs8042680 1.12 (1.03 – 0.12) 0.006  1.12 (1.04 – 1.21) 0.005 0.48  1.11 (1.02 – 1.20) 0.01 0.47 
FTO 16 rs3751812 1.00 (0.93 – 0.15) 0.92  0.97 (0.90 – 1.06) 0.54 0.30  0.99 (0.91 – 1.07) 0.77 0.39 
SRR 17 rs391300 0.95 (0.88 – 0.16) 0.15  0.94 (0.87 – 1.02) 0.137 0.48  0.94 (0.87 – 1.02) 0.14 0.47 
HNF1B 17 rs4430796 1.08 (1.00 – 0.13) 0.07  1.09 (1.01 – 1.18) 0.03 0.41  1.08 (1.00 – 1.17) 0.06 0.49 
PEPD  19 rs4362488 1.01 (0.92 – 0.15) 0.89  1.02 (0.93 – 1.11) 0.67 0.42  1.01 (0.93 – 1.10) 0.78 0.46 
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CHAPTER 6 
GENOME-WIDE ASSOCIATION STUDY IN PEOPLE OF 
INDIAN ASIAN ANCESTRY IDENTIFIES SIX NOVEL 
SUSCEPTIBILITY LOCI FOR TYPE-2 DIABETES 
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6.1 ABSTRACT 
Background 
Individuals of Indian Asian ancestry are at 4-fold higher risk of T2D compared 
to Europeans. This increased susceptibility is unexplained by differences in 
lifestyle and dietary patterns, suggesting a role for genetic factors. 
  
Methods 
I carried out a genome wide association study (GWAS) of T2D amongst 20,119 
people of Indian Asian ancestry (5,561 with T2D). Top ranking SNPs from the 
GWAS were further tested amongst 13,170 T2D cases and 25,398 controls of 
Indian Asian Ancestry (P<10-4).  A fixed-effects meta-analysis was then used to 
combine the results for each SNP across all replication studies with available 
data, and then in combined analysis with results from the genome-wide 
association stage.  
 
Results 
In the GWAS I identified 20 independent SNPs associated with T2D at P<10-4 
for testing amongst a further 38,568 Indian Asians (13,170 with T2D). In 
combined analysis, common genetic variants at six novel loci (GRB14, 
ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) were associated with T2D 
(P=4.1x10-8 to P=1.9x10-11); SNPs at GRB14 were also associated with insulin 
sensitivity, and at ST6GAL1 and HNF4A with pancreatic beta-cell function 
respectively.  
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Conclusions 
For the first time in Indian Asians I identified common genetic variants at six 
novel loci (GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2 and HNF4A) in 
association with T2D. My findings provide additional insight into mechanisms 
underlying T2D, and demonstrate the potential for new discovery from genetic 
association studies in Indian Asians who have increased susceptibility to T2D.  
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6.2 AIMS 
To discover common genetic variants associated with T2D among Indian 
Asians.  
 
6.2.1 Specific aims 
1. To carry out a genome-wide association study to identify common genetic 
variants in association with T2D among Indian Asians. 
2. To confirm associations identified in stage-1 by replicating top ranking 
signals in a well-powered Indian Asians replication cohort. 
3. To use eQTL analysis to identify causal genes at signals identified in 
GWAS. 
4. To determine the contribution of novel T2D SNPs to the increased risk of 
T2D amongst Indian Asians compared to Europeans.  
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6.3 INTRODUCTION 
  People of Indian Asian ancestry are at up to 4 fold higher risk of T2D 
compared to European populations. T2D currently affects ~55 million Indian 
Asians worldwide, and is projected to affect ~80 million Indian Asians by 2030, 
which will comprise one-quarter of all people with T2D worldwide7. Though 
unhealthy diet, obesity and physical inactivity contribute, T2D also has an 
important genetic contribution. T2D is heritable in Indian Asians, as in other 
populations256. 
  To date, genome-wide association studies (GWAS) have identified 
variants in and around 49 genes as determinants of T2D risk56. However, these 
studies have been predominantly performed in populations of European 
ancestry. I therefore used genome-wide association to identify common genetic 
variants underlying risk of T2D in Indian Asians.  
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6.4 METHODS AND MATERIALS 
The study design is summarised in Figure 6.1. 
 
6.4.1 Study participants 
6.4.1.1 Genome-wide association study 
 Genome-wide association was carried out amongst 5,561 Indian Asian 
T2D cases and 14,458 Indian Asian controls from the London Life Sciences 
Population (LOLIPOP) study216, the Pakistan Risk of Myocardial Infarction 
Study (PROMIS)217 and the Singapore Indian Eye (SINDI) study218.  
 
6.4.1.2 Replication cohorts 
Replication testing amongst Indian Asians was carried out amongst 
13,170 T2D cases and 25,398 controls from the following studies: the Chennai 
Urban Rural Epidemiology Study (CURES)220 the COBRA study219 the 
Diabetes Genetics in Pakistan (DGP) and UK Asian Diabetes Study 
(UKADS)221, the Mauritius study222, the Ragama Health Study (RHS)223, the 
Sikh Diabetes Study (SDS)224, the Singapore Consortium of Cohort Studies 
(SCCS), the Sri Lankan Diabetes Study (SLDS)11, and the LOLIPOP and 
PROMIS studies (Figure 6.2). For LOLIPOP and PROMIS, there was no 
overlap of participants between the genome-wide association and replication 
testing stages. Full details of individual cohorts are provided in chapter 2. 
 
6.4.1.3 European T2D cases and controls 
  Data for European participants were obtained from the DIAGRAM+ 
study, which comprises 8,130 T2D cases and 38,987 controls of European 
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ancestry195. T2D case-control statuses were deﬁned using individual study 
speciﬁc criteria.  
 
6.4.2 Genotyping and quality control 
  Genome-wide association methodology and quality control measures 
are described in detail in chapter 2. In brief, genome-wide association scans 
were performed using Illumina Infinium Beadchips, and genotypes were called 
using GenCall or Illuminus algorithms (Table 6.1). Samples with a SNP call 
rate of <95% were removed, as were SNPs with call rate <97%, minor allele 
frequency<1%, or Hardy–Weinberg equilibrium P<1.0x10-6. Genotyping of 
replication samples was performed by KASPAR (K-Bioscience Ltd, UK), 
Sequenom MassArray or TaqMan assays (Table 6.2). Principal components 
analysis (PCA) was used to identify population outliers by comparison to 
reference samples from the Hapmap YRI, CHB, JPT and CEU panels and the 
Indian samples collected by Reich and colleagues.   
 
6.4.3 Statistical analysis 
  Associations of SNPs with T2D were tested using logistic regression and 
an additive genetic model. Analyses were carried out in men and women 
separately. Principal components were included as covariates to adjust for 
residual population stratification; no other covariate adjustments were made.  
The number of principal component included was study specific: LOLIPOP 10; 
PROMIS 5 and SINDI 3. A fixed-effects inverse variance meta-analysis was 
used to combine the results for individual studies. P values were adjusted for 
study-level genomic control inflation factor before the meta-analysis, and then 
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again for the meta-analysis genomic control inflation factor (double GC 
correction).  
  The primary analysis comprised meta-analysis of association results for 
men and women combined at the 568,976 SNPs. Secondary analyses included 
the following four GWA meta-analyses:  
i. Male gender specific 
ii. Female gender specific 
iii. BMI adjusted 
iv. Lean T2D cases (BMI<25kg/m2) vs overweight controls 
(BMI>25kg/m2) 
 
6.4.4 Selection for replication testing 
  SNPs that were located within a locus that had been previously reported 
to be associated with T2D were excluded, as were SNPs in LD (r2>0.5) with 
another SNP that had a more significant association with T2D. SNPs carried 
forward for replication testing, comprised the following:  
i. All SNPs associated with T2D at P≤10-5 in the primary Indian Asian specific 
genome-wide association analysis of directly genotyped SNPs. 
ii. All SNPs associated with T2D at P<5x10-8 in one of the four secondary GWA 
analyses.  
iii. SNPs associated with T2D at P>10-5 and P≤10-4 in the primary analysis were 
tested in silico using a fixed-effects inverse variance meta-analysis with 
results from the GWA stage of the DIAGRAM+ study. SNPs associated with 
T2D at P<10-3 in combined analysis with DIAGRAM+ were carried forward 
for replication testing in Indian Asians.  
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6.4.5 Replication testing 
  The associations of SNPs with T2D were tested in each cohort 
separately; heterogeneity between studies was assessed using Cochran’s Q 
statistic. A fixed-effects meta-analysis was then used to combine the results for 
each SNP across all replication studies with available data, and then in 
combined analysis with results from the genome-wide association stage. 
Statistical significance was inferred at P<2.5x10-3 in the replication stage 
(P<0.05 after Bonferroni correction for 20 SNPs). For the combined analysis of 
genome-wide and replication data, genome-wide significance was inferred at 
P<5x10-8. 
 
6.4.6 Power 
  For SNPs with minor allele frequency >20% the study had >80% power 
to identify SNPs with odds ratios for T2D of: >1.11 per allele copy at P<10-4 in 
the genome-wide association phase, 1.06 per allele copy at P<2.5x10-3 in the 
replication testing stage, and 1.08 per allele copy at P<5x10-8 in combined 
analysis.  
 
6.4.7 Expression Quantitative Trait Locis (eQTL) 
 To determine whether the T2D-risk variants detected in this study 
influenced expression of nearby genes, I accessed a variety of sources, 
including (a) publicly available cis eQTL data for brain, lymphoblastoid cell 
lines, fibroblasts, liver, and T-cells, (b) expression data from HapMap3 and the 
MuTHER consortium; and (c) cis-eQTL data for GRB14 reported in a recent 
genome wide association study of fat distribution226,257-261. 
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6.5 RESULTS 
6.5.1 Clinical characteristics 
 Clinical characteristics of Indian Asian genome-wide association study 
participants are summarised in table 6.1. In each cohort T2D cases were older, 
had larger BMI and WHR and higher blood pressure. Total cholesterol and HDL 
cholesterol were lower, and triglycerides, fasting glucose and HbA1c higher 
amongst T2D cases compared to controls. Clinical characteristics of 
participants of the contributing replication cohorts are provided in table 6.2. QQ 
plots showed good adherence to null hypothesis (table 6.3 and figure 6.3). 
 
6.5.2 Genome-wide association and further testing 
  In the primary analysis, one locus reached genome-wide significance 
(P<5x10-8); the lead SNP was rs7903146 in TCF7L2, a well described T2D risk 
variant (figure 6.4). There were a further 59 independent loci associated with 
T2D at P≤1x10-4; 50 of which have not previously been linked with T2D in GWA 
studies (table 6.4). To help prioritise these novel loci for replication testing in 
stage two, I carried out a combined analysis of the Indian Asian discovery data 
with results from the DIAGRAM+ GWA meta-analysis (8,130 T2D cases and 
38,987 controls of European ancestry). I then took forward for replication 
testing:  
i. All loci associated with T2D in Indian Asians alone at P≤1x10-5 (N=7) 
ii. Amongst the loci associated with T2D in Indian Asians at P>1x10-5 
and P≤1x10-4, the 12 independent SNPs with lowest P value in 
combined analysis with results from DIAGRAM+ (corresponding to 
~P<10-3).  
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  This strategy was designed to maximise discovery of both genetic loci 
specific to Indian Asians, as well as loci shared with European populations, with 
whom Indian Asians show greatest genetic proximity (figure 6.5).  
  Six SNPs were associated with T2D in the Indian Asian replication 
samples at P<2.5x10-3 (P<0.05 after correction for multiple testing): rs3923113 
near GRB14, rs16861329 in ST6GAL1, rs1802295 in VPS26A, rs2028299 near 
AP3S2, rs7178572 in HMG20A, and rs4812829 in HNF4A (table 6.5 and 
figure 6.6). The 6 SNPs reached genome-wide significance (P<5x10-8) in 
combined analysis of GWA data from Indian Asians, and results for Indian 
Asians from the replication samples (table 6.5 and figures 6.4 and 6.6).   
  Of the 12 SNPs carried forward for replication testing from the primary 
analysis based on combined analysis with DIAGRAM+, there were 4 with some 
evidence for association in Europeans (P<0.05, table 6.4); of these, 2 showed 
replication and reached genome-wide significance in Indian Asians. Amongst 
the 8 carried forward despite little supporting evidence in Europeans (P>0.05, 
table 6.4), only 1 replicated in Indian Asians. These observations lend support 
to the view that selection of SNPs based on combined analysis with Europeans 
is likely to enrich for true signals.  
  As secondary analyses I carried out the following four GWA meta-
analyses: i. male gender specific; ii. female gender specific; iii.  BMI adjusted; 
and iv. lean T2D cases (BMI<25kg/m2)  vs overweight controls (BMI>25kg/m2). 
One locus reached P<5x10-8 for association with T2D amongst women (figure 
6.7). However, the sentinel SNP (rs17052370, near UBBP4, OR=1.37 [1.23-
1.52], P=8.9x10-9) did not replicate amongst Indian Asian women, either in the 
replication samples (OR=1.03 [0.97-1.09], P=0.32) or in combined analysis of 
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GWA and replication data (OR=1.10 [1.04-1.15], P=3.4x10-4). There were no 
additional loci identified from the other secondary analysis.  
  Principal components analysis was used to assess for population 
substructure; results confirmed that the GWA samples were representative of 
Indian Asian ancestry (figures 6.5 and 6.8), with no evidence for significant 
stratification between cases and controls, or between the three studies (tables 
6.6 and 6.7). 
 
6.5.3 Role of adiposity underlying the associations with T2D  
  Since overweight and obesity are major risk factors for T2D, I 
investigated whether the relationship of the sentinel SNPs with T2D might be 
mediated through adiposity. I found that the sentinel SNPs are not associated 
with body mass index or waist-hip ratio (table 6.8). Furthermore, the 
association of the sentinel SNPs with T2D is not materially influenced by 
additional adjustment for measures of obesity amongst Indian Asians in the 
replication samples (table 6.9).  
 
6.5.4 Association of identified SNPs with glucose and related metabolic 
traits 
 After correcting for multiple tests, rs4812829 was associated with increased 
glucose levels, rs16861329 with reduced glucose levels, and rs3923113 was 
associated with increased glucose and increased insulin levels. In addition 
rs3923113 was also associated with reduced insulin sensitivity and rs4812829 
with reduced pancreatic beta cell function in Indian Asians. The six T2D SNPs 
were not associated with blood pressure or plasma lipid parameters (table 6.8). 
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6.5.5 Transcriptional mechanisms at the six novel loci  
  To investigate possible transcriptional mechanisms underlying my 
associations with T2D, I investigated the relationships of sentinel SNPs with 
cis-eQTLs in adipose tissue, liver, peripheral blood leucocytes and other 
tissues (table 6.10). At 2q24, rs3923113 is in high LD (r2=0.85) with 
rs10195252, previously reported to be associated with central adiposity and 
increased expression of GRB14 in adipose tissue (P<10-10).  At 15q26, 
rs2028299 is closely associated with expression of C15orf38 in skin and fat 
(P<10-16). At 15q24, rs7178572 is weakly associated with expression of 
PSTPIP1, but is in low LD (r2<0.3) with the peak SNP associated with this 
eQTL; PSTPIP1 is unlikely to be the causal gene at this locus.  
 
6.5.6 Contribution of novel loci to the increased risk of T2D amongst 
Indian Asians compared to Europeans 
  I compared risk allele frequencies and effect sizes of the newly 
discovered loci with European data from DIAGRAM+ (table 6.5). Compared to 
Europeans, risk allele frequencies were higher at two loci in Indian Asians and 
lower at four. Comparing effect sizes, there were no differences at all six loci 
between populations. In logistic regression, a 3.5-fold increased risk of T2D 
remained amongst Indian Asians compared to Europeans, despite adjustment 
for age, sex, BMI, WHR and the 6 novel T2D SNPs (table 6.11). 
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6.6 DISCUSSION 
 For the first time in Indian Asians I identify common variants at six novel 
genetic loci associated with T2D in people of Indian Asian ancestry. At 2q24, 
rs3923113 is nearest to GRB14, a strong candidate for the observed 
association. GRB14 is an adapter protein, which binds to insulin receptors and 
insulin-like growth-factor receptors, to inhibit tyrosine kinase signalling262,263. 
Grb14-/- mice have higher lean mass, better glucose homeostasis despite 
lower insulin, and improved insulin sensitivity264. SNP rs3923113 is associated 
with T2D and with reduced insulin sensitivity in Indian Asians suggesting gain 
of function. SNP rs3923113 is also in high LD (r2=0.85) with rs10195252, 
recently reported to be associated with central adiposity and expression of 
GRB14 in adipose tissue265.  
 At 3q27, rs16861329 is intronic in ST6GAL1, encoding an enzyme 
predominantly membrane bound and located in the golgi apparatus, is involved 
in post-translational modification of cell-surface components by glycosylation. 
Although ST6GAL1 has not previously been linked with glucose metabolism or 
T2D, glycosylation through addition of sialic acid residues is reported to 
influence both insulin action and cell surface trafficking266. SNP rs16861329 is 
also near ADIPOQ encoding adiponectin, a hormone secreted by adipocytes 
which promotes insulin sensitivity. Adiponectin knockout-mice show severe 
insulin resistance and previous candidate gene studies have suggested an 
association of genetic variation at ADIPOQ with adiponectin levels, obesity and 
T2D267,268. However, these associations have not been consistently found, and 
rs16861329 (identified in the present study) is not in LD (r2<0.1) with reported 
ADIPOQ variants. At 10q22, rs1802295 is in VPS26A, encoding a component 
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of the retromer complex, a multimeric protein involved in transport of proteins 
from endosomes to the trans-Golgi network269,270. VPS26A is expressed in 
pancreatic, adipose and other tissues271, but a relationship with glucose 
metabolism or T2D has not been described. At 15q26, rs2028299 is nearest 
AP3S2, encoding a clathrin associated adaptor complex expressed in 
adipocytes, pancreatic islets and other tissues, which may be involved in 
vesicle transport and sorting272.  SNP rs2028299 is associated with expression 
of C15orf38, encoding a member of an uncharacterised family of proteins. 
Amongst the other genes at this locus, PLIN1 is also a possible candidate for 
the association with T2D. PLIN1 encodes Perilipin-1, a phosphoprotein which 
coats fat droplets in adipocytes and regulates lipolysis by hormone sensitive 
lipase273. Genetic variation at PLIN1 has been associated with obesity in man 
and in experimental animal models274. SNP rs2028299 is 1.2MB away from 
rs8042680 in PRC1, which is associated with T2D in Europeans195. Although 
these two SNPs are not in LD (r2=0), I cannot exclude the possibility of a 
shared mechanism through remote regulatory effects. At 15q24, known biology 
does not identify any compelling candidates. SNP rs7178572 is intronic in 
HMG20A, a non-histone chromosomal protein that is widely expressed, which 
may influence histone methylation and be involved in neuronal 
development275,276. At 20q13, the lead genotyped SNP rs4812829 is intronic in 
HNF4A, a strong candidate for the observed association. HNF4A is a nuclear 
transcription factor strongly expressed in liver, which regulates transcription of 
a number of genes including HNF1A277,278. Mutations in HNF4A are known to 
cause maturity-onset diabetes of the young (MODY) type 1, characterised by 
defective pancreatic beta cell function and impaired insulin secretion278. In 
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keeping with this, risk allele of rs4812829 is associated with reduced pancreatic 
beta cell function in Indian Asians.  
  I investigated whether the 6 T2D SNPs discovered in this study account 
for differences in T2D risk between Indian Asians and Europeans. I found no 
systematic differences in risk allele frequency or effect size and the novel T2D 
SNPs did not account for the increased risk of T2D amongst Indian Asians 
compared to Europeans. 
  This is the first GWA study to investigate genetic factors underlying T2D 
amongst people of Indian Asian ancestry who have increased susceptibility to 
T2D. I identify common genetic variants at six novel loci (GRB14, ST6GAL1, 
VPS26A, AP3S2, HMG20A, and HNF4A) associated with T2D. My findings 
provide insight into the genetic mechanisms underlying T2D, and demonstrate 
the potential for new discovery from genetic association studies in populations 
of non-European ancestry. 
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Figure 6.1: Summary of study design 
 
 
Stage one: Genome-wide association in South Asians
5,561 T2D cases and 14,458 controls
Stage two: Replication testing of 20 SNPs in South Asians 
13,170 T2D cases & 25,398 controls
Combined analysis with South Asian GWA result
Six SNPs reach P<0.0025 in replication testing 
and P<5x10-8 in South Asian combined analysis 
SNPs at P≤10-5
Top SNP at all 
7 loci selected
SNPs at P>10-5 and P≤10-4
Combined analysis DIAGRAM+ 
Top SNP at 12 / 44 loci selected
Stage three: Population specific effects and mechanisms
Sequencing eQTLsLD structure Effect sizes
Secondary 
GWA analyses
One SNP selected
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Figure 6.2: Replication cohorts 
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Figure 6.3:  QQ plot for SNPs in the genome-wide association. Black symbols - all genotyped SNPs included; green symbols -
known T2D loci removed. Red line expected distribution under the null hypothesis 
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Figure 6.4: Manhattan plot for the primary Indian Asian genome-wide association analysis. of men and women, using directly 
genotyped SNPs. At the six novel loci reaching genome wide-significance, the sentinel SNPs are indicated: green dot for GWA 
result, and red dot for combined analysis of GWA and replication data in Indian Asians 
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LOLIPOP study
Illumina 317 array
LOLIPOP study
Illumina 610 array
SINDI study
Illumina 610 array
PROMIS study
Illumina 660 array
Reich samples
Figure 6.5: Principal component maps of the individual studies with Hapmap II panels of YRI, CEU, CHB and JPT. For comparison, 
results are also shown for Indians from a survey of genetic variation in India by Reich and colleagues. 
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Figure 6.6: Regional plots for the six novel loci. SNPs are colour coded according to LD with sentinel SNP 
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Figure 6.7: Manhattan plots for secondary GWA analyses 
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(2) SINDI 
Figure 6.8: Principal component maps of the individual studies without HapMap scaling. T2D cases and controls are coloured pink 
and grey respectively 
228 
 
229 
 
Table 6.1: Characteristics of participants in the genome-wide association cohorts. 
 
 
LOLIPOP 610 LOLIPOP 317 SINDI PROMIS 
T2D Controls P T2D Controls P T2D Controls P T2D Controls P 
N 1783 4773 - 440 1699 - 977 1169 -- 2361 6817 - 
Age 59.4 (9.2) 53.9 (10.7) <0.001 54.1 (10.1) 46.8 (10.1) <0.001 60.7 (9.9) 55.7 (9.7) <0.001 55.0 (9.4) 52.9 (10.5) <0.001 
Gender (% male) 82.9 84.8 0.058 100.0 100.0 - 54.4 48.4 0.007 76.5 83 <0.001 
             
SBP (mmHg) 140. 6 (20.4) 133.5 (18.9) <0.001 139.8 (20.6) 132.0 (20.2) <0.001 140.0 (19.7) 131.7 (19.2) <0.001 129.9 (21.5) 127.1 (20.5) <0.001 
DBP (mmHg) 80.7 (10.9) 82.4 (10.7) <0.001 84.0 (11.7) 82.5 (12.1) 0.020 77.1 (10.1) 77.2 (9.9) 0.801 81.6 (11.9) 80.8 (11.6) 0.005 
Weight (kg) 78.1 (14.0) 75.6 (13.0) <0.001 80.0 (15.9) 78.4 (13.9) 0.035 70.9 (14.0) 66.7 (12.5) <0.001 71.0 (12.5) 69.1 (13.2) <0.001 
BMI (kg/m2) 28.1 (4.6) 26.8 (4.2) <0.001 27.6 (4.7) 26.6 (4.2) <0.001 27.1 (5.1) 25.3 (4.4) <0.001 26.0 (4.0) 25.3 (3.9) <0.001 
Waist (cm) 100.8 (11.5) 96.6 (10.9) <0.001 100.0 (12.2) 96.3 (11.4) <0.001 -- -- -- 92.0 (12.0) 90.1 (11.7) <0.001 
WHR 0.99 (0.07) 0.95 (0.07) <0.001 0.99 (0.07) 0.95 (0.07) <0.001 - - - 0.95 (0.06) 0.94 (0.07) <0.001 
             
Cholesterol (mmol/L) 4.65 (1.20) 5.21 (1.12) <0.001 4.94 (1.09) 5.46 (1.04) <0.001 4.86 (1.11) 5.36 (0.98) <0.001 4.81 (1.39) 4.74 (1.29) 0.03 
HDL chol (mmol/L) 1.16 (0.30) 1.22 (0.30) <0.001 1.17 (0.29) 1.247 (0.31) <0.001 1.02 (0.30) 1.10 (0.31) <0.001 0.88 (0.25) 0.89 (0.25) 0.09 
Triglycerides 
(mmol/L) 1.94 (1.55) 1.77 (1.12) <0.001
 1.82 (0.86) 1.65 (0.82) <0.001 2.09 (1.22) 1.85 (1.13) <0.001 2.51 (1.58) 2.20 (1.36) <0.001 
Glucose (mmol/L) 8.6 (3.1) 5.2 (0.6) <0.001 8.9 (2.9) 5.1 (0.6) <0.001 9.71 (4.44) 5.38 (1.06) <0.001 13.31 (5.47) 6.89 (2.91) <0.001 
HbA1c (mmol/mol) 57.7 (12.4) 41.1 (4.0) <0.001 58.4 (13.2) 40.1 (3.7) <0.001 55.5 (11.0) 40.2 (2.0) <0.001 65.0 (14.9) 42.4 (3.3)  <0.001 
             
Genotyping array Illumina 610Quad  Illumina Hap317  Illumina 610Quad  Illumina 660Quad  
Calling algorithm GenCall  GenCall  GenCall  Illuminus  
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Table 6.2: Characteristics of participants in the replication cohorts (NA: not available). 
 
 
 Location Genotyping method Group Number Male (%) Age (yrs) BMI (kg/m
2) Glucose (mmol/L) 
HbA1c 
(mmol/mol) 
COBRA  Pakistan Kaspar 
Cases 465 40.9 53.3 (10.5) 26.9 (5.6) 10.5 (3.9) NA 
Controls 1580 47.1 51.0 (10.5) 25.3 (5.3)  5.4 (0.6) NA 
Chennai Urban Rural 
Epidemiology Study India Sequenom 
Cases 1316 47.3 52.9 (10.8) 25.3 (4.6) 9.6 (3.9) 65.0 (16.1) 
Controls 1265 43.1 47.0 (12.0) 24.4 (4.5) 4.9 (0.5) 40.9 (2.9) 
Diabetes Genetics in Pakistan 
study Pakistan Kaspar 
Cases 840 47.0 54.7 (11.7) 26.1 (4.7) NA 70.9 (23.4) 
Controls 1225 47.4 56.5 (10.8) 24.3 (5.0) 4.8 (0.5) NA 
London Life Sciences 
Population study UK Kaspar 
Cases 1132 40.0 54.0 (10.6) 29.2 (5.1) 8.5 (10.6) 58.5 (12.4) 
Controls 7652 38.2 46.6 (10.4) 27.3 (4.7) 5.0 (0.5) 40.9 (40.9) 
Mauritius study Mauritius Kaspar 
Cases 780 47.2 54.9 (11.5) 26.2 (4.4) 9.7(3.5) NA 
Controls 1536 43.8 46.3 (11.4) 24.3 (4.2) 5.2 (0.4) NA 
Pakistan Risk of Myocardial 
Infarction Study Pakistan Kaspar 
Cases 3128 64.3 56.7 (10.5) 26.6 (4.3) NA 63.6 (15.3) 
Controls 5277 74.3 53.9 (12.3) 25.7 (4.4) NA 42.4 (2.9) 
Ragama Health study Sri Lanka TaqMan 
Cases 776 44.6 54.7 (6.9) 24.6 (4.0) 9.2 (3.1) 57.0 (57.0) 
Controls 1981 44.1 50.8 (8.3) 23.2 (4.3) 5.4 (0.4) 38.7 (38.7) 
Sikh Diabetes Study India Sequenom 
Cases 1387 56.5 54.7 (10.5) 27.1 (4.9) 9.2 (3.6) NA 
Controls 1732 54.0 49.2 (14.4) 26.0 (4.7) 5.3 (0.7) NA 
Singapore Consortium of 
Cohort Studies Singapore Sequenom 
Cases 1613 38.8 55.4 (9.5) 27.7 (5.0) NA NA 
Controls 1230 50.1 41.8 (12.0) 25.8 (5.1) 4.9 (0.4) 41.7 (41.7) 
Sri Lankan Diabetes Studies Sri Lanka TaqMan 
Cases 841 40.2 39.0 (8.1) 24.7 (4.0) 8.9 (3.8) NA 
Controls 1471 43.3 44.7 (14.4) 21.2 (4.2) 4.8 (1.2) NA 
United Kingdom Asian 
Diabetes Study UK Kaspar 
Cases 892 54.9 57.1 (12.0) 28.5 (4.6) NA 60.7 (13.9) 
Controls 449 48.3 55.0 (11.8) 28.0 (4.7) 5.4 (0.9) NA 
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Table 6.3: Genomic control inflation factors in the individual samples, and in meta-analysis. 
 
 
 
 Lambda 
Individual samples  
LOLIPOP Illumina 610 array - Male 1.030 
LOLIPOP Illumina 610 array - Female 1.013 
LOLIPOP Illumina 317 array - Male 1.014 
PROMIS – Male 1.017 
PROMIS – Female 1.002 
SINDHI – Male 1.023 
SINDHI – Female 1.029 
  
Meta-analysis  
Primary - Gender stratified 1.023 
Secondary - Male only 1.008 
Secondary - Female only 1.005 
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Table 6.4: Sentinel SNP for loci associated with T2D at P<10-4 in the primary GWA analysis. RAF: Risk allele frequency: IA = 
Indian Asians, Eu = Europeans. Dir: 1=concordant SAT2D and DIAGRAM+, -1=discordant SAT2D and DIAGRAM+. RS = rank in 
SAT2D GWA data. RN = rank amongst novel SAT2D loci. RM = rank in meta-analysis of SAT2D and DIAGRAM GWA data. ** = 
Locus previously reported in Europeans. 
 
 
     RAF   SAT2D   DIAGRAM+  COMBINED      
SNP Chr Position Nearest Gene (A/R) IA Eu N OR P N OR P OR P Dir RSA RN RM 
rs12730665 1 96456230 PTBP2 A / G 0.19 0.33 15486 1.13 (1.06-1.20) 7.7x10-5 22570 1.01 (0.96-1.05) 0.74 1.05 (1.01-1.09) 8.6x10-3 1 49 42 30 
rs10495334 1 230879034 KIAA1383 G / A 0.03 0.09 18194 1.27 (1.13-1.43) 8.7x10-5 13971 0.98 (0.89-1.08) 0.70 1.08 (1.01-1.17) 3.3x10-2 -1 53 45 40 
rs4803 2 27520801 IFT172 A / G 0.41 0.39 18177 1.10 (1.05-1.15) 9.3x10-5 22570 1.00 (0.96-1.04) 0.91 1.04 (1.01-1.08) 6.8x10-3 1 58 ** ** 
rs17031236 2 105538433 FHL2 C / A 0.68 0.73 18173 1.11 (1.05-1.16) 4.7x10-5 22570 1.02 (0.98-1.07) 0.38 1.06 (1.03-1.10) 5.3x10-4 1 35 28 14 
rs10206685 2 107921321 RGPD4 G / A 0.86 0.95 15503 1.16 (1.08-1.25) 3.1x10-5 22570 0.93 (0.86-1.01) 0.09 1.06 (1.00-1.12) 3.5x10-2 -1 25 18 41 
rs6749633 2 111704487 BCL2L11 A / G 0.86 0.70 15503 1.16 (1.08-1.24) 5.4x10-5 22570 1.00 (0.95-1.04) 0.87 1.04 (1.00-1.08) 4.2x10-2 -1 39 32 42 
rs7588481 2 137365673 THSD7B C / A 0.75 0.87 15499 1.12 (1.06-1.19) 4.0x10-5 22570 1.00 (0.94-1.06) 0.98 1.07 (1.02-1.11) 2.1x10-3 -1 30 23 21 
rs3923113 2 165210095 GRB14 C / A 0.74 0.64 18174 1.15 (1.09-1.21) 3.7x10-7 22570 1.05 (1.01-1.10) 0.02 1.09 (1.05-1.13) 4.9x10-7 1 2 1 3 
rs2577583 2 197313645 FLJ39660 G / A 0.70 0.73 8688 1.17 (1.09-1.26) 4.3x10-5 NA - - - - - 33 26  
rs3731918 2 220123961 OBSL1 G / A 0.73 0.53 18184 1.11 (1.06-1.17) 5.9x10-5 22570 0.98 (0.94-1.02) 0.26 1.03 (0.99-1.06) 1.0x10-1 -1 42 35 46 
rs4672997 2 221864514 EPHA4 G / A 0.69 0.66 15487 1.11 (1.05-1.17) 9.1x10-5 22570 0.98 (0.93-1.02) 0.30 1.03 (1.00-1.07) 6.9x10-2 -1 55 47 45 
rs11711167 3 126521709 ZNF148 A / G 0.32 0.23 18190 1.10 (1.05-1.16) 7.8x10-5 22570 1.02 (0.98-1.07) 0.35 1.06 (1.03-1.10) 5.7x10-4 1 50 43 15 
rs4298067 3 140437463 MRPS22 A / G 0.77 0.75 15500 1.13 (1.07-1.20) 3.1x10-5 22570 1.00 (0.95-1.06) 0.94 1.06 (1.02-1.10) 2.8x10-3 1 26 19 24 
rs13322501 3 179075818 KCNMB2 A / G 0.83 0.93 15500 1.15 (1.08-1.23) 2.6x10-5 22570 0.94 (0.86-1.02) 0.12 1.07 (1.01-1.12) 1.6x10-2 -1 21 14 35 
rs1470579 3 187011774 IGF2BP2 A / C 0.41 0.31 18185 1.12 (1.07-1.17) 3.1x10-6 22570 1.14 (1.09-1.19) 2.2x10-9 1.13 (1.09-1.16) 1.8x10-14 1 6 ** ** 
rs16861329 3 188149155 ST6GAL1 A / G 0.76 0.86 18186 1.12 (1.07-1.19) 2.3x10-5 13971 1.02 (0.95-1.09) 0.62 1.09 (1.04-1.13) 2.0x10-4 1 19 12 10 
rs709087 3 192938993 POP2 A / G 0.70 0.72 18170 1.10 (1.05-1.16) 9.8x10-5 22570 1.01 (0.97-1.06) 0.62 1.05 (1.02-1.09) 2.7x10-3 1 60 50 23 
rs6835176 4 40199309 RBM47 G / A 0.04 0.03 18196 1.27 (1.14-1.42) 3.4x10-5 22570 1.03 (0.93-1.15) 0.57 1.14 (1.05-1.23) 9.6x10-4 1 28 21 18 
rs2882659 4 113466153 ALPK1 A / G 0.64 0.72 18185 1.10 (1.05-1.15) 9.0x10-5 13971 0.99 (0.94-1.05) 0.83 1.05 (1.02-1.09) 4.5x10-3 -1 54 46 28 
rs9496773 6 144183238 PHACTR2 G / A 0.65 0.75 15490 1.11 (1.06-1.17) 2.9x10-5 20049 1.04 (0.98-1.09) 0.22 1.08 (1.04-1.12) 7.0x10-5 1 23 16 9 
rs6462276 7 31430557 NEUROD6 G / A 0.91 1.00 15430 1.19 (1.09-1.30) 9.1x10-5 22570 0.96 (0.89-1.04) 0.31 1.06 (1.00-1.12) 5.9x10-2 -1 56 48 43 
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rs17146516 7 123384357 SPAM1 G / A 0.80 0.84 15505 1.13 (1.07-1.20) 5.3x10-5 22570 0.98 (0.92-1.04) 0.46 1.05 (1.01-1.09) 2.2x10-2 -1 38 31 37 
rs2111815 7 132349786 CHCHD3 G / A 0.41 0.33 18191 1.10 (1.05-1.15) 4.2x10-5 22570 1.05 (1.00-1.09) 0.04 1.07 (1.04-1.10) 1.3x10-5 1 32 25 5 
rs16923500 8 59551647 CYP7A1 G / A 0.24 0.20 15493 1.12 (1.06-1.18) 4.5x10-5 22570 1.05 (1.00-1.10) 0.05 1.08 (1.04-1.12) 2.8x10-5 1 34 27 7 
rs12056692 8 87699905 CNGB3 C / A 0.25 0.17 15501 1.12 (1.06-1.18) 4.1x10-5 22570 0.95 (0.90-1.01) 0.10 1.04 (1.00-1.08) 6.6x10-2 -1 31 24 44 
rs13266634 8 118253964 SLC30A8 A / G 0.76 0.70 18192 1.13 (1.07-1.19) 1.6x10-5 21198 1.15 (1.10-1.21) 1.5x10-8 1.14 (1.10-1.18) 9.0x10-13 1 14 ** ** 
rs13255292 8 129145755 PVT1 G / A 0.22 0.33 15496 1.13 (1.07-1.19) 3.3x10-5 22570 1.00 (0.96-1.04) 0.96 1.04 (1.01-1.08) 1.2x10-2 -1 27 20 33 
rs16904391 8 132063575 ADCY8 A / G 0.14 0.06 15505 1.14 (1.07-1.22) 8.2x10-5 22570 1.00 (0.92-1.09) 0.97 1.09 (1.03-1.15) 1.5x10-3 1 52 44 20 
rs2570961 9 8835429 PTPRD G / A 0.15 0.19 18190 1.15 (1.08-1.22) 1.4x10-5 22570 1.00 (0.95-1.06) 0.97 1.06 (1.02-1.10) 3.9x10-3 1 13 8 27 
rs2383208 9 22122076 ANRIL G / A 0.86 0.83 18185 1.19 (1.11-1.28) 5.7x10-7 22570 1.19 (1.13-1.25) 1.8x10-10 1.19 (1.14-1.24) 6.9x10-16 1 4 ** ** 
rs4295736 9 81072159 CHCHD9 A / G 0.88 0.94 15485 1.19 (1.10-1.28) 1.6x10-5 22570 1.22 (1.12-1.32) 3.1x10-6 1.20 (1.13-1.27) 1.7x10-10 1 15 ** ** 
rs10512225 9 95266921 FAM120A G / A 0.61 0.45 18189 1.11 (1.06-1.16) 2.3x10-5 22570 0.99 (0.96-1.04) 0.79 1.04 (1.01-1.07) 9.8x10-3 -1 18 11 31 
rs1562042 9 105747435 SMC2 A / G 0.77 0.90 15492 1.12 (1.06-1.19) 7.2x10-5 22570 1.04 (0.97-1.11) 0.31 1.09 (1.04-1.13) 2.1x10-4 1 46 39 11 
rs10983119 9 118177001 PAPPA A / G 0.01 0.03 13369 1.62 (1.28-2.04) 6.3x10-5 NA - - - - - 44 37  
rs10903814 10 2611182 PFKP C / A 0.15 0.09 18183 1.14 (1.07-1.21) 5.9x10-5 22570 1.00 (0.93-1.07) 0.99 1.08 (1.03-1.13) 2.1x10-3 1 43 36 22 
rs11257622 10 12335345 CDC123 A / G 0.12 0.18 18166 1.17 (1.10-1.26) 5.8x10-6 22570 1.04 (0.99-1.10) 0.11 1.09 (1.04-1.13) 5.6x10-5 1 9 ** ** 
rs1802295 10 70601480 VPS26A G / A 0.27 0.31 15506 1.14 (1.08-1.20) 1.9x10-6 22570 1.04 (1.00-1.09) 0.06 1.08 (1.04-1.11) 7.2x10-6 1 5 3 4 
rs2616646 10 78559423 KCNMA1 A / G 0.15 0.17 18185 1.16 (1.09-1.23) 4.8x10-6 22570 1.02 (0.96-1.08) 0.50 1.08 (1.03-1.12) 4.0x10-4 1 8 5 13 
rs2497304 10 94482696 HHEX G / A 0.28 0.47 18166 1.11 (1.05-1.16) 8.1x10-5 22570 1.13 (1.08-1.18) 5.2x10-9 1.12 (1.08-1.16) 2.7x10-12 1 51 ** ** 
rs7903146 10 114748339 TCF7L2 G / A 0.30 0.30 18193 1.25 (1.19-1.31) 2.8x10-19 22570 1.40 (1.34-1.46) 2.2x10-51 1.33 (1.29-1.37) 5.1x10-68 1 1 ** ** 
rs234857 11 2809105 KCNQ1 G / A 0.75 0.69 18193 1.13 (1.07-1.19) 6.5x10-6 22570 1.07 (1.02-1.12) 0.01 1.09 (1.06-1.13) 4.0x10-7 1 10 ** ** 
rs4287347 11 132191217 OPCML A / G 0.48 0.51 18187 1.10 (1.05-1.15) 7.7x10-5 22570 1.02 (0.98-1.07) 0.24 1.06 (1.02-1.09) 3.9x10-4 1 48 41 12 
rs10082842 12 24192169 SOX5 A / G 0.45 0.62 18180 1.10 (1.05-1.15) 6.7x10-5 NA - - - -  45 38  
rs3748265 12 122982416 DNAH10 G / A 0.01 0.04 8952 2.86 (1.72-4.73) 5.7x10-5 22570 1.09 (0.98-1.21) 0.11 1.14 (1.02-1.26) 1.6x10-2 1 40 33 36 
rs17084821 13 26340325 GPR12 A / G 0.14 0.10 15502 1.15 (1.08-1.23) 4.0x10-5 22570 0.99 (0.91-1.07) 0.72 1.08 (1.03-1.13) 3.5x10-3 -1 29 22 26 
rs7996689 13 49291645 KPNA3 G / A 0.23 0.28 15508 1.13 (1.07-1.19) 2.9x10-5 22570 1.00 (0.95-1.05) 0.93 1.05 (1.01-1.09) 7.6x10-3 -1 22 15 29 
rs4981720 14 19609145 OR4L1 A / G 0.87 0.91 18185 1.15 (1.08-1.24) 5.3x10-5 22570 0.99 (0.91-1.07) 0.81 1.08 (1.03-1.14) 3.0x10-3 -1 37 30 25 
rs10873073 14 53159106 BMP4 A / G 0.70 0.60 18171 1.11 (1.05-1.17) 7.4x10-5 22570 1.00 (0.96-1.04) 0.93 1.04 (1.01-1.08) 1.1x10-2 -1 47 40 32 
rs6576426 15 23254656 UBE3A A / G 0.17 0.10 15498 1.15 (1.08-1.23) 7.5x10-6 22570 1.03 (0.97-1.10) 0.29 1.09 (1.05-1.14) 6.4x10-5 1 11 6 8 
rs17560758 15 24387495 GABRB3 A / G 0.62 0.57 15496 1.11 (1.06-1.17) 2.9x10-5 22570 0.99 (0.95-1.03) 0.71 1.04 (1.01-1.08) 1.3x10-2 -1 24 17 34 
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rs620739 15 47852704 ATP8B4 A / G 0.36 0.43 18173 1.11 (1.06-1.16) 2.2x10-5 22570 1.02 (0.98-1.06) 0.41 1.05 (1.02-1.09) 6.0x10-4 1 17 10 16 
rs7178572 15 75534245 HMG20A A / G 0.52 0.71 18193 1.10 (1.05-1.15) 2.4x10-5 22570 1.07 (1.02-1.12) 2.6x10-3 1.08 (1.05-1.12) 2.8x10-7 1 20 13 2 
rs2028299 15 88175261 AP3S2 A / C 0.31 0.28 18076 1.11 (1.05-1.16) 4.8x10-5 22570 1.05 (1.00-1.09) 0.04 1.07 (1.04-1.11) 1.8x10-5 1 36 29 6 
rs4392054 16 20630271 ACSM1 G / A 0.12 0.09 15511 1.17 (1.09-1.26) 1.0x10-5 22570 0.99 (0.92-1.07) 0.87 1.09 (1.03-1.15) 1.3x10-3 -1 12 7 19 
rs1560916 17 28973892 ACCN1 G / A 0.46 0.51 18177 1.11 (1.06-1.16) 1.6x10-5 21198 0.98 (0.94-1.02) 0.31 1.03 (1.00-1.07) 2.7x10-2 -1 16 9 38 
rs3744763 17 33164998 HNF1B A / G 0.41 0.41 18191 1.10 (1.05-1.15) 9.2x10-5 13971 1.08 (1.03-1.14) 2.1x10-3 1.09 (1.05-1.13) 6.0x10-7 1 57 ** ** 
rs2280146 17 76490264 KIAA1303 A / G 0.39 0.24 15505 1.10 (1.05-1.16) 5.7x10-5 22570 0.97 (0.92-1.02) 0.19 1.04 (1.00-1.08) 3.2x10-2 -1 41 34 39 
rs1912379 18 66460710 RPS2P6 A / G 0.25 0.16 15492 1.14 (1.08-1.20) 3.8x10-6 22570 1.00 (0.94-1.06) 0.87 1.07 (1.03-1.11) 8.5x10-4 -1 7 4 17 
rs4812829 20 42422681 HNF4A G / A 0.29 0.16 18186 1.14 (1.08-1.19) 4.5x10-7 22570 1.08 (1.02-1.14) 0.01 1.11 (1.07-1.15) 2.4x10-8 1 3 2 1 
rs6005312 22 25878374 MIAT A / G 0.05 0.21 18178 1.21 (1.10-1.34) 9.4x10-5 22570 0.95 (0.91-1.01) 0.08 1.01 (0.96-1.06) 7.3x10-1 -1 59 49 47 
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Table 6.5: Genomic location and association test results for the sentinel SNPs from the six loci reaching P<5x10-8 amongst Indian Asians. 
Results are provided as odds ratio [OR] (95% confidence interval) per copy of risk allele. (Alleles: R=risk, A=alternate. RAF: risk allele 
frequency in Indian Asians (IA) and Europeans (Eu). Results for Europeans are from the GWA stage of DIAGRAM+.  Phetero is for the comparison 
between the odds ratios for T2D amongst Indian Asians in the replication sample, and Europeans in DIAGRAM+).  
 
 
 
  
 
 RAF GWA  Indian Asians 
Replication   
Indian Asians 
Combined analysis 
Indian Asians Europeans (DIAGRAM+) Global analysis 
SNP Chr (position) 
Nearest 
Gene 
Alleles  
(A/R) SA Eu N OR P OR P OR P OR P Phetero OR P 
rs3923113 2  (165210095) GRB14 C / A 0.74 0.64 18,174 
1.15 
(1.09-1.21) 
3.7 
x10-7 
1.07 
(1.03-1.11) 
6.7 
x10-4 
1.09  
(1.06-1.13) 
1.0 
x10-8 
1.05 
(1.01-1.10) 
2.0 
x10-2 0.64 
1.08 
(1.05-1.11) 
1.6 
x10-9 
rs16861329 3 (188149155) ST6GAL1 A / G 0.75 0.86 18,186 
1.12 
(1.07-1.19) 
2.3 
x10-5 
1.07 
(1.03-1.11) 
1.6 
x10-4 
1.09  
(1.06-1.12) 
3.4 
x10-8 
1.02  
(0.95-1.09) 0.62 0.21 
1.08 
(1.05-1.11) 
1.3 
x10-7 
rs1802295 10 (70601480) VPS26A G / A 0.26 0.31 15,506 
1.14 
(1.08-1.20) 
1.9 
x10-6 
1.06 
(1.03-1.10) 
6.6 
x10-4 
1.08  
(1.05-1.12) 
4.1 
x10-8 
1.04  
(1.00-1.09) 
6.0 
x10-2 0.50 
1.07 
(1.05-1.10) 
2.1 
x10-8 
rs7178572 15 (75534245) HMG20A A / G 0.52 0.71 18,193 
1.10 
(1.05-1.15) 
2.4 
x10-5 
1.08 
(1.05-1.12) 
7.0 
x10-7 
1.09  
(1.06-1.12) 
7.1 
x10-11 
1.07 
(1.02-1.12) 
2.6 
x10-3 0.59 
1.08 
(1.06-1.11) 
9.2 
x10-13 
rs2028299 15 (88175261) AP3S2 A / C 0.31 0.31 18,076 
1.11 
(1.05-1.16) 
4.8 
x10-5 
1.09 
(1.06-1.13) 
1.1 
x10-7 
1.10  
(1.07-1.13) 
1.9 
x10-11 
1.05 
(1.00-1.09) 
4.0 
x10-2 0.12 
1.08 
(1.06-1.11) 
1.2 
x10-11 
rs4812829 20 (42422681) HNF4A G / A 0.29 0.19 18,186 
1.14 
(1.08-1.19) 
4.5 
x10-7 
1.07 
(1.04-1.11) 
2.8 
x10-5 
1.09  
(1.06-1.12) 
2.6 
x10-10 
1.08 
(1.02-1.14) 
1.0 
x10-2 0.90 
1.09 
(1.06-1.12) 
8.2 
x10-12 
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Table 6.6:  Tests for heterogeneity of effect (Phetero) between the SAT2D GWA cohorts at the loci identified in the present study. 
 
 
       LOLIPOP 610 LOLIPOP 317 PROMIS SINDI  
SNP Chr Pos Nearest gene Ref 
Alleles 
(A/R) OR P OR P OR P OR P Phetero 
               
rs17031236 2 105538433 FHL2 SAT C/A 1.10 (1.01-1.20) 0.03 1.21 (1.03-1.43) 0.02 1.09 (1.02-1.17) 0.02 1.06 (0.93-1.20) 0.40 0.68 
rs3923113 2 165210095 GRB14 SAT C/A 1.18 (1.07-1.29) 5E-04 1.24 (1.02-1.50) 0.03 1.11 (1.03-1.20) 0.01 1.16 (1.00-1.35) 0.06 0.72 
rs11711167 3 126521709 ZNF148 SAT A/G 1.11 (1.02-1.21) 0.02 1.20 (1.03-1.41) 0.02 1.10 (1.02-1.18) 0.01 1.01 (0.89-1.15) 0.84 0.58 
rs16861329 3 188149155 ST6GAL1 SAT A/G 1.15 (1.05-1.27) 4E-03 1.24 (1.03-1.49) 0.02 1.11 (1.03-1.20) 0.01 1.06 (0.92-1.22) 0.44 0.65 
rs6835176 4 40199309 RBM47 SAT G/A 1.44 (1.17-1.76) 6E-04 1.44 (0.99-2.09) 0.07 1.14 (0.97-1.35) 0.12 1.25 (0.92-1.68) 0.15 0.46 
rs9496773 6 144183238 PHACTR2 SAT G/A 1.12 (1.03-1.22) 0.01 0.95 (0.80-1.13) 0.56 1.09 (1.02-1.17) 0.01 1.19 (1.05-1.34) 0.01 0.29 
rs2111815 7 132349786 CHCHD3 SAT G/A 1.15 (1.06-1.24) 9E-04 1.06 (0.91-1.24) 0.45 1.07 (1.00-1.15) 0.05 1.08 (0.95-1.22) 0.23 0.70 
rs16923500 8 59551647 CYP7A1 SAT G/A 1.15 (1.05-1.26) 4E-03 1.02 (0.84-1.24) 0.85 1.12 (1.04-1.21) 3.0E-03 1.05 (0.91-1.21) 0.53 0.66 
rs1562042 9 105747435 SMC2 SAT A/G 1.13 (1.02-1.25) 0.01 0.99 (0.82-1.20) 0.92 1.15 (1.06-1.25) 5.9E-04 1.04 (0.90-1.19) 0.62 0.48 
rs1802295 10 70601480 VPS26A SAT G/A 1.17 (1.07-1.28) 6E-04 NA NA 1.09 (1.01-1.17) 0.03 1.20 (1.04-1.39) 0.01 0.50 
rs2616646 10 78559423 KCNMA1 SAT A/G 1.13 (1.01-1.26) 0.03 1.17 (0.95-1.43) 0.14 1.16 (1.06-1.28) 2.1E-03 1.18 (0.99-1.40) 0.07 0.98 
rs4287347 11 132191217 OPCML SAT A/G 1.10 (1.01-1.19) 0.02 1.06 (0.91-1.23) 0.47 1.13 (1.06-1.21) 4.0E-04 1.00 (0.89-1.13) 0.94 0.59 
rs6576426 15 23254656 UBE3A SAT A/G 1.15 (1.03-1.28) 0.01 1.14 (0.93-1.41) 0.21 1.18 (1.08-1.29) 1.7E-04 1.11 (0.95-1.31) 0.19 0.95 
rs620739 15 47852704 ATP8B4 SAT A/G 1.13 (1.04-1.23) 2E-03 1.03 (0.88-1.20) 0.76 1.10 (1.03-1.18) 4.8E-03 1.15 (1.00-1.31) 0.04 0.74 
rs7178572 15 75534245 HMG20A SAT A/G 1.06 (0.98-1.15) 0.15 1.17 (1.00-1.36) 0.05 1.10 (1.03-1.18) 0.01 1.17 (1.03-1.32) 0.01 0.64 
rs2028299 15 88175261 AP3S2 SAT A/C 1.11 (1.01-1.20) 0.02 0.96 (0.82-1.13) 0.63 1.10 (1.02-1.18) 0.01 1.24 (1.09-1.41) 1.0E-03 0.24 
rs4392054 16 20630271 ACSM1 SAT G/A 1.17 (1.04-1.32) 0.01 NA NA 1.18 (1.06-1.31) 1.8E-03 1.17 (0.98-1.40) 0.09 1.00 
rs17052370 17 21660480 UBBP4 SAT G/A 1.07 (0.98-1.17) 0.13 1.10 (0.91-1.33) 0.33 1.08 (1.01-1.17) 0.03 1.13 (0.99-1.29) 0.07 0.95 
rs1912379 18 66460710 RPS2P6 SAT A/G 1.15 (1.04-1.26) 4E-03 0.97 (0.82-1.16) 0.75 1.15 (1.06-1.24) 5.3E-04 1.11 (0.96-1.28) 0.16 0.44 
rs4812829 20 42422681 HNF4A SAT G/A 1.21 (1.11-1.32) 3E-05 1.19 (1.01-1.40) 0.04 1.04 (0.96-1.12) 0.33 1.28 (1.12-1.46) 1.9E-04 0.05 
               
 
 
 236 
 
237 
 
Table 6.7: Tests for heterogeneity of effect (Phetero) between male and female participants in the SAT2D GWA cohorts at the 
previously reported T2D loci, and at the loci identified in the present study. 
 
 
      Male  Female   
SNP Chr Pos Nearest gene Reference 
Alleles 
(A/R) OR P OR P Phetero 
           
rs17031236 2 105538433 FHL2 SAT2D C/A 1.11 (1.05-1.18) 1.4E-04 1.04 (0.94-1.16) 0.43 0.27 
rs3923113 2 165210095 GRB14 SAT2D C/A 1.17 (1.10-1.24) 9.3E-07 1.08 (0.96-1.22) 0.19 0.27 
rs11711167 3 126521709 ZNF148 SAT2D A/G 1.11 (1.05-1.17) 2.0E-04 1.05 (0.95-1.17) 0.34 0.37 
rs16861329 3 188149155 ST6GAL1 SAT2D A/G 1.14 (1.07-1.21) 5.1E-05 1.10 (0.97-1.23) 0.13 0.59 
rs6835176 4 40199309 RBM47 SAT2D G/A 1.29 (1.13-1.47) 1.4E-04 1.21 (0.94-1.56) 0.15 0.65 
rs9496773 6 144183238 PHACTR2 SAT2D G/A 1.09 (1.03-1.15) 2.9E-03 1.15 (1.04-1.28) 0.01 0.32 
rs2111815 7 132349786 CHCHD3 SAT2D G/A 1.08 (1.02-1.13) 0.01 1.17 (1.06-1.29) 1.8E-03 0.14 
rs16923500 8 59551647 CYP7A1 SAT2D G/A 1.12 (1.05-1.18) 3.8E-04 1.10 (0.98-1.23) 0.10 0.83 
rs1562042 9 105747435 SMC2 SAT2D A/G 1.12 (1.05-1.19) 5.3E-04 1.09 (0.97-1.23) 0.13 0.75 
rs1802295 10 70601480 VPS26A SAT2D G/A 1.14 (1.07-1.21) 3.3E-05 1.11 (0.99-1.24) 0.07 0.69 
rs2616646 10 78559423 KCNMA1 SAT2D A/G 1.18 (1.10-1.27) 6.5E-06 1.05 (0.91-1.21) 0.49 0.15 
rs4287347 11 132191217 OPCML SAT2D A/G 1.09 (1.04-1.15) 8.7E-04 1.10 (1.00-1.21) 0.06 0.93 
rs6576426 15 23254656 UBE3A SAT2D A/G 1.17 (1.09-1.25) 9.4E-06 1.13 (0.99-1.29) 0.07 0.66 
rs620739 15 47852704 ATP8B4 SAT2D A/G 1.13 (1.07-1.19) 8.0E-06 1.05 (0.94-1.16) 0.40 0.18 
rs7178572 15 75534245 HMG20A SAT2D A/G 1.08 (1.03-1.14) 3.1E-03 1.18 (1.07-1.30) 1.0E-03 0.13 
rs2028299 15 88175261 AP3S2 SAT2D A/C 1.11 (1.05-1.17) 3.2E-04 1.11 (1.00-1.24) 0.05 0.92 
rs4392054 16 20630271 ACSM1 SAT2D G/A 1.16 (1.07-1.26) 5.2E-04 1.23 (1.06-1.42) 0.01 0.53 
rs17052370 17 21660480 UBBP4 SAT2D G/A 1.02 (0.97-1.08) 0.43 1.36 (1.22-1.52) 3.2E-08 6.1E-06 
rs1912379 18 66460710 RPS2P6 SAT2D A/G 1.13 (1.06-1.20) 8.7E-05 1.11 (0.99-1.25) 0.07 0.85 
rs4812829 20 42422681 HNF4A SAT2D G/A 1.12 (1.06-1.19) 7.3E-05 1.17 (1.05-1.31) 3.5E-03 0.46 
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Table 6.8:  Association of sentinel SNPs with secondary quantitative anthropometric and metabolic traits in the LOLIPOP and 
PROMIS cohorts. Association results are given as change in phenotype per copy of risk allele, and are adjusted for age and 
gender. Associations were calculated in LOLIPOP and PROMIS separately, and results combined by inverse variance meta-
analysis. Associations nominally significant at P<0.05 are shaded in grey. Associations significant after correcting for multiple 
testing are shown in yellow (P<0.005). 
 
 
 
 rs3923113 rs16861329 rs1802295 rs2028299 rs7178572 rs4812829 
Phenotype Beta P Beta P Beta P Beta P Beta P Beta P 
             
Weight (kg) -0.30 3×10-2 0.15 3×10-1 0.18 2×10-1 0.16 2×10-1 -0.24 5×10-2 -0.03 8×10-1 
BMI (kg/m2) -0.09 7×10-2 0.08 1×10-1 0.07 2×10-1 -0.02 7×10-1 -0.07 2×10-1 -0.02 7×10-1 
WHR -0.001 2×10-1 0.001 4×10-1 0.000 9×10-1 0.000 6×10-1 -0.001 3×10-1 0.000 6×10-1 
             
Systolic BP (mmHg) 0.33 2×10-1 0.04 8×10-1 0.11 6×10-1 0.19 3×10-1 -0.22 3×10-1 -0.01 9×10-1 
Diastolic BP (mmHg) 0.07 6×10-1 0.16 3×10-1 0.11 4×10-1 0.00 9×10-1 -0.05 7×10-1 -0.08 6×10-1 
             
Insulin (% change) 4.71 1×10-3 1.62 2×10-1 1.16 4×10-1 0.69 6×10-1 -0.69 5×10-1 0.46 7×10-1 
Glucose (% change) 1.62 3×10-4 -1.37 3×10-3 1.16 8×10-3 -0.46 3×10-1 -0.92 4×10-2 2.33 1×10-6 
HOMA-S (% change) -4.50 5×10-4 -0.23 9×10-1 41.25 7×10-1 -0.46 7×10-1 1.62 2×10-1 -2.28 8×10-2 
HOMA-B (% change) 0.93 5×10-1 3.28 2×10-2 -1.83 2×10-1 1.86 1×10-1 1.39 2×10-1 -4.50 1×10-3 
             
Cholesterol (mmol/L) 0.01 6×10-1 0.00 8×10-1 0.01 6×10-1 0.00 8×10-1 -0.01 6×10-1 0.00 9×10-1 
HDL cholesterol (% change) -0.56 4×10-1 0.91 2×10-1 1.09 9×10-2 -0.94 1×10-1 -0.80 2×10-1 -0.32 6×10-1 
Triglycerides (% change) 1.86 5×10-2 2.09 2×10-2 0.46 6×10-1 -0.92 3×10-1 -1.37 1×10-1 0.69 4×10-1 
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Table 6.9: Association of sentinel SNPs with T2D in the replication samples, with no adjustment amongst for adiposity, with 
adjustment for BMI or with adjustment for waist-hip ratio. Results are presented as odds ratio [OR] (95% confidence interval) for 
T2D per copy of risk allele, with P value. All analyses are adjusted for age and gender. Associations were calculated in each 
replication sample separately, then combined by inverse variance meta-analysis.  
 
 
 
     Unadjusted BMI adjusted WHR adjusted 
SNP Chr Position Nearest gene 
Risk 
allele OR P OR P OR P 
           
rs3923113 2 165210095 GRB14 A 1.07 (1.03-1.11) 6.7E-04 1.09 (1.04-1.14) 1.0E-04 1.05 (1.01-1.10) 2.6E-02 
rs16861329 3 188149155 ST6GAL1 G 1.07 (1.03-1.11) 1.6E-04 1.07 (1.02-1.11) 3.4E-03 1.07 (1.03-1.12) 1.7E-03 
rs1802295 10 70601480 VPS26A A 1.06 (1.03-1.10) 6.6E-04 1.07 (1.02-1.11) 1.9E-03 1.06 (1.02-1.11) 3.7E-03 
rs7178572 15 75534245 HMG20A G 1.08 (1.05-1.12) 7.0E-07 1.07 (1.02-1.11) 1.4E-03 1.07 (1.03-1.11) 1.1E-03 
rs2028299 15 88175261 AP3S2 C 1.09 (1.06-1.13) 1.1E-07 1.09 (1.05-1.13) 6.1E-06 1.09 (1.05-1.13) 2.7E-05 
rs4812829 20 42422681 HNF4A A 1.07 (1.04-1.11) 2.8E-05 1.08 (1.03-1.12) 2.1E-04 1.08 (1.04-1.12) 2.0E-04 
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Table 6.10:  Expression Quantitative Trait Loci (eQTLs) for SNPs associated with type-2 diabetes amongst Indian Asians. 
Results are for all eQTLS associated with the GWA SNP, or a close proxy, at P<10-5 in available public and proprietary datasets 
(see methods).  Results are also provided for the SNP most closely associated with eQTL in the experiment, to assess whether 
the GWA SNP is coincident with the peak eQTL SNP. LCL = lymphoblastoid cell lines. 
 
 
 
              GWA SNP Peak eQTL SNP 
GWA SNP Chr Position Nearest Gene Source Tissue eQTL Beta P ID  
r2 between 
SNPs P 
            
rs3923113 2 165210095 GRB14 Heid et al  Subcutaneous fat GRB14 n/a n/a rs10195252 0.83 4.4x10-11 
rs3923113 2 165210095 GRB14 Heid et al  Subcutaneous fat GRB14 n/a n/a rs10184004 0.83 5.5x10-6 
rs3923113 2 165210095 GRB14 Heid et al  Omental fat GRB14 n/a n/a rs10195252 0.83 1.0x10-13 
rs7178572 15 75534245 HMG20A MuTHER LCL PSTPIP1 0.060 8.8x10-6 rs12908255 <0.3 3.3x10-14 
rs2028299 15 88175261 AP3S2 MuTHER Fat C15orf38 -0.143 9.0x10-27 rs3803534 0.88 1.9x10-28 
rs2028299 15 88175261 AP3S2 MuTHER Skin C15orf38 -0.135 8.0x10-17 rs3803534 0.88 2.9x10-19 
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Table 6.11: Multivariate regression analysis for association of Indian Asian ethnicity with T2D. Results are shown as OR (95% CI) 
for T2D amongst Indian Asians compared to Europeans before and after adjustment for known environmental and lifestyle risk 
factors. (BMI= body mass index, WHR=waist-to hip ratio, LTPA= leisure time physical activity) and the six novel T2D SNPs 
discovered amongst Indian Asians (rs3923113, rs16861329, rs1802295, rs2028299, rs7178572, rs4812829). 
 
 
 
 
 
 
 
 Indian Asians vs Europeans OR (95% CI) for T2D 
 
P 
   
Age, Sex 4.31 (3.39 – 5.48) <0.001 
Age, Sex, BMI 4.56 (3.57 – 5.79) <0.001 
Age, Sex, BMI, WHR 3.73 (2.92 – 4.77) <0.001 
Age, Sex, BMI, WHR, LTPA 3.57 (2.78 – 4.58) <0.001 
Age, Sex, BMI, WHR, LTPA, 6 Novel T2D SNPs 3.41 (2.65 – 4.39) <0.001 
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7.1 Lifestyle studies 
In the epidemiological studies I investigated the prevalence of T2D and 
related glycaemic disturbances amongst Indian Asians compared to Europeans 
living in West London. In addition I examined the association of adiposity and 
leisure time physical activity with T2D in both populations and investigated the 
extent to which these lifestyle factors account for the increased risk of T2D 
amongst Indian Asians compared to Europeans.  
Consistent with previous data I found the prevalence of T2D and related 
glycaemic disturbances to be ~4 fold higher amongst Indian Asians than 
Europeans12. Although weaker, I demonstrate that obesity is an important risk 
factor for T2D and pre-diabetes in Indian Asians as in Europeans. Among 
Indian Asians, levels of LTPA are consistently lower between both genders and 
at all age-groups, compared to Europeans. Although there are important 
limitations with the methodology used to characterise physical activity in this 
work (discussed later), my data does not support a role for the beneficial effects 
of LTPA on T2D risk in Indian Asians.  
To my knowledge this is the first study to establish that population 
differences in adiposity and LTPA do not account for the increased prevalence 
of T2D and pre-diabetes amongst Indian Asians compared to Europeans. 
Furthermore I show that aggressive measures to reduce weight or increase 
LTPA alone are unlikely to bridge the 4-fold excess risk of T2D observed 
between the two racial groups. 
Major strength of my analyses include use of a large representative 
population sample, and limited responder bias evidenced by limited material 
differences between study participants and non-responders. However, other 
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sources of bias associated with cross-sectional data may have influenced my 
findings and are worthy of mention. For example prevalent T2D cases may 
have taken measures to reduce weight, modify dietary patterns or increase 
levels of physical activity following diagnosis. In addition anti-diabetic 
medications are associated with weight gain as well as weight loss279, and their 
use may have confounded associations of BMI and WHR with T2D. As with all 
cross-sectional data sets, LOLIPOP may be subject to survival bias leading to 
under-representation of individuals with the most aggressive forms of T2D in 
the population sample.  
Although LOLIPOP forms the largest collection of Indian Asian men and 
women within a research effort world-wide, caution is drawn when generalising 
results presented herewith to other Indian Asian groups. Indian Asians are a 
heterogeneous population, stratified by differences in religion, language and 
cultural practice. Furthermore, work by Reich et al. confirms genetic 
heterogeneity among Indian Asians with Ancestral North Indians (e.g. Punjabis, 
Gujratis and Pakistanis) forming one end of the genetic spectrum and Ancestral 
South Indians (Sri Lankans, Bangladeshis and Andaman islanders) the other. 
Majority of Indian Asian LOLIPOP participants comprise men and women of 
Punjabi Sikh ancestry, with fewer Bangladeshis and Sri Lankans. Therefore, 
my findings are applicable only in the context of men and women of Indian 
Asian ancestry living in the Borough of Ealing, West London; relevance to other 
migrant and non-migrant Indian Asian population groups is unclear.     
Besides the drawbacks of a cross-sectional study design, failure of 
adiposity to account for the excess risk of T2D amongst Indian Asians 
compared to Europeans may relate to failure of simple clinical measures of 
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obesity to fully capture the complex distribution and spectrum of biological 
effects associated with adipose tissue. BMI and WHR remain the most widely 
used phenotypes for human adiposity, but correlations with insulin resistance 
are generally modest. Support for this comes from a cross-sectional study of 
304 normal-weight, overweight and obese subjects which demonstrates that 
the relationship between BMI and WHR with insulin resistance is moderate, 
with correlation coefﬁcients between 0.38 and 0.40280-282. My own work shows 
that risk of T2D was greatest among the leanest Indian Asians and risk of T2D 
similar in the most obese, suggesting that BMI and WHR are suboptimal 
measures of metabolically active fat. 
Adipocyte cell size is increased in Indian Asians101 and larger adipocyte 
volume is associated with higher risk of T2D102. When adipocytes become 
enlarged they undergo endoplasmatic reticulum stress, either induced by 
hypoxia or nutrient excess, which leads to an unfolded protein response 
(UPR)283. The UPR induces genes involved in assembling, folding, modifying, 
and degrading proteins, which activate stress and inflammatory pathways and 
the production of cytokines and chemokines that interfere with the insulin 
signalling pathway. It is unclear whether simple measures such as WHR/ BMI 
are correlated with adipocyte hypertrophy and thus these simple measures may 
not capture this specific phenotype.  
Hepatic steatosis has emerged as an important determinant of insulin 
resistance. Fat accumulation in liver is associated with hepatic insulin 
resistance as well as with peripheral insulin resistance in skeletal muscle and 
adipose tissue282,284,285. Hepatic fat is not strongly correlated with BMI and 
WHR, and therefore these simple anthropometric measures may not capture 
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the full metabolic profile of this ectopic deposition of adipose tissue. In a study 
of 83 severely obese individuals who underwent liver biopsies during anti-
obesity surgery, without histories of liver disease, T2D, or hepatotoxic 
exposure, correlation of WHR with hepatic fat was moderate (r2=0.4)286. 
Furthermore, Korenblat et al. found that hepatic triglyceride content was the 
best predictor of insulin sensitivity in liver independent of BMI and percent body 
fat285.  
 Data has emerged that hepatic accumulation of fat is more prevalent 
amongst Indian Asians. In a study of young, lean, healthy but sedentary Indian 
Asians and Europeans living in the United States, Indian Asian men showed a 
higher prevalence of insulin resistance, associated with 2-fold higher hepatic 
lipid content relative to European men287. In addition, degree of ectopic 
pancreatic fat deposition varies depending on ethnicity and race. Although 
causality remains unproven, recent studies utilizing non-invasive imaging 
techniques strengthen associations of pancreatic steatosis, obesity and T2D288. 
Szczepaniak et al. investigated ethnic differences in pancreatic triglyceride 
levels (assessed using proton magnetic spectroscopy) along with their 
relationship with β-cell dysfunction289. In a sample comprising individuals of 
African-American, European and Hispanic ancestry, with mild obesity and 
without T2D, they demonstrated marked ethnic differences in levels of 
pancreatic triglycerides, and in the relationship between pancreatic triglycerides 
and β-cell dysfunction. In particular, pancreatic triglyceride levels were highest 
among Hispanics, an ethnic group with marked insulin resistance and high 
levels of obesity and T2D. To date, no studies have characterized pancreatic 
fat in Indian Asians. Future studies using state of the art imaging modalities, to 
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characterise hepatic and pancreatic fat among Indian Asians will provide useful 
insights into the contribution of ectopic fat deposition to T2D in this ethnic 
group. 
 Consistent with previous work, Indian Asians were 57% less likely than 
Europeans to participate in the minimum amount of LTPA according to current 
recommendations115. Even among the most physically active I show a striking 
~6-fold excess of T2D amongst Indian Asians compared to Europeans, and 
adjustment for LTPA did not account for the excess risk of T2D between the 
two racial groups as a whole. Previous studies show that LTPA is an important 
determinant of T2D among Europeans110, and I confirm a protective role for 
LTPA among men and women of European ancestry. Although LTPA was 
protective in Indian Asian men and women, the association did not reach 
statistical significance. Data from interventional studies amongst Indian Asians 
and Europeans confirm an important contribution made by lifestyle 
interventions, including increased levels LTPA, in attenuating risk of future T2D. 
Therefore, my findings do not refute the important association of LTPA and 
T2D risk among Indian Asians79,81. 
A lack of association of LTPA with T2D among Indian Asians is 
surprising given that the interview-based questionnaire used comprised a 
comprehensive assessment of intensity, duration, frequency and type of leisure 
time physical activity. However, the validity of self-reported physical activity 
questions as a measure of activity and energy expenditure has not been 
specifically been evaluated in Indian Asian populations. Although I characterize 
LTPA, I did not collect data on physical activity from occupation, transportation, 
or housework. In addition I did not examine the contribution of environmental 
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factors known to limit physical activity, including neighbourhood safety, 
crowding, and access to exercise facilities; all the aforementioned may have 
confounded my association testing235. 
Errors with estimation of physical activity in epidemiological studies are 
well recognised290. Improved technology to directly measure total energy 
expenditure can refine understanding of the protective mechanisms of physical 
activity to health. The development of and availability of lightweight monitors 
that can store large amounts of detailed information, including analyses of body 
motion, posture changes, heart rate and movement, will improve direct 
estimation of physical activity291,292. Their application to large Indian Asian 
epidemiological studies will help define the association of physical activity to 
risk of T2D. 
With regards dietary studies I conducted the first study to chemically 
characterise duplicate diet samples in a representative population sample of 
Indian Asian and European men to investigate the contribution of dietary 
nutrients to insulin resistance. The primary finding is that differences in dietary 
patterns do not account for the 25% higher levels of HOMA-IR observed 
amongst Indian Asians compared to Europeans. In addition I show that low 
fibre intake is a risk factor for insulin resistance amongst Indian Asians, and the 
association is independent of total energy intake, BMI and WHR, implicating 
mechanisms other than obesity mediating mediating the protective effect. The 
exact mechanisms by which dietary fibres achieve their effects are largely 
unresolved. 
Reasons underlying the lack of an association between dietary 
macronutrients and differences in insulin resistance between Indian Asians and 
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Europeans include small sample size, exclusion of women and single 24-hour 
collection of dietary samples. In addition previous longitudinal studies 
demonstrate an association for low glycaemic index (GI) foods and reduced 
risk of insulin resistance and T2D and no association with carbohydrates245,246. 
Present knowledge of the variation in glycaemic response to carbohydrate-
containing foods comes largely from measurements of GI. GI may directly be 
assessed in vitro by determining rapidly available glucose, slowly available 
glucose and starch fractions. Diets that contain large amounts of rapidly 
digested carbohydrates may be detrimental to health while diets rich in slowly 
digested carbohydrates may protect against chronic disease247. There is no 
data on rapidly and slowly digested carbohydrate content of Indian Asian diets, 
and characterization for theses markers of glycaemic index in Indian Asian 
duplicate diet samples may provide insights in the reasons underlying the 
increased levels of insulin resistance in this population compared to 
Europeans.  
Further reasons for a lack of association of dietary macronutrients may 
relate to transformation of chemical components of food in the gastrointestinal 
tract and/or liver. These metabolites derived from food form the food 
metabolome. Investigation of the food metabolome in biofluids has the potential 
to give objective information about the short-term or long-term dietary intake of 
individuals, to identify potential biomarkers and to reduce the current reliance 
on subjective dietary records293. Recent metabolomics-based studies using 
unbiased comprehensive metabolite profiling approaches have identified 
association of branch chain amino acids with obesity, T2D and related 
metabolic disturbances294-296. In addition the EPIC study has provided proof-of-
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principle that the metabolomics methodology can be translated to large 
prospective studies297. Application of untargeted and targeted metabolomic 
scans in large prospective Indian Asian cohorts have the potential to provide an 
objective assessment of the contribution of metabolites derived from food and 
their contribution to T2D risk.  
I have assessed the contribution of lifestyle factors to the increased risk 
of T2D amongst Indian Asians compared to Europeans. However, to fully 
evaluate the role of the environment to T2D risk other important factors need 
consideration. Individuals are exposed to and interact with multiple 
environments: the physical environment (chemical exposures and daily 
light/dark cycles), the “built” environment, the food environment, as well as the 
psychosocial and socio-economic environment. In addition, the concept of 
environmental exposures includes pollution of air and water, as well as passive 
chemical exposures, which can disrupt endocrine function298. Oestrogen 
receptor agonists such as bisphenol A, is an example of an endocrine 
disrupter, which is derived from polycarbonate plastics for coatings and food 
containers, and has been implicated in the development of obesity and insulin 
resistance299. Environmental drivers of overeating include the presentation of 
large portions, the ubiquitous availability of food, social acceptance of frequent 
eating, and susceptibility to food marketing tools300. In addition recent data 
indicates that sleep disturbances plays a causal role energy imbalance and 
insulin dysfunction301. Misalignment of sleep/wake cycles and eating behaviour 
is thought to distort the normal synchronization of metabolic gene transcription. 
The contribution of these factors to T2D amongst Indian Asians merit further 
evaluation in the setting of large epidemiological study. 
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7.2 Genetic studies 
In the genetic studies I investigated the contribution of previously 
reported T2D genetic variants to the excess risk of T2D amongst Indian Asians, 
compared to European. Amongst Indian Asians I demonstrate that known T2D 
genetic loci have similar risk allele frequencies and lower odds ratios compared 
to Europeans. These findings exclude a role for previously reported T2D 
genetic susceptibility factors underlying the 4-fold increased risk of T2D 
observed in Indian Asians compared to Europeans. I generated a genetic risk 
score (GRS) based on number of risk allele, and found that although the GRS 
marginally improved identification of Indian Asians at risk of T2D, its 
discriminatory value is limited. 
Since commencement of this work, other groups have investigated the 
role of T2D common genetic variants amongst Indian Asians. Rees et al. 
investigated the role of 13 known T2D loci in 1,678 Indian Asian participants 
with T2D and 1,584 normoglycaemic Indian Asians control participants from 
two regions; one resident in the UK and one indigenous to the District of 
Mirpur302. SNPs in or near PPARG, TCF7L2, FTO, CDKN2A/ B, HHEX/IDE, 
IGF2BP2, SLC30A8, KCNQ1, JAZF1, IRS1, KLF14, CHCHD9 and DUSP9 
displayed significant (p<0.05) associations with T2D. After correcting for 
multiple testing. only TCF7L2, IRS1, PPARG and CDKN2A/B retained 
statistical significance. Gupta et al. carried out an assessment of 31 T2D loci 
amongst 3089 Indian Asians sib pairs303. The confounding effects of population 
stratification on genetic association studies are well recognized; therefore a 
major strength of this study was the use of sib-pairs to reduce the confounding 
effects of population stratification. The principle finding from this study was 
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replication of the association of THADA with T2D in participants of Indian Asian 
ancestry. No previous studies have directly investigated the contribution of all 
known T2D genetic variants to the increased risk of T2D amongst Indian 
Asians compared to Europeans. Janipalli et al., investigated 32 T2D previously 
reported genetic variants in 1808 Indian Asian patients and 1549 Indian Asian 
controls304. They confirmed earlier association of T2D genetic variants in or 
near TCF7L2, FTO, PPARG, HHEX ⁄ IDE, CDKN2A ⁄ B, KCNJ11, IGF2BP2, 
CDKAl1 and SLC30A8, CDC123 ⁄ CAMK1D, GCKR, MC4R, TCF2, THADA and 
WFS1 with risk of T2D. They also evaluated the combined effects of 32 T2D 
variants to detect subgroups at increased risk of T2D, and similarly found that 
T2D SNPs adds only a minor discriminatory advantage over conventional risk 
factors.  
Possible reasons for the failure to replicate many of the associations of 
previously identified T2D risk alleles among Indian Asians may relate to 
limitations of sample size and power, allelic heterogeneity and differences in 
patterns of linkage disequilibrium between known T2D SNPs and functional 
variants at these loci in different ethnic populations. Alternatively, gene-
environment interactions may operate in the pathogenesis of T2D252,253 and 
that differences in the level of environmental risk factors in different populations 
may alter the impact of susceptibility loci on T2D risk.  
  Lastly, I carried out a genome wide association and replication study of 
T2D amongst 58,687 people of Indian Asian ancestry, and identified common 
variants at six novel genetic loci associated with T2D: GRB14, ST6GAL1, 
VPS26A, HMG20A, AP3S2 and HNF4A. Identified variants are in or near loci 
that harbour genes that are plausible biological candidates for the observed 
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associations. For example at 2q24, rs3923113 is nearest to GRB14, an adapter 
protein, which binds to insulin receptors and insulin-like growth-factor 
receptors, to inhibit tyrosine kinase signalling262,263. At 3q27, rs16861329 is 
intronic in ST6GAL1, encoding an enzyme predominantly membrane bound 
and located in the golgi apparatus, is involved in post-translational modification 
of cell-surface components by glycosylation266, and is reported to influence 
both insulin action and cell surface trafficking. SNP rs16861329 is also near 
ADIPOQ encoding adiponectin, a hormone secreted by adipocytes which 
promotes insulin sensitivity303. At 20q13, the lead genotyped SNP rs4812829 is 
intronic in HNF4A, a nuclear transcription factor strongly expressed in 
liver277,278. Mutations in HNF4A are known to cause maturity-onset diabetes of 
the young (MODY) type 1278. I found no systematic differences in risk allele 
frequency or effect size, and and novel T2D SNPs did not account for the 
increased risk of T2D amongst Indian Asians compared to Europeans. 
Therefore novel and previously reported T2D common genetic variants do not 
explain the increased risk of T2D amongst Indian Asians compared to 
Europeans. 
The observation that loci detected by GWAS explain only a small 
minority of the inferred genetic variance among Europeans and Indian Asians 
refutes the common disease-common variant hypothesis and suggests further 
genetic factors remain to be discovered195. The ‘missing heritability’ may be 
explained by one of three causes: a large number of small-effect common 
variants across the entire allele frequency spectrum (the infinitesimal model), a 
large number of large-effect rare variants (the rare allele model) or some 
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combination of genotypic, environmental and epigenetic interactions (the broad 
sense heritability model).  
To extend the discovery and characterization of common genetic variants 
influencing T2D susceptibility, recent large-scale genotyping efforts using the 
Metabochip has led to the discovery of 10 novel T2D common genetic variants 
in Europeans305. This custom array of 196,725 SNPs was designed to facilitate 
follow-up of nominal associations for T2D and other traits, and to enhance fine 
mapping of established loci. The T2D component of Metabochip comprises 
21,774 SNPs that capture the strongest independent association signals from 
DIAGRAM195. Identification of further common genetic variants in this study 
lends support to the view that much of the overall variance in T2D susceptibility 
can be attributed to the impact of a large number of common causal variants, 
most of very modest effect. Future experiments among Indian Asians utilizing 
the Metabochip platform may lead to the discovery of additional T2D genetic 
variants in this ethnic group which may help explain their increased risk of T2D 
compared to Europeans. 
  The counterview to the common disease-common variant model is the 
rare allele model, which argues that common diseases such as T2D comprise 
genetic variants that are rare in the population306. As rare variants will have 
occurred recently in evolutionary history they do not segregate with the 
common SNPs that have been used on current GWAS chips. Resources such 
as the 1000 Genomes Project have utilized next-generation whole genome 
sequencing technology to catalogue variants at frequencies lower than 
accessed ever before (≥0.1% MAF in coding regions and ≥1% outside coding 
regions) which provides an improved resource for SNP tagging and fine-scale 
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mapping255. Future whole genome sequencing endeavours to catalogue genetic 
variation amongst Indian Asians will permit accurate imputation of both shared 
and Indian Asian specific variants, which will inform design of microarrays 
specific for this population. This will enhance the search for both rare and 
common genetic variants underlying susceptibility to T2D and other diseases 
important amongst Indian Asians. 
Recent data has emerged which highlights a role for epigenetic 
modifications and risk of T2D. Epigenetic regulation refers to heritable changes 
in gene expression and phenotype that are not determined by changes in DNA 
sequence307. Birth cohort studies show that maternal undernutrition, low birth-
weight, and rapid postnatal child growth are all associated with increased risk 
of T2D in the off-spring308. These risks appear to be mediated through 
epigenetic modification and may be trans-generational. More than 96% of low 
birth-weight occurs in the developing world, with highest incidence in Indian 
Asians (31% of live births)309. Results of The Pune Maternal Nutrition Study, a 
prospective population-based observational study of rural Indian Asian women 
and their offspring, show that Asian mothers are shorter (mean 152cm), thinner 
(mean BMI 18.1kg.m2) than their European counterparts, and that full-term 
Indian Asian neonates are ~700g lighter than the average European308. These 
neonatal differences are accompanied by changes in body composition with 
greater reduction in lean, muscle tissue than truncal fat. Birth cohort studies in 
India confirm the association of maternal undernutrition, low-birth weight and 
thinness in infancy with later development of impaired glucose tolerance and 
T2D308. Risk of impaired glucose tolerance and T2D is highest amongst Indian 
Asians who had shorter mothers, parents with lower BMI, low birth weight, 
256 
 
thinness in infancy and greater weight gain during childhood and adolescence, 
independent of their adult BMI. These observations of adverse intrauterine and 
postnatal exposures in Indian Asians raise the possibility that epigenetic 
modification of gene expression may contribute to age-dependent changes in 
key metabolic genes, and increased susceptibility to T2D. Future whole 
epigenome-wide experiments amongst Indian Asians are needed to investigate 
the contribution of epigenetic factors to T2D the increased risk of T2D in this 
population compared to Europeans.  
 
7.3 Conclusions 
I have investigated the contribution of obesity, leisure time physical 
activity, dietary nutrients and known T2D common genetic variants to the 
increased risk of T2D amongst Indian Asians compared to Europeans. I confirm 
a ~3-fold higher prevalence of T2D and related glycaemic disorders amongst 
Indian Asians compared to Europeans, unexplained by the lifestyle and genetic 
risk factors. I have carried out a genome-wide association study amongst 
58,687 Indian Asians and discover 6 novel genetic risk factors in association 
with T2D; however, these common genetic variants do not account for the 
increased susceptibility to T2D in this racial group. An urgent international 
programme is called for to address the factors underlying the increased 
prevalence of T2D amongst individuals of Indian Asian ancestry.  
Figure 7.1: Overview of pathways implicated in the aetiology of T2D which affect risk of T2D through yet undiscovered 
mechanisms. 
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